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ABSTRACT
There are limited reports describing the effects of extracorporeal membrane
oxygenation (ECMO) on drug disposition with minimal emphasis on assessing the
appropriateness of dosing regimens. The studies described in this thesis were designed
to investigate sorption of drugs by the polymeric components of an ECMO circuit and
the clinical pharmacokinetic consequences of both loss of drugs and the expanded
circulating blood volume. Derived pharmacokinetic parameters were used to evaluate
the significance of these effects and to develop improved dosing regimens.
In vitro investigations of diazepam, lorazepam, midazolam and propofol in
contact with plasticised polyvinyl chloride (pPVC) circuit tubing and silicone
membrane from the oxygenator, both as static solutions and during simulation of flow
through an intact ECMO circuit, revealed a significant capacity for drug loss (range 40-
98%, p<O.OO5).In contrast, a reduced loss of morphine was observed with pPVC
(16%), whilst no loss was observed with silicone membrane (p>0.05). Fractional loss
was correlated with the drug's log P value and ionisation status and consistent with a
first order diffusion controlled process. Priming the circuit components with human
albumin solution significantly decreased sorption by the silicone membrane (p<O.OS).
Sorption was shown to be a reversible process and analysis of ex vivo neonatal ECMO
circuits confirmed sequestration of midazolam administered during normal clinical care.
The influence of sorption on midazolam pharmacokinetics was investigated in
20 neonates during ECMO. A population pharmacokinetic analysis revealed a one
compartment model with time dependent increase in volume of distribution (V) to a
maximum mean population value of 4.1 Ukg, three to four times greater than
previously reported in neonates, and attributed to reversible sorption by the circuit.
Consequently the median (range) steady state half-life of midazolam was substantially
prolonged, 33.3 (7.4-178) hours. These results help explain elevated plasma midazolam
concentrations observed in the group.
Population pharmacokinetic analysis of aminophylline and vancomycin in a
wide age range ECMO population revealed a substantial impact of the expanded
circulating blood volume. Estimates of V were significantly higher (e.g. mean 0.S7 and
0.71 Ukg respectively in neonates) and clearance was lower (e.g. mean 0.023 and 0.041
Ukglhr respectively in neonates), than previously reported in non ECMO patients of
similar age. Pharmacokinetic parameters were correlated with demographic and clinical
covariates such as age, weight and serum creatinine. Additional influences identified
include blood recirculation during veno venous cannulation and altered renal and
hepatic physiology in this critically ill group. Large interpatient variability in
parameters reflected the heterogeneous nature of patients treated on ECMO. Similarly,
linear regression analysis of plasma gentamicin concentrations from neonates revealed
an enlarged V (0.8 Ukg), and the use of normal dosing regimens, 2.5-3.5mglkg 8-12
hourly, resulted in a greater frequency of potentially toxic trough levels compared to a
modified regimen of 2.Smglkg 24 hourly (46% and 6.3% respectively, p < 0.05). The
results of these studies are discussed in terms of their potential impact on
pharmacotherapy during ECMO.
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Extracorporeal membrane oxygenation (ECMO) is often a final attempt at sustaining
life, when conventional methods fail. The clinicians and researchers who pioneered this
technique, did so in an attempt to push back the frontiers of critical care. Significant
advances in oxygenator technology, surgery, and clinical and technical skills made this
possible. In contrast, efforts to improve pharmacotherapy during ECMO remained
limited.
It is perhaps quite obvious to the clinical pharmacist or pharmacologist during
their first consultation with a patient supported by ECMO that drug disposition will be
altered. But the important questions are how, to what extent, and will the alteration be
clinically significant. Certainly the answer to the last question, at least empirically,
appeared to be in the affirmative. Clinical staff often claimed altered therapeutic
response particularly with sedative drugs and routinely monitored antibiotics. Though a
number of 'theories' were put forward, in particular sorption in to the circuit, there
appeared to be very little published evidence. More importantly, there were no
suggestions as to how dosing regimens may be optimised.
The series of investigations described in this thesis start with the chemical
analysis of drug loss in in vitro systems and combine this data with clinical
pharmacokinetic studies to establish the influence on drug disposition of two ECMO
circuit related phenomenon: drug sorption and an expanded circulating volume. An
initial laboratory approach was essential to investigate the physico-chemical factors
related to the drug, mobile phase and circuit polymers that may be important in
predicting and quantifying the degree of sorption. But to assess the clinical impact of
these phenomena, the drug concentration-time relationship in the body also needed to be
investigated. Only once the pharmacokinetics were defined, could pharmacotherapy be
improved. An additional advantage is that the basic concepts of pharmacokinetics are
common to all drugs; information gained about the pharmacokinetics of one drug during
ECMO can help in anticipating the pharmacokinetics of another. Thus, clinical
pharmacokinetic studies were planned for a number of drugs during ECMO. However,
in order to avoid ethical difficulties associated with blood sampling in children and the
rigours of traditional pharmacokinetic studies, a population pharmacokinetic approach
was utilised.
1.2 History of ECMO
ECMO is a complex life support technique for critically illpatients, which has been
developed through modification of the heart lung bypass machine (Peek et al., 1998).
ECMO is capable of sustaining life for days or weeks, permitting treatment and
recovery during severe respiratory or cardiorespiratory disease. In practice, the average
duration of ECMO support is 5 days for neonates and 10 days for adult patients (Mull a
et al., 1998). Over the last three decades, the technology has been developed and
improved in the laboratory, investigated in clinical research settings and applied in
routine clinical practice (Bartlett et al., 1985). Although the equipment and its
application have changed and evolved over time, the basic concept of continuous
extracorporeal circulation of blood to provide gas exchange and perfusion remains
unaltered (Bartlett et al., 2000).
ECMO was first introduced as a treatment for respiratory failure in the 1970's.
The earliest recorded clinical use was in an adult patient with acquired respiratory
distress syndrome (Hill et al., 1972). This generated widespread enthusiasm for the
technique (Bartlett et al., 1976a; Bartlett et al., 1976b). However, a multicentre trial of
ECMO for adult respiratory distress syndrome, reported in 1979, failed to demonstrate
any improvement in survival compared with conventional medical therapy (Zapol et al.,
1979). As a result, the early enthusiasm for using ECMO in adults waned. In contrast,
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however, Bartlett et al (1976b) and other groups were able to show the effectiveness of
ECMO in neonatal respiratory failure.
Results in neonates have rapidly improved and, since 1985, ECMO has been
considered the standard treatment for severe neonatal respiratory failure in the United
States, with survival rates exceeding 90 % in some centres (Bartlett, 1990; Bartlett et
al., 1985).
ECMO support for neonates was first introduced in the UK in 1989 at Heartlink
ECMO Centre, Groby Road Hospital, Leicester. The initial UK experience reported
survival rates comparable with the United States (Pearson et al., 1992). Despite this,
some British clinicians were reluctant to refer potentially suitable neonates for ECMO
because of uncertainty about its clinical and cost effectiveness. Although neonatal
ECMO had been subjected to two modified design, randomised controlled trials in the
United States comparing it with conventional medical management, there was varying
interpretation, with considerable controversy and criticism (Elliott, 1991). Others were
concerned that improved survival with the technique might be offset by an increased
risk of long term disability.
As a result of this uncertainty in the UK, a multi centre randomised controlled
trial of neonatal ECMO was conducted between 1993 and 1995. This study compared
neonates referred to ECMO centres against continued conventional management
without transfer. The findings of this study again conclusively demonstrated improved
survival rates (68% versus 41%) achieved with a well staffed and organised neonatal
ECMO service (UK ECMO Collaborative Trial, 1996).
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1.3 Neonatal ECMO
There is no doubt that ECMO support should be actively considered for term or near
term infants, who have severe cardiorespiratory disease that is potentially reversible,
and who meet the eligibility criteria (Table 1.1) (UK ECMO Collaborative Trial, 1996).
ECMO is currently contraindicated in premature infants because of the difficulties in
cannulation and the inevitability of intracranial haemorrhage. It is also excluded in
infants who have received mechanical ventilation for greater than 10 days. Such
prolonged ventilation can cause bronchopulmonary dysplasia, resulting in chronic lung
disease that is not easily reversed.
Table 1.1. Eligibility Criteria/or Neonatal ECMO
~ Gestational age greater than 34 weeks
~ Birth weight greater than 2,000 g
~ Reversible lung damage (high pressure mechanical ventilation less than 10 days)
~ No major intracranial haemorrhage (grade 1 or less)
~ No uncorrectable congenital cardiac lesions
~ No lethal congenital anomalies
» No significant coagulopathy or uncontrolled bleeding complications
ECMO is not suitable for use in all neonates. Out of 1,000 neonatal intensive
care admissions, approximately 0.5 % will be potential ECMO candidates. The vast
majority do well on conventional treatment that includes other technological advances,
such as high frequency ventilation and specific pulmonary vasodilators such as nitric
oxide.
ECMO does not treat acute lung disease, but simply "buys time" for the lungs to
recover spontaneously, and allows the implementation of pharmacological and other
types of direct lung treatment (for example, physiotherapy and bronchoscopy) while
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avoiding the baro and volutrauma caused by mechanical ventilation. The commonest
diagnoses that ECMO is used to support are persistent pulmonary hypertension of the
newborn (PPHN), associated with meconium aspiration (MAS), congenital
diaphragmatic hernia (CDH), respiratory distress syndrome (RDS), isolated persistent
foetal circulation, neonatal sepsis and pneumonia.
1.4 Paediatric and Adult ECMO
ECMO is also used as a life support for a wide range of diagnoses in older children and
adults. Although the principal criterion remains unaltered, i.e. the underlying disease
must be reversible, case selection is all important to prevent merely delaying the onset
of death in cases of irreversible lung disease. It is more difficult to draw up definitive
suitability criteria for adults than for neonates. Patients ventilated for more than seven
days are normally excluded.
Worldwide, the number of older patients treated is much smaller than the
number of neonates, and the success rate (to hospital discharge) is less dramatic.
However, the programme in Leicester has made significant contribution to the total
numbers, with a success rate of 80 % in paediatrics and 70 % in adults, compared with
the worldwide average of 52 and 45 % respectively (Peek et al., 1998).
1.5 Principles and Practice of ECMO
1.5.1 Cannulation
As the acronym suggests, the technique of ECMO involved oxygenating the blood
outside the body and thus obviates the need for gas exchange in the lungs. The
technique is categorised as either veno-venous (VV) or veno-arterial (VA), depending
on the type of cannulation. In VV ECMO, deoxygenated blood is drained and
oxygenated blood re-infused via venous sites. In neonates, this is achieved by placing a
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double lumen cannula in the right internal jugular vein (Figure 1.1). In VA ECMO,
deoxygenated blood drawn from the right internal jugular vein is returned oxygenated
via the right common carotid artery. While VV ECMO provides support purely with
gas exchange, VA ECMO also supports the heart.
1.5.2 Blood Circulation
Blood syphons from the venous cannula through tubing, driven by the right atrial
pressure and a drop of one metre, into a distensible venous reservoir at floor level. A
roller pump draws blood from the bladder and pushes it through artificial lungs
(oxygenators) and then a heat exchanger (to compensate for the cooling effect of the
oxygenators), before returning it to the patient (see Figure 1.1).
Figure 1.1. Schematic Diagram of a Paediatric ECMO Circuit
1.5.3 Gas Exchange
Gaseous exchange of oxygen and carbon dioxide occurs in the artificial lung
oxygenator, and is a function of the rate of blood flow through the oxygenator and the
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diffusion gradient between the gaseous phase and venous blood. The latter is
maximised by operating a counter current flow of blood and gas through the
oxygenator. Monitoring indices of blood oxygenation is an integral part of management,
not only in the ECMO circuit, but also directly in the patient to ensure adequate oxygen
delivery to tissues.
1.5.4 Pharmacotherapy
Extracorporeal circulation of blood requires anticoagulation to prevent thrombus
formation in the circuit and oxygenator. Therefore, during cannulation, the patient is
administered a loading dose of heparin, followed by a continuous infusion to maintain
the whole blood activated clotting time (ACT) at approximately 180-200 seconds.
While on ECMO, whole blood ACT is measured hourly, and more frequently if
necessary, to minimise the risk of bleeding, clotting and embolisation. Anaemia and
thrombocytopenia are common as a result of red blood cell and platelet destruction by
oxygenators, and therefore regular transfusions are made.
All drugs are administered via the ECMO circuit, since the high anticoagulation
status of the patient means direct interventions, e.g. intravenous line insertion, are kept
to a minimum. Many patients develop renal failure and are managed with continuous
veno venous haemofiltration (CVVH), which is attached directly to the circuit. Patients
are sedated with continuous infusions of midazolam and morphine titrated to apparent
patient comfort, and may be initially paralysed with atracurium to facilitate ventilation.
There is a serious risk of infection during ECMO because of the underlying disease
processes, compromised immune system, prolonged exposure of blood to the large
plastic surfaces, cannulation of major blood vessels and multiple entries into the ECMO
circuit. Broad spectrum antibiotics are therefore used prophylactically on a routine
basis.
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Nutrition is initiated as soon as possible after cannulation with total parenteral
nutrition, again infusing it directly into the circuit. Calorific and protein requirements
are calculated as in other critically ill patients, and the aim is to sustain positive nitrogen
balance.
1.5.5 Complications
Complications during ECMO can be patient related or mechanical. Patient related
complications include intracranial infarct or bleed, major bleeding, seizures, metabolic
abnormalities (renal failure), and infection. Meticulous monitoring, anticipation and
prevention and treatment of these complications is essential. Mechanical complications
include clots and air in the circuit, tubing rupture, cannula problems and oxygenator
failure. These technical problems require urgent corrective actions, and are kept to a
minimum by highly trained ECMO specialists.
1.6 Components of the ECMO Circuit
John Gibbon (1937) was responsible for developing the first extracorporeal
cardiopulmonary bypass (CPB) system. The machine provided oxygenation and
removal of carbon dioxide via direct contact between the blood and oxygen. The same
technique is still applied in the form of the bubble oxygenators, which are frequently
used during CPB in the operating room. However, direct blood-gas contact for longer
than approximately 6 hours results in red blood cell haemolysis, platelet consumption
and protein denaturation (Bartlett et al., 1976a). Bubble oxygenators are therefore not
appropriate for use in prolonged applications such as ECMO.
In order to enable prolonged ECMO support, a means for separating the blood
and oxygen is required. The ECMO circuit is comprised of four basic components:
plasticised polyvinyl chloride (pPVC) tubing, roller pump, membrane lung and heat
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exchanger (see Figure 1.1). These four components provide the goals of ECMO:
perfusion of warmed, oxygenated blood into the patient.
1.6.1 Circuit tubing
The tubing utilised in the ECMO circuit is TygonTMS-65-HL, a plasticised polyvinyl
chloride (pPVC) construct that is hematocompatible, with extended flex life and low
spallation (liberation of particles) properties (Peek et al., 2000; Peek et al., 1999). The
'raceway' tubing (the section within the pump housing which is swept by the rollers) is
advanced at specified intervals (usually every 1-7 days) dependent on pump flow rates
to avoid rupture due to wear (Zwischenberger et al. 20ooa).
Leaching of di-ethylhexyl-phthalate (DEHP), the most common plasticiser used
in PVC medical devices (Tickner et al., 2001), with subsequent accumulation in human
tissue and serum has been frequently documented (Ganning et al., 1984; Hillman et al.,
1975; Jaeger et al., 1970; Lewis et al., 1978), raising concerns (Hill et al., 2001;
Tickner et al., 2001). Particular concern has been raised in the paediatric setting because
of DEHP exposure in newborns, potentially receiving high doses from blood
transfusions and ECMO (Schneider et al., 1989; Sjoberg et al., 1985). In comparison to
other medical devices, infants on ECMO may be exposed to the greatest amount of
DEHP, between 42-140 mg/kg during the period on ECMO (Schneider et al., 1989).
1.6.2 Roller Pump
The roller pump has been integral to extracorporeal perfusion since the inception of
ECMO. However, it requires continuous servo-regulation and monitoring to prevent
application of high levels of negative pressure to the drainage circuit and high level of
positive pressure, with the risk of circuit disruption, to the infusion circuit should
occlusion occur. To prevent generation of negative pressures, a distensible 30ml
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silicone venous reservoir, which compresses a spring loaded mechanical switching
device that interrupts flow of power to the roller pump, is interposed between the
drainage line and the roller pump. The reservoir remains distended as long as venous
drainage is adequate for pump flow rate, and the reservoir pressure remains> -20
mmHg (26.7mbar). If pump flow rate exceeds venous drainage (for example due to
hypovolaemia, a kink in the venous catheter or connector tubing), the reservoir will
collapse, and the power to the pump will be interrupted (Zwischenberger et al, 2000a).
1.6.3 Oxygenator
The design of the oxygenator is central to the successful performance of prolonged
ECMO support. Excellent gas exchange must be provided while a separation between
the ventilating gas and the blood is maintained. The lung should also be non-compliant
so that the blood volume remains constant. Finally, blood flow characteristics must be
such that development of thrombosis and haemolysis is minimised. There are currently
two types of oxygenators that are commercially available for ECMO: membrane lung
and hollow fibre. Silicone membrane oxygenators are currently the standard device used
for ECMO patients of all ages worldwide. In the year 2000, 76% of all adult ECMO
runs were carried out using silicone devices (Peek et al., 2002). However, recently a
novel polymethyl pentene (PMP) hollow fibre oxygenator has been marketed, to
overcome some of the limitations of silicone membrane oxygenators (see below). The
Avecor® Silicone membrane oxygenator was in use at Glenfield Hospital until April
2002, after which it was replaced by the Medos Hilite® LT Hollow fibre oxygenator.
1.6.3.1 Silicone Membrane Oxygenator
First developed by Kobolow et al in 1963, this artificial lung consists of two sheets of
silicone that are separated by a polypropylene diamond mesh and sealed at the edges.
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Connector tubing segments at opposite ends are in continuity with the inside of the
silicone envelope (Figures 1.2 and 1.3). The envelope is wound on to a polycarbonate
spool. Blood flows through the connector tubing into a manifold region from which it is
distributed around the envelope of a membrane lung. Oxygen, mixed with small
amounts of carbon dioxide and/or room air, flows through the inside of the membrane
envelope in a counter current direction to blood flow. Membrane lungs are available
from 0.4m2 to 4.5m2 in surface area with relatively low priming volumes, lOOcm3 and
665cm3 respectively (see Chapter 3, Section 3.6). They have excellent gas exchange
properties because of the high residence time of blood as it flows between the coils of
the spiral wound membrane. Although areas of stasis occur, membrane lungs are
relatively non-thrombogenic with moderate levels of systemic anticoagulation. The
main disadvantages of the membrane lung are a high resistance to blood flow, and a
difficult and time consuming priming process (Zwischenberger et al. 2000b)
1.6.3.2 Medos Hilite® LT Hollow fibre oxygenator
This long term hollow fibre oxygenator designed for prolonged extracorporeal support
was launched in 2001. The gas exchange plasma tight (non porous) hollow fibres are
constructed from PMP and have an advantage over the older micro-porous capillaries in
that plasma leakage (plasma components on the gas side during long term use) is
prevented. The gas exchange efficiency of the hollow fibre lung is far superior to that of
the membrane lung. In addition it has a small priming volume, is non-compliant, and is
easy to prime and debubble. The hollow fibre oxygenator also has a lower resistance to
blood flow, a smaller surface area and a reduced propensity for platelet consumption,
compared to the silicone membrane oxygenator. This is as a result of a faster blood
transfer rate.
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Figure 1.2. Avecor™Silicone Membrane Oxygenators (Neonatal and Infant)
Figure 1.3. An unravelled Avecor™Silicone Membrane Oxygenator
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1.6.4 Heat Exchanger
Since heat is lost through the evaporation of water as blood flows through the artificial
lung, it is necessary to warm the extracorporeal blood before return. This is especially
important for newborn temperature maintenance. At times the heat exchanger may also
be used to cool the patient to a preset temperature in order to effect a decrease in oxygen
consumption, for example if cerebral hypoxia is a concern.
1.7 Drug Disposition During ECMO
Pharmacological therapy in the ECMO patient presents a challenge since the continuous
extracorporeal circulation of blood may conceivably impact on pharmacokinetics and
pharmacodynamics. Despite the rapid advancement in many of the technical aspects of
ECMO, much remains to be discovered regarding pharmacotherapy. Many of the
previous studies investigating the impact of extracorporeal circuits on drug disposition
have been in the context of CPB. These studies provide a useful introduction to the
complexities of the issues. However, whereas the CPB phase of cardiac surgery lasts a
few hours, ECMO support for cardiorespiratory failure may run for days or weeks.
Furthermore, many of the pharmacokinetic changes studied during CPB have been
hampered by the short time period on bypass, at most a few hours. Pharmacokinetic
analysis is often best conducted under steady state conditions, which for most drugs will
not be reached during bypass. Moreover, pharmacokinetic evaluation and modelling
assumes that the physiological processes remain fairly constant during the study period,
which is certainly not the case during CPB. Therefore, only limited conclusions may be
drawn from observations made during CPB, and cannot necessarily be extrapolated to
ECMO. It is also important to draw a distinction between the likely effects on
disposition of drugs administered prior to ECMO (bolus and continuous infusion),
where the initial effects of haemodilution and protein binding changes may be greater,
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and those administered during ECMO where sorption of drugs and altered hepatic and
renal blood flow may playa greater role.
The overall paucity of clinical data available on drug disposition in ECMO
presents a clinical challenge. Intensivists managing patients during ECMO should have
an understanding of the potential effects that extracorporeal circuits may have on the
disposition of drugs.
1.7.1 The Effects of Flow Rates and Injection Sites on Drug Delivery
One of the most fundamental differences between ECMO and non-ECMO patients is
the site of drug delivery. The ECMO circuit has multiple ports available for infusion of
drugs, blood products, parenteral nutrition, for blood sampling and for attachment of
CVVH circuits although the exact location of these ports varies amongst centres. The
method of drug administration during ECMO also varies amongst centres with no
current accepted or published guidelines.
Although it is possible to administer drugs via direct access into the patient,
systemic heparinisation necessitates minimal direct interventions, such as intravenous
line insertion, in order to avoid excessive bleeding. Drugs administered via an umbilical
venous catheter opening at the entrance of the right atrium may be recirculated to the
ECMO circuit, though there is probably an element of drug recirculation during VV
ECMO anyway (see section 1.7.4.2). Most drugs are therefore administered directly into
the ECMO circuit, although the exact location may differ amongst centres.
The effects of circuit injection sites and flow rates on the distribution of injected
solutions have been studied in vitro using isolated ECMO circuits with different sized
venous reservoirs (30 and 50cm\ minus the membrane oxygenator and heater (Hoie,
1993). A bolus of 0.8cm3 of Bordeaux red, a water-soluble dye, followed by a 3cm3
flush, was injected into the circulating fluid at sites proximal, distal and directly into the
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venous reservoir. Samples taken at varying ECMO flow rates and intervals were
analysed for dye concentration. Dye injected proximal and directly into the venous
reservoir pooled at the top of the reservoir at flow rates of 75 cm3/minute (such as
during the weaning phase of ECMO). The concentration of dye at the top of the venous
reservoir during stagnation was 30 times greater than in the ECMO circuit and this
stagnation lasted approximately one hour. Furthermore, the investigators determined
that some pooling of dye was possible at flow rates less than 250 crrr'rmtn. Dye injected
distal to the reservoir did not pool in the venous reservoir at any flow rate studied (Hoie,
1993).
These results may be explained by the lack of turbulence at low ECMO flow
rates, so that the dye, which has a lower specific gravity, stagnates at the top of the
venous reservoir, an area of decreased flow. In fact, the specific gravity of most drugs
used clinically is lower than blood and hence, pooling may contribute to incomplete
drug delivery. Although these results suggest that drug administration distal to the
reservoir may be optimal, this site increases the risk of air embolism. Thus many
ECMO centres choose to administer drugs proximal to the reservoir, allowing the top of
the venous reservoir to serve as an air trap.
1.7.2 Haemodilution
The most obvious alteration to pharmacokinetics occurs on initiation of ECMO, when
the patients own blood volume mixes with the priming volume in the extracorporeal
circuit. For example in neonates, the effective circulating volume will be approximately
doubled to 900cm3 on initiation of ECMO. One possible effect of this acute
haemodilution is a decrease in the total blood concentration of any drug present. The
pharmacological impact will depend on the apparent volume of distribution (V) of the
drug, the degree of protein binding and the extent of equilibration between tissue
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concentrations and plasma concentrations on initiation of ECMO. Drugs with a large V
(e.g. fentanyl) would be expected to show only a slight change following the expansion
of plasma volume, the initial lowering of plasma concentration from haemodilution
being counteracted by the back diffusion of the drug into plasma from the large tissue
reservoirs. In contrast, a drug with a small V (e.g. gentamicin) may be significantly
affected, since the resultant enlarged apparent V may affect elimination of the drug.
The acute haemodilution on initiation of ECMO also produces a large reduction
in circulating plasma protein concentration such as albumin and al acid glycoproteins.
In blood, drugs exist as free (unbound) drug in equilibrium with protein bound drug and
it is the free drug that interacts with the receptor site to exert a pharmacological effect.
For drugs that are highly protein bound, decreased concentration of binding proteins
will lead to an increase in the fraction of unbound drug. This favours transfer of drug
from the plasma to the tissues and contributes to the lowering of plasma concentration.
The pharmacodynamic result of this may be an increased effect because of an increased
free fraction at the receptor sight. Another effect is acute anaemia, which may affect the
degree of drug binding to red blood cells (Hynynen, 1987). This would be a transient
effect in ECMO however, as following cannulation it is standard practice to normalise
the effects of haemodilution by transfusing blood and related products, including
albumin.
The effects of continuous heparin administration on plasma protein binding may
also be of importance. In addition to displacing drugs bound to proteins, heparin induces
release of lipoprotein lipase and hepatic lipase, increasing the plasma concentration of
free fatty acids, which may further displace drugs from protein binding sites and
increase free drug levels with resultant enhanced pharmacological effect.
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The immediate effects on plasma concentration of haemodilution only
(disregarding changes in protein binding effects) may be described by the formula
(Mets,2000):
~Cp = Cpx Vc
(Vl+Vc)
~Cp = Change in drug concentration Vc = Volume of circuit
Cp = Plasma concentration prior to haemodilution
VI = Volume of distribution of the central compartment
1.7.2.1 The Effects of Haemodilution and Protein Binding changes on Drugs
administered during ECMO
The expanded circulating volume should not significantly affect drugs with a high V
and low protein binding administered during ECMO. However, it is possible that the
properties that confer a higher V (e.g. lipid solubility) may result in greater interactions
with the circuit (see Section 1.7.5). A drug with a low V administered during ECMO
will tend to have a lower initial plasma concentration due to the dilution effect and its
elimination may be significantly affected. The effect on a drug with high protein
binding will depend on whether the drug has a high or low extraction ratio. A drug with
high extraction ratio could have higher effective (free drug) plasma concentration
(because of decreased protein binding) through heparin displacement and hence greater
distribution into tissues resulting in a higher apparent V. A drug with a low extraction




Anderson et al (1992) noted an initial increase in bodyweight of between 5 and 30% in
neonates with severe respiratory failure post cannulation for ECMO. They attributed
this increase to the initial resuscitation prior to cannulation and intrinsic increases in
intracellular and extracellular water. Such a fluid expansion could significantly affect
the V of many water soluble drugs. Furthermore, many ECMO patients will require
CVVH in an effort to diurese to dry weight and improve lung function. Although
CVVH improves outcome, it adds uncertainty to the pharmacokinetics of drugs.
Perfusion of tissues may also be altered as a result of activation of the systemic
inflammatory response syndrome releasing a variety of autonomic, endocrine and local
cytokine reflexes that may affect not only tissue distribution of drugs but probably
clearance mechanisms as well (Gravlee et al., 2000).
1.7.4 Changes in Blood Flow
1.7.4.1 Pulsatile versus Non Pulsatile Blood Flow
Whereas VV ECMO results in pulsatile blood flow, VA ECMO at high low rates (> 100
cm3/kglmin) may produce non-pulsatile flow. Non-pulsatile blood flow can alter
perfusion of tissues, reducing capillary circulation and aerobic metabolism (Shevde et
al., 1987). Under experimental conditions, pulseless perfusion of the kidneys of dogs
resulted in reduced urine production and impaired sodium excretion, although
glomerular filtration was not affected (Many et al., 1986). The kidneys interpret
pulseless blood flow as hypotension and activate the renin-angiotensin system (Bartlett,
1990). Regional blood flow changes in the liver can also affect drug clearance, in
particular those drugs with a high extraction ratio e.g. propranolol, lignocaine
(Mckindley et al., 1998).
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1.7.4.2 Recirculation
The recirculation phenomenon is a major disadvantage of the VV mode of cannulation.
A fraction of blood that has been oxygenated in the circuit flows directly from the
reinfusion site to the drainage catheter and back into the circuit instead of the patient's
circulation. Figure 1.4 demonstrates this for a double lumen catheter used in neonates.
Four main factors affect recirculation: pump flow, catheter position, cardiac output and
right atrial size (intravascular volume). The most important parameter and one that
changes throughout the course of ECMO is pump flow. If the pump flow is high, the
drainage of blood from the right atrium back into the ECMO circuit is higher, and
streaming of blood from the reinfusion catheter to the venous drainage catheter is more
likely to occur (Figure 1.4). Recirculation fraction increases linearly with increasing
pump flow, whereas effective flow (oxygen delivery) versus pump flow reveals a non-
linear relationship (Figure 1.5). The reason for the decreased effective oxygen delivery
is that the recirculation proportion has limited the amount of oxygen delivered to the
patient.
Effective Flow = Total Flow - (Total Flow x Recirculation Fraction)
When total flow is zero, the effective flow is zero. At some maximal flow the
recirculation fraction is 100 %, and effective flow again becomes zero. The ideal pump
rate is the one that provides the highest effective flow at the lowest revolutions per
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Figure 1.5. The effect of recirculation (¢) on effective flow (.). As pump flow
increases, recirculation increases, whereas effective pump flow increases initially to a
maximum and then decreases.
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It can be postulated that recirculation will also have a significant effect on
pharmacokinetics. Consider a bolus dose of a drug administered into the circuit. At high
flow rates and therefore high recirculation, only a proportion of the dose will be directed
into the systemic circulation for distribution into tissues, the remainder will be
redirected into the circuit. Sampling of blood immediately after the dose would reveal
lower drug concentrations from systemic sites than from the circuit. At high flow rates
however, equilibrium between circuit and systemic drug concentrations would be
rapidly attained. The concentration-time profile would possibly reveal an ECMO
distribution phase, distinct from the tissue distribution phase. As well as influencing
distribution, elimination of drug is also expected to be reduced since less drug is
available to organs such as liver and kidney. The impact of recirculation is discussed
further in Chapters 5 and 7.
1.7.S Drug Sorption
1.7.S.1 Interaction of drugs with Plastic Intravenous Delivery Systems
The use of plastic components in intravenous delivery systems is widespread in clinical
practice. However, there has arisen the problem of drug sorption to the plastic and
consequent reduction in bioavailability. For example, drugs such as insulin, glyceryl
trinitrate and diazepam are well known to bind to plasticised polyvinyl chloride (pPVC)
infusion bags, administration sets and filters (Baaske et al., 1980; Cloyd et al., 1980;
HirschI, 1981; Kowaluk et al., 1981; Kowaluk et al., 1982; Martens et al., 1990; Parker
et al., 1980; Roberts et al., 1980). Such interactions may result in reduced drug delivery
to the patients and, in some cases, diminished therapeutic response (Kowaluk et al.,
1981). As the availability of medication through the intravenous route is of critical
importance in patient therapy, it is essential to know not only which substances may be
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lost during intravenous infusion, but also which drugs may be safely administered using
plastic intravenous delivery systems.
Factors affecting the degree of uptake include the physico-chemical
characteristics of the drug, the nature of the plastic, plastic surface area, solution
volume, solution pH, time and temperature (Kowaluk et al., 1982; Roberts et al., 1991).
The extent of ionisation and the lipid solubility of a drug are among the main physico-
chemical determinants of its sorption by plastic components. Previous studies have
shown that uptake of weakly ionised drugs by plastic infusion bags is pH dependent, the
loss being accounted for by the preferential uptake of the non ionised species (Kowaluk
et al., 1981). The octanol/water partition coefficient (log P value) is a measure of a
chemical compound's affinity for the organic or aqueous phase, or distribution between
the two. Thus compounds with a high ratio will be very soluble in organic materials
such as plastics and can be expected to exhibit considerable loss. Roberts et al (1991)
showed it is possible to predict drug loss given the log P value of the drug of interest
(Table 1.2). Differences in the predicted drug loss between l00cm3 and 500cm3 bags are
probably due to differences in the surface area to volume ratios (see below).
Table 1.2. Observed and Predicted Losses of Drugs from Sodium Chloride 0.9%
solutions stored in Polyvinyl Chloride Bags at 22°C for 8 hours
L_______ _ ~~!£..~_~L~LQ_~_g!~_~!__~_~~_~~_~!~~!i~!!_~~~~_
_________~ r~!=i=O~~~:±=:Q!i~r~t:=~~~:::
Diazepam ! 2.7! 59 I 41 i 31 I 27
-----------------------------------------J---------------,' ------------------------ri -----------------------1---------------------------+--------------------------
Oxazepam i 2.2 22 30! 12 I 16
I I I :
,I I I I~===~~itr~~~am=~~~Tr---15~~=--T--~~~~_=~~~~~J==~=~~~~~=I=~~=~--1~~~~=~
Glyceryl Trinitrate I 2.2 I 54 i 31 I - i 16
I I I I :
_______________________________ j'-------------1------------------+------------------4------- + _
Thiopentone ,3.0 I 25 ! 49 I - i 19
I! I I I------------------------------t----------i----------------------~----------------------1' ---------------------+--------------------
Pentobarbitone i 2.0, 0 ! 27 0 I 14
!! 1 ! i
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Studies on different types of plastics show differing degrees of sorption.
Sorption to containers, syringes and infusion lines can be avoided by using materials
such as glass, polyolefin (polyethylene or polypropylene) whilst studies with
polybutadiene manufactured and polyethylene lined pPVC administration sets have
revealed significantly reduced sorption (Bianchi et al., 1992; Kowaluk et al., 1983; Lee,
1986; Martens et al., 1990). The rate and extent of uptake for a given drug is
significantly higher in the more flexible pPVC and may be dependent on the nature and
concentration of the plasticiser or other additives used in the polymer (Yahya et al.,
1988).
Kowaluk et al (1980) and Baaske et al (1982) also demonstrated that the uptake
of drugs by plastic infusion devices is dependent on the surface area of plastic-to-
volume of solution ratio. The amount of sorption will increase when the ratio is higher.
For example, small containers will increase the amount of sorption because the ratio is
higher than in large containers (Table 1.2). This ratio and therefore consequent drug loss
is higher still in tubing compared to containers (Cloyd et al., 1980). Yliruusi et al. 1986
showed with simulations of diazepam infusions through pPVC intravenous
administration sets that sorption of drug is a biexponential process and is dependent on
duration of infusion as well as length of tubing. Furthermore, in a follow on study the
same workers also revealed that sorption was highest when the diazepam infusion rate
was lowest (Yliruusi et al., 1986).
1.7.5.2 Drugs sorption by Extracorporeal Circuits
Much of the work investigating drug uptake by extracorporeal circuits has been carried
out as in vitro experiments in CPB circuits. These report significant sequestration of
opioids (alfentanil, fentanyl, morphine), benzodiazepines (midazolam, diazepam,
lorazepam), glyceryl nitrate and propofol (Booth et al., 1991; Dasta et al., 1983; Dasta
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et al., 1986; Hynynen, 1987; Hynynen et al., 1994; Keaveny et al., 1991; Koren et al.,
1984; Rosen et al., 1988a; Rosen et al., 1988b; Silvasi et al., 1989; Skacel et al., 1986).
The component with the greatest capacity for binding is the silicone membrane
oxygenator (Rosen et al., 1990). Furthermore, reversibility of this binding appears to be
related to the drug's protein-binding characteristics, lipophilic drugs that are more
highly protein bound displaying more reversibility (Rosen et al., 1990). The majority of
CPB oxygenators currently available on the market today are polypropylene based.
They have a microporous structure in a microtubular or sheet design and appear to
sequester drugs to a much lesser degree (Rosen et al., 1990).
The component materials of an ECMO circuit are very similar to the CPB
circuit. The circuit tubing is composed of pPVC whilst the most common oxygenator is
the Avecor™ silicone membrane construction. It is therefore perfectly plausible that
both of these components will lend themselves heavily to drug sorption and hence
reduce bioavailability since the patient's blood is continuously exposed to a large
surface area during ECMO. Comparatively fewer in vitro investigations have been
conducted in ECMO circuits (Table 1.3) (Dagan et al., 1993; Marx et al., 1991).
The clinical significance of sorption may be difficult to predict. A susceptible
drug administered as a bolus dose may result in attenuation of the expected plasma
concentration. This is likely to be a first order process i.e. fractional uptake is
independent of circulating concentration. The rate of uptake into the plastic is thought to
be an equilibrium process between the mobile phase (blood) and the plastic
components, although true equilibrium will not be attained in a flowing circuit. Thus,
the level of drug reaching the patient will be at some intermediate concentration
between that injected and the steady state equilibrium value. In a drug with a small V,
the pharmacological impact of the decrease in plasma concentration will depend on the
effect this will have on the concentration at the receptor site. Drugs with a large volume
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of distribution may be less affected since any drug removed by the circuit will be
replaced by the large tissue reservoirs.
Table 1.3. Sorption of Drugs by the ECMO Circuit
Ii Component TestedI I
" ~-----.-------------------------
Drug Referenees I Circuit ~ pPVC I Silicone Membrane log P
------Pheoyioiii--------j--- D~gan et ai~---r--?- -::---r-----:-----I--z.5-
---------~~!~~--------- -- - --~~~:----------t_--------j---------------J--------------------------------------j----------------
I Marxetal., 1991, - I ./, X I
Phenobarbitone I I I 1.5
Sodium Dagan et al., ! ./ I I I
1993 I I I ,
---------------------------------~------------------------t---------------1----------------J------------------------------------------1-----------------
Gentamicin ',' Dagan et al., i ./ II - I - ,I Ve~
Sulphate 1993, Low"
------------------------------------1-------------------------f-------------j------------------i----------------------------------11--------------
Vancomycin I Dagan et al., I ./ I - I - Very
Hydrochloride I 1993 ! I i I Low"
I : I
./ = Loss of drug X = no loss of drug
a. Log P values not be determined since their partition coefficients are less than or equal to the minimum
values (Jenke, 1994).
The impact of this phenomenon may also be different in CPB compared to
ECMO because the two processes differ in terms of time span. For example. uptake of
drugs is assumed to be a first order diffusion process with circuit polymers behaving as
sinks (see Chapter 3). This assumption will only apply for the time before drug diffuses
to the outside surface of the plastic. An estimate of the lag time for the appearance of
the drug in the outside environment assumes a constant concentration of drug in
solution and is defined by the thickness of the plastic and diffusivity of the drug in
plastic. For most drugs this is only likely to be reached during prolonged administration
(greater than 7 days), and therefore only in ECMO (Roberts et al., 1991). Furthermore,
in an ECMO circuit that has been used for several days it is possible that once infusion
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of drug ceases, sequestered drug will be liberated back into the circulating blood,
prolonging the pharmacological effect. In fact it is also conceivable that metabolites of
parent drugs or another co-administered drug that has a higher affinity for the circuit
plastic may affect the rate of uptake of the parent drug.
1.7.6 Photodegradation
The catalysis by light of drug degradation reactions such as oxidation or hydrolysis, has
been reported for a number of drugs; amphotericin B, furosemide, dacarbazine,
doxorubicin, vitamin A and sodium nitroprusside (Trissel, 2001). Sodium nitroprusside
is so susceptible to photodegradation that during normal (non-ECMO) clinical use the
intravenous container and administration set is protected from light by wrapping in foil.
A variety of reactions may occur from the absorption of radiation energy, but the net
effect is that energy concentrated at a chemical bond causes it to break or to rearrange
into a new chemical entity. The energy imparted per photon of light increases as the
wavelength increases. Consequently, ultraviolet light is more deleterious than visible
light and daylight is more deleterious than fluorescent light. Photodegradation reactions
also depend on the intensity of the light source, and therefore the closer the photolabile
drugs are to these light sources, the greater the rate and degree of photodegradation
(Trissel,2oo1).
The patient supported by an ECMO circuit is in a unique clinical scenario, since
the patient's blood circulation passes through a transparent pPVC tube circuit, exposed
to light. Thus drug in circulating blood, periodically and for a length of time dependent
on the pump flow rates, is exposed to light. The nature of the light will on the whole be
fluorescent, though ECMO circuits may be exposed to some sunlight depending on their
position in the intensive care unit. Such exposure of drugs in blood to light has not been
investigated, but it is plausible that susceptible drugs may be significantly affected.
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Although this is not an area explored, drugs investigated in this thesis are not acutely
degraded by light in aqueous solutions (Trissel, 2001). Drugs used for in vitro
evaluation in this thesis showed no loss when exposed to ambient light (See Chapter 2,
Section 2.3.1), though photodegradation may be an issue with drugs such as
amphotericin B, often used during ECMO to treat fungal infections and septicaemias.
1.8 The Effect of ECMO on the Disposition of Specific Drugs
1.8.1 Fentanyl
Although opioids are extensively used in infants during ECMO, very few studies have
investigated their disposition. In contrast, the disposition of opioids (apart from
morphine) during CPB has been extensively reported (Bovill et al., 1980; Hug et al.,
1994; Hug et al., 1982; Koren et al., 1984; Kumar et al., 1988; Lunn et al., 1979;
Robbins et al., 1990; Sprigge et al., 1982).
1.8.1.1 Haemodilution
Studies of single large bolus doses of fentanyl (60-75~glkg) administered at induction
of anaesthesia to adult cardiac surgical patients, have demonstrated reductions in plasma
concentrations of fentanyl of between 30-60% of pre-CPB concentrations within
minutes of the onset of CPB. This decrease was greater than that which could be
attributed to haemodilution alone. The concentration of fentanyl remained stable during
CPB. In these studies, bubble oxygenators, crystalloid primes and hypothermia to 25 -
30 DCwere used (Bovill et al., 1980; Hug et al., 1982; Lunn et al., 1979). Studies
investigating the continuous infusions of fentanyl, started before CPB, at an initial high
rate (30-50 ug/kg/min) followed by a lower maintenance infusion (0.15-0.5~glkglmin),
have demonstrated a smaller decrease (mean 30%) in plasma concentrations at the onset
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of CPB compared with a single large bolus dose (Hug et al., 1982; Sprigge et al., 1982).
This is presumably because the maintenance of continuous infusion counteracts the
initial decrease. Furthermore, during CPB, the concentration of fentanyl returned to near
pre-CPB values within 30min.
1.8.1.2 Sorption
In vitro investigations have demonstrated significant sorption of fentanyl by
components of the circuits (Hynynen, 1987; Koren et al., 1984; Rosen et al., 1988a;
Skacel et al., 1986). Addition of fentanyl to the prime was shown to prevent the initial
decrease in plasma concentration at the initiation of bypass, but after 2.5 minutes similar
concentrations to those measured without the addition of prime were recorded
(Hynynen, 1987). A decrease in concentration of 68% was observed after the first pass
through a membrane oxygenator (Rosen et al., 1985). Loss of fentanyl was greater at
high pH, suggesting lipophilic (non ionised) binding to the circuit (Skacel et al., 1986).
The use of bubble or membrane oxygenators, or blood or crystalloid solutions for
priming did not appear to influence the degree of sorption, although subsequent studies
revealed that membrane oxygenator type does have a bearing (Hynynen, 1987; Rosen et
al., 1989).
In contrast to fentanyl, studies investigating the sequestration of alfentanil to
bypass circuitry have shown zero or minimal loss using both membrane and bubble
oxygenators (Hynynen, 1987; Skacel et al., 1986). In fact, free alfentanil concentrations
have been shown to remain relatively constant throughout CPB, as a result of an
increase in the unbound fraction. The decrease in total alfentanil concentrations was
explained by a dilution of a.l acid glycoprotein (Hug et al., 1994; Kumar et al., 1988).




In a retrospective review of 37 newborn infants on ECMO, unexpectedly large doses of
fentanyl to achieve adequate sedation were reported, with the infusion rate of fentanyl
increasing with length of time on ECMO (Leushen et al., 1993). Withdrawal symptoms
were observed in 57% of the neonates, duration of ECMO being the most powerful
predictor. In the same study, continuous infusion doses of fentanyl were correlated with
plasma fentanyl concentrations in five neonates. Plasma concentrations climbed steadily
during the period of infusion, suggesting the development of tolerance to the sedating
effects and possibly explaining the large doses administered. The authors suggest that if
binding to the ECMO circuit was the reason for the increased dosing requirements, the
dose would have decreased over time as the membrane oxygenator became saturated
(Leushen et al., 1993).
In another prospective study, plasma levels of fentanyl were analysed in 12
infants undergoing VA ECMO who received a bolus dose followed by an infusion.
Plasma levels were taken 6 hours following the initiation of infusion. This time lag was
chosen as the researchers felt this would ensure the membrane oxygenator would reach
saturation. Adequate sedation was achieved in all neonates with continuous infusion
doses not exceeding 7J.lglkglhour. Overall, there was no correlation between the plasma
fentanyl levels and either the time on ECMO or the fentanyl infusion rate. The plasma
levels generally increased over the first four days and then tended to decrease thereafter
without significant increase in infusion rates (Leushen et al., 1993). The authors
attributed the elevations in plasma levels to decreased clearance, and curiously
correlated this with renal function despite evidence that fentanyl is primarily cleared via
the liver (AHFS Drug Information. 2001). However, a rise in plasma levels is expected
with continuous infusion as a steady state level is approached. Although not clear from
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the data provided, the decrease in plasma levels beyond day 4 may have been related to
the improvements in the patient's hepatic and pulmonary blood flow.
I.S.2 Morphine
Although there has been little work on the effect of CPB on plasma morphine
concentrations, there have been 2 in vivo (Dagan et al., 1994; Geiduschek et al., 1997)
and 1 in vitro (Dagan et al., 1993) study investigating morphine disposition in ECMO
(Tables 1.3 and 1.4).
I.S.2.1 Sorption
Dagan et al (1993) conducted a preliminary study of the in vitro effects of two ECMO
circuits (primed with blood) on the disposition of common paediatric drugs (Table 1.3).
One circuit was new and the other was used clinically for 5 days. Blood samples drawn
from the circuit at 10,30,60 and 240 minutes revealed a 36% decrease in the morphine
concentration in the new circuit and a lesser decrease of 16% in the used circuit. These
results suggest that the process of drug uptake may be influenced by factors such as
prior exposure of the circuit.
I.S.2.2 Pharmacokinetic Studies
In a prospective comparative study, Dagan et al (1994), investigated morphine
pharmacokinetics during and after ECMO. They did not stipulate whether it was VA or
VV EeMO, although stated that it was for cardiopulmonary support, implying VA
EeMO. Data was collected on seven infants (age range 1 day to 12 months) receiving
continuous infusion of morphine between 20 and 40~glkglhour. The opioid infusion rate
remained unchanged for at least 22 hours during EeMO, and the infusion rate was not
changed after decannulation. Blood samples were taken at 10 hour intervals whilst on
EeMO and off EeMO. Mean morphine serum concentrations were found to be twice
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those taken after EeMO was discontinued. Two of the study infants (neonates aged 1
and 2 days) who recorded the steepest decline in serum morphine concentrations post
EeMo, experienced symptomatology consistent with opioid withdrawal. The calculated
clearance of morphine approximately doubled when the infants were taken off EeMO
(Table 1.4).
Table 1.4. Summary of mean (SD) pharmacokinetic values obtained in neonatal
ECMO patients
Tl/2
* Comparison of values obtained during ECMO and after decannulation
The authors suggested that impaired hepatic metabolism and/or hepatic blood
flow may be the reason for decreased clearance on EeMO, although there was no
clinical evidence of this and no direct measurement of hepatic blood flow was
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conducted. A renewal of blood flow to the lungs at the end of ECMO and therefore an
increase in V causing an initial decrease in the serum concentration was also suggested
as a possible reason. However, this would have been a transient effect and mean steady
state concentrations should return to normal. The researchers conclude that the
mechanisms leading to the changes in morphine disposition are unclear, but it is wise to
carefully monitor pharmacological effects on and off ECMO (Dagan et al., 1994).
In another prospective study by Geiduschek et al (1997), morphine sulphate
pharmacokinetics during continuous infusion was determined in 11 neonates with
severe persistent pulmonary hypertension and receiving VA ECMO support. All
patients received 1 or 2 boluses of morphine before commencing an infusion of 10-20
ug/kg/hour. Blood samples were taken at baseline (before the cannulation procedure)
and compared with samples obtained from sites immediately proximal and distal to the
membrane oxygenator at 5 mins, and 1 and 3 hours after commencement of ECMO.
Morphine clearance was also calculated using paired samples collected on days 1, 3 and
5 of ECMO, beginning at least 12 hours after the start of ECMO and any change in
morphine infusion rate.
A baseline (pre ECMO) morphine concentration was only obtained in 5 patients.
No significant decrease in serum morphine concentrations was seen in these 5 patients
on initiation of ECMO. This is somewhat surprising since a decrease in concentration
would have been expected due to the haemodilutional effect. It is possible that since the
first sample was not collected until 5 minutes, the plasma levels had re-equilibrated
from tissue stores. Morphine concentrations were also not significantly different in
samples obtained simultaneously from sites immediately proximal and distal to the
silicone membrane oxygenator, suggesting that morphine sulphate does not bind to the
membrane oxygenator. Values for clearance were significantly depressed in 4 patients,
although clinical information regarding their hepatic and renal function was not
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supplied. Three patients in the study had a primary diagnosis of congenital
diaphragmatic hernia, although it was not stated if these were included in any of the 4
patients with depressed clearance. Five patients had increased clearance during ECMO,
contradicting the results of the previously discussed study. The authors conclude that
the clearance for morphine in patients receiving ECMO is variable and the range of
clearance values exceed those published previously for infants who are receiving
morphine infusions (Geiduschek et al., 1997).
1.8.3 Benzodiazepines
1.8.3.1 Haemodilution
The administration of a bolus dose of midazolam (O.15mglkg) was found to suffer a
decrease in concentration on establishing CPB and an increase in concentration post
CPB with a prolonged elimination half-life (Kanto et al., 1985). Dawson et al (1997)
noted that although the total concentration of midazolam dropped on CPB, the unbound
concentration remained stable, and so the unbound fraction had increased from 5.6% to
11.2%. Similar effects have been observed with lorazepam (Boscoe et al., 1984).
1.8.3.2 Sorption
Although sorption of benzodiazepines in contact with pPVC intravenous administration
containers and administration sets has been frequently demonstrated (see Section 1.6.5),
no such studies with ECMO circuits have as yet been reported.
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1.S.4 Propofol
Although the therapeutic use of propofol in paediatric or adult ECMO has not been
described, it has been widely studied in the context of CPB, with conflicting results
(Dawson et al., 1997; Hammaren et al., 1996; Massey et al., 1990; Russell et al., 1989).
In two studies, the initiation of bypass, when propofol was being administered as a
continuous infusion of 3-6mglkglhr, resulted in a decrease in total concentration of 50-
78% (Hammaren et al., 1996; Russell et al., 1989). A corresponding increase in free
fraction and free concentration was demonstrated, probably from haemodilution. In
another study, no change in total concentration of propofol was observed (Massey et al.,
1990).
Propofol is a highly lipophilic (log P 3.7) and protein bound drug and therefore
significant sequestration by the extracorporeal circuit is expected. In an in vitro
evaluation of propofol interactions with closed CPB circuits, Hynynen et al (1994)
reported that at 5 and 120 mins after addition of propofol into the circulating solution,
only 65% and 25%, respectively, of the predicted levels were measurable in the
solution. Hammaren and colleagues (1999) demonstrated that priming CPB circuits with
heparin did not prevent loss of propofol during in vitro tests. Although the sorption of
propofol to components of the ECMO circuit is anticipated, no such studies have as yet
been conducted.
1.S.S Anticonvulsants
Marx et al (1991), evaluated the interaction of phenobarbitone with the ECMO circuit
prompted by a retrospective chart review of 20 neonates on ECMO, which showed that
twice the normal doses were required to maintain therapeutic drug concentrations.
However, specific doses and serum concentration data were not revealed.
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The in vitro evaluation of phenobarbitone interactions from three repeat
investigations revealed mixed results. In two of the three experiments, phenobarbitone
concentrations were within 90% of expected values. However, the third circuit had only
47% of the expected level. Furthermore, the researchers were able to extract the
sequestered phenobarbitone from the circuit using methanol.
Dagan et al (1993), have also demonstrated similar in vitro loss of
phenobarbitone and phenytoin in ECMO circuits. This may explain an increased V for
phenobarbitone observed in a neonate on ECMO (Elliott et al., 1999).
1.S.6Glyceryl Trinitrate.
GTN may be administered during ECMO to treat hypertension and/or to prevent cardiac
ischaemia. It is possible however that bioavailability is reduced since there is substantial
loss to the circuit and oxygenators (Booth et al., 1991; Dasta et al., 1983; Dasta et al.,
1986). This is anticipated since the drug is known to be sequestered by several plastics
(Baaske et al., 1980).
1.S.7Antibiotics
1.S.7.1Gentamicin
Gentamicin pharmacokinetics has been widely studied in ECMO with varying results
(Table 1.4) (Bhatt-Mehta et al., 1992; Cohen et al., 1990; Dodge et al., 1994;
Munzenberger et al., 1991; Southgate et al., 1989). Although an increase in V is
hypothesised, results from three studies did not support this (Bhatt-Mehta et al., 1992;
Munzenberger et al., 1991; Southgate et al., 1989). However, prolonged half-lives and
decreased clearance was demonstrated in all but one of these studies (Muzenberger et
al., 1991). The choice of historical controls used in this one study was probably
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inappropriate. A fourth study compared gentamicin pharmacokinetics in neonates who
continued on gentamicin after coming off ECMO (Cohen et al., 1990). They reported a
decrease in V after cessation of ECMO and suggested that a loading dose was required
to attain appropriate therapeutic levels. In a fifth study by Dodge et al (1994), data from
11 neonates who received gentamicin on ECMO, including 6 infants who received
gentamicin both on and off ECMO, was presented. For six infants, while on ECMO
their median V was 0.748 Ukg, considerably greater than the median V of 0.47 Ukg
after ECMO was discontinued. Clearance was also shown to be reduced whilst on
ECMO (median 0.239 Uhr versus 0.350 Uhr). Similarly, median half-life was 9.24 hr
on ECMO compared with 3.87 hr when off ECMO. The range of target peak and trough
plasma levels recommended by all the groups was 5-8 and <2.0 mg/L, respectively.
1.8.7.2 Vancomycin
Vancomycin pharmacokinetics during neonatal ECMO has also been described (Table
1.4) (Amaker et al., 1996; Buck et al., 1998; Hoie et al., 1990). The results of these
studies are described in detail elsewhere in this thesis (See Chapter 7).
1.9 Pharmacokinetic Investigations in Clinical Practice
The development of pharmacokinetic principles and subsequent application to the
evaluation of drug disposition in man has resulted in an understanding of the processes
of absorption, distribution, metabolism and elimination (Sheiner et al., 1977).
It is now widely recognised that point estimates of pharmacokinetic and
pharmacodynamic parameters are often inadequate, and it is more appropriate to
describe parameters by a probability distribution. An important factor driving the
change to probability based estimates of parameters is the recognition that there can be
significant variability in dose-response in human populations. Conceptually, variability
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in dose-response is caused by variability in pharmacokinetic and pharmacodynamic
responses. The former relates to variability in tissue concentration-time profiles,
whereas the latter to variability in the response on a given target tissue dose (Sheiner et
al., 1977). The influence of patient characteristics such as body weight, gender, age,
physical and pathophysiologic states, genetics, environment and concurrent therapy on
various pharmacokinetic parameters has received extensive attention. This appreciation
has resulted in a proliferation of studies designed to quantify the effect of these factors
on drug pharmacokinetics with the overall goal of minimising the extent of unexplained
variability (Sheiner et al., 1977).
Certain groups, however, including the elderly, critically ill and paediatric
patient population have proven difficult to study because of the ethical and logistical
issues which arise when one attempts to subject these patients to the rigors of a
pharmacokinetic trial (see section below). The application of pharmacokinetics during
normal clinical practice (outside the confines of a controlled study) is often limited to
those drugs monitored routinely as part of the assessment of therapeutic effect.
Pharmacokinetic parameters are estimated from limited observations using log linear
regression analysis. Dosage adjustments are then based on these estimates. However, in
order to address the effect of pharmacokinetic variability on dose response, it is
necessary to progress from pharmacokinetic models for the 'average' individual to
population pharmacokinetic models.
1.10 Problems in Performing Pharmacokinetic Studies in Children
The ethics of non-routine blood sampling from children has been much debated, and
many studies have relied on the 'in practice approach' with samples being taken for
routine therapeutic drug monitoring. Recently though, the Royal College of Paediatrics
and Child Health (RCPCH) has assessed the taking of blood samples as a low risk
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procedure. This aside, the Royal College emphasises that children do fear needles and
so a careful explanation for the need of venepuncture and the application of an effective
local anaesthetic cream is important. Informed consent from the patient or their
guardian must be obtained and it is considered inappropriate to insist on taking blood
samples where a child indicates otherwise (RCPCH, 2000). Pharmacokinetic
investigations in neonates can be especially difficult due to the small blood volumes
available. The use of urine and saliva samples has obvious attractions in children.
Blood sampling can be kept to a minimum by the use of Bayesian forecasting
whereby only one or two blood samples are required. Bayesian programs combine
measured concentrations and information from population studies to estimate a
posteriori CL and V parameters and design dosage regimens for individual patients
(Lannigan et al., 2001). Although originally developed for adults, such programs have
been adapted for use in neonates (Lannigan et al., 2001). However, the paucity of
paediatric population pharmacokinetic parameters is the main limitation to the use of
this method. Sheiner and colleagues (1977) have advocated the use of information
generated during the routine care of patients to obtain estimates of population
pharmacokinetic parameters. These parameters can then be used to assist the clinician or
clinical pharmacist in making decisions regarding drug prescribing for patients.
1.11 Population Pharmacokinetics
Population pharmacokinetics is the study of the time course of a drug and its
metabolites in groups of patients having similar characteristics. The approach is to
develop a model, identifying the measurable pathophysiologic factors that cause
changes in the dose-concentration relationships and the extent of these changes so that
dosages can be modified if there are clinically significant shifts in the therapeutic index
(Guidance for Industry: Population Pharmacokinetics. (1999). US Department of
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Health and Human Services Food and Drug Administration). Such guidelines, in an
ideal scenario, would allow the clinician to select an appropriate dosage regimen once a
patient has been characterised with respect to medical history, diagnosis, physical
examination and clinical laboratory tests. Of course, essentially all models are imperfect
and therefore a dosage regimen predicted for an individual may vary to some degree
from the optimum regimen (Ludden, 1988).
The magnitude of unexplained (random) variability is important because the
efficacy and safety of a drug may decrease as unexplainable variability increases.
Sources of variability that contribute to differences between predicted and observed are
categorised as interpatient and intrapatient in origin. The presence of interpatient
variation suggests that even though expected parameter values can be calculated for an
individual based on the population mean, the particular individual at hand may have
parameter values that differ from the expected values (Ludden, 1988). Intrapatient
variability (also known as residual error) is exemplified in the degree to which steady
state drug concentrations within individuals typically vary when followed over a course
of time. Concentrations may vary due to inexplicable day to day or week to week
kinetic variability, or measurement errors or model misspecification. Estimates of
residual error are particularly important for therapeutic drug monitoring.
1.12 Approaches to Estimating Population Pharmacokinetic Parameters
There are a number of methods for obtaining estimates of population pharmacokinetics
parameters: -
1.12.1 Naive Pooled Data
This method consists of pooling all drug concentration measurements from individuals,
and analysing them together as though they all came from the same individual. These
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yield point estimates and standard errors from which 95% confidence regions can be
computed. No estimates of the random interpatient effect on parameters are obtained,
and the estimate of interpatient variability that is obtained is actually an estimate of the
magnitude of the variability from all random sources, and therefore is of limited
interest.
1.12.2 Two Stage Method
This approach proceeds in two stages. First each individual's data are separately fitted,
using nonlinear (weighted) least squares. For each individual, estimates of parameters
and the residual sum of weighted squares are obtained. Population averages and
standard deviations are then estimated from the sample of individual parameters using
standard statistical methods. Although this approach gives unbiased estimates of
population averages of pharmacokinetic parameters, estimates of variability are biased
towards higher values. Furthermore the two stage approach is strictly applicable to data
from balanced experiments, such as randomised controlled trials, and sufficient data
from each individual are needed to estimate the pharmacokinetic parameters of the
individual. This approach cannot therefore utilise the significant amount of sparse,
unbalanced data that is routinely collected in clinical settings.
1.12.3 Non-Linear Mixed EtTectsModels
In sparse data situations, where the traditional two-stage approach is not applicable
because estimates of individual parameters are, a priori, out of reach, a single-stage
approach such as non-linear mixed effects modelling can be used (Guidance for
Industry: Population Pharmacokinetics. (1999). US Department of Health and Human
Services Food and Drug Administration). The major advantage of the approach is that it
uses individual pharmacokinetic data of the observational type, which may be sparse,
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unbalanced, and fragmentary, in addition to, or instead of, conventional
pharmacokinetic data from traditional pharmacokinetic studies characterised by rigid
and extensive sampling design (rich data situation).
In mixed effects modelling, the population pharmacokinetic model consists of
mean parameter values (also known as fixed effect parameters) and their variability
within the population (also known as random effects parameters). In contrast to the two
stage method, the approach consists of estimating directly the fixed and random effects
parameters of the population from the full set of individual concentration values.
Importantly, the individuality of each subject is maintained and accounted for, even
when the data are sparse (Guidance for Industry: Population Pharmacokinetics. (1999).
US Department oj Health and Human Services Food and Drug Administration).
As is expected, attention to sampling times can increase the quality of the
information obtained. Samples obtained at the time of peak serum concentrations
usually contain the most information about the V whereas samples obtained at later
times are informative about CL (Ludden, 1988). Steady state peak and trough are useful
when both V and CL are to be estimated. Data obtained prior to the attainment of steady
state provide particularly useful in formation about V and CL (Ludden, 1988),
1.12.4 Computer Software for Population Pharmacokinetic Modelling
When there are not sufficient data to estimate regression parameters for each individual,
population parameters may be estimated using methods based on first order linearisation
of a hierarchical non-linear model (see Appendix II). These methods are based on
approximations to the marginal likelihood within the relevant non-linear mixed model
framework and are computationally, extremely intensive. A number of computer
software packages are available for population pharmacokinetic analysis. The one used
throughout this project is WinNonMix, Version 2.0.1. The output from the WinNonMix
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program contains many important components. However, WinNonMix is only an aid or
tool for the modelling process. As such, it can only use the model and data supplied by
the researcher and find a 'best fit' of the model to the data. The program cannot
determine the correctness of the model; nor can it determine the value of any decisions
or interpretations based on the model. The program does, however, provide some
information about the 'goodness of fit' of the model to the data and about how well the
parameters are estimated. These include the objective function value (minus 2 x log
likelihood), the population parameter estimates and their variances, the standard errors
(indicating the precision of the estimates), the covariance matrix and correlation matrix
of the estimates, scatter plots of parameters, weighted residuals and their relationships
with covariates. The entire output is necessary in assessing the goodness of fit.
In addition the individuals' parameter estimates are also determined. These are
derived based upon Bayes theorem for conditional probabilities. The population
information and the patient specific data are combined to predict the most probable
parameter values for an individual patient from the observed concentrations.
1.12.5 Assessing Goodness of Model Fits
Although statistical tests such as the objective function value (OFV) are useful in
comparing hierarchical models, it is not the only test for model discrimination. The
standard errors, covariance and correlation matrices of the estimates provide
information about the parameter estimation procedure itself. For example, poorly
estimated parameters may exhibit large relative standard errors or there may be high
correlation between parameter estimates. Difficulties in parameter estimation may arise
because there is insufficient data to support the parameters or because of inappropriate
initial parameter estimates. Scatterplots are extremely useful for initial examination of
the data set for input errors and for obvious correlations. Moreover, critical analysis of
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plots of weighted residuals versus predicted concentrations, time and other covariates is
essential. A non random distribution of weighted residuals indicates that the model used
is not entirely appropriate, usually indicating that the model is not adequately
parameterised. For example, the model needs to be changed from a one to two
compartment model. A model is thought to be good when (Gabrielsson et al., 2000):
~ Predicted values mimic data and residuals show random scatter
~ Parameter estimates are unbiased and have high precision
~ Parameters have low correlation
1.13 Local Experience with Pharmacotherapy during ECMO and Background to
the Research Project
In the paediatric intensive care unit at this institution, midazolam and morphine are the
most commonly used agents for sedating ECMO and mechanically ventilated non-
ECMO (mainly post-operative cardiac surgical) infants. It had been noted by clinicians
and nurses that doses of sedati ve drugs required to achieve desired levels of sedation in
ECMO patients were far greater (between 2-10 times) than for non-ECMO patients, a
phenomenon that has previously been reported by other workers (Rosen et al., 1991;
Tobias et al., 1995). These differences could not readily be accounted for by any
variation in patient types, clinical status or sedation levels. Furthermore, once ECMO
patients were decannulated, their sedative requirements often decreased considerably to
more 'normal' levels, once again suggesting that the ECMO circuit may have an effect
on drug disposition.
To test the hypothesis that neonates receiving ECMO require higher doses of
sedation, a retrospective audit to determine and contrast doses of midazolam and
morphine administered to comparable ECMO and post cardiac surgical neonates in the
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PICU was undertaken. Inclusion criteria included comparability in terms of age and
duration of ECMO and mechanical ventilatory support. The data was compiled as 12
hour cumulative doses for midazolam and morphine respectively. For direct comparison
with the post cardiac surgical neonates only data from the first 72 hours was utilised.
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Figure 1.6. Total doses administered in the first 72 hours (A) Morphine (B)
Midazolam
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Table 1.5 Doses of Midazolam and Morphine administered over a 72 hour period
I Midazolam Morphine
! It-----------r-------------t--------------1----------------
i ECMO ! Cardiac I ECMO Cardiac-----------------------------------t-----------+-------~---------1----------------
I 21283 " i 2364
Mean Total dose (JIg) (SD) I (10446) 9599 (5504) I (1280) 1158 (457)
__________________________________________________~--- L ~----------------- _
! I
I II:p = 0.0076
I I------------------------------------------------------1------------------------------1-------------------------------------------
Estimate ofDiffe~nce (JIg) ,I 11684 (4365, 19003) I 1206 (364,2048)
(95% Confidence Intervals) I !
----------------------------------------t---------r----------r---------]-------------------
Min-Max doses (Jlg/kglhour) I 112 - 503 I 25 - 240 I 9 - 70 4 - 27
_______________________________________________ ~------ ...J ~-------------- _
Recommended Dose Range i 30-200 I 10-30
(Jlg/kglhr)B I j
p-value p = 0.017
a.Medicines For Children (2000).
The results revealed that total doses of midazolam and morphine administered
were higher in the ECMO neonates over the first 72 hours. Differences in the mean total
doses administered to the two groups were significant for both midazolam (p=0.0076)
and morphine (p=O.O17) with the estimate of difference suggesting doses administered
to the ECMO neonates were of the order 2-3 times the post cardiac surgical neonates.
The range of midazolam doses administered to the ECMO and non-ECMO neonates
(112-503 ug/kg/hour versus 25-240 ug/kg/hour, respectively) reflect not only the wide
interpatient variability, but also differences in the hourly requirements between the two
groups. Similar results are observed with the morphine. In addition, whereas doses
administered to the cardiac patients reflected the 'normal' recommended doses for
ventilated neonates (30-200 J.lg/kglhour), the doses administered to the ECMO neonates
were frequently above the upper normal range (Table 1.5) (Medicines For
Children,2000 ).
Since the same clinical staff cares for both groups of patients on the same
intensive care unit, it can be assumed that bias as a result of differing knowledge,
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philosophy and practice had to a large extent been reduced. Although it could be argued
that the goals of sedation may at times be different between neonates on EeMO and
those requiring mechanical ventilation, such divergent aims could not explain the
differences in total doses of the order of 2-3 times. These results suggested altered drug
disposition during EeMO.
In addition to the sedation experience, it was felt that potentially toxic steady
state gentamicin trough and aminophylline levels were observed with greater frequency
amongst EeMO compared to non-EeMO neonates. This resulted in an opposite
response to the sedation issue i.e. a dose reduction.
1.14 Aims of the Research
Patients supported by EeMO receive a myriad of pharmacological agents, yet there are
few reports of drug administration during EeMO. As already outlined in this chapter,
the effect of EeMO on drug disposition is a complex issue with the interplay of many
factors, including physiological changes, sorption of drugs into components of the
circuit and volume expansion. The broad scope of this research was to increase
understanding of the effect of drug sorption and an expanded circulating volume on
drug disposition during EeMO.
Although sorption of drugs by intravenous administration sets and lines has
previously been reported, few such investigations have been conducted with EeMO
circuit components. The availability of such data in the application of drug treatment
during EeMO is vital since the circuit is an extension of the patient's blood circulatory
system. Unlike drug sorption in intravenous delivery systems, drug-EeMO circuit
interactions have the potential to dramatically affect pharmacokinetics.
In vitro investigations were designed not only to determine the rate and extent of
sedative drug sorption, if any, but how this affects drug delivery and to delineate
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physico-chemical factors of drugs and characteristics of plastic components that may
influence the degree of loss. Since ultimately it is important to be able to demonstrate
the in vivo sorption of drugs by ECMO circuits, ex vivo analysis of neonatal ECMO
circuits for midazolam sorption was conducted. Next, the impact of potential midazolam
sorption on plasma concentrations and pharmacokinetics was investigated in neonates
treated on ECMO.
In the second part of this thesis, the effect of the expanded circulatory volume as
well as other clinically significant covariates on pharmacokinetics of routinely
monitored water soluble drugs (aminophylline, vancomycin and gentamicin) is explored
and compared with similar non ECMO patients. Derived pharmacokinetic parameters







Studies into drug disposition during extracorporeal membrane oxygenation followed
two investigational routes: in vitro and Clinical. The aim of the in vitro investigation
was to evaluate the sorption of commonly used intensive care sedatives by those
polymeric components of an ECMO circuit that are in continuous contact with
circulating blood: pPVC tubing and silicone membrane from the oxygenator. These
experiments were designed so that sorption of known concentrations of aqueous drug
solutions with components of the circuit could be determined, under static conditions
and also during simulation of flow through an intact circuit. All analyses during this
stage of the investigation were carried out using HPLC with UV detection. The final
stage of these studies involved analysis of ex vivo circuits i.e. circuits that had
previously been used to support neonates requiring ECMO. The purpose of this was to
confirm the presence, or otherwise, of midazolam that had been administered as a
continuous infusion during the period on ECMO. For this phase of the investigation and
since potentially a variety of sequestered agents could interfere with the analysis, an
LC-MS analytical method was developed.
The clinical investigations were designed to assess the impact on
pharmacokinetics of two ECMO circuit associated phenomena: drug sorption to
polymeric components and the expanded circulating volume. Plasma concentration
observations for these studies were obtained either prospectively, through designed
protocols (and therefore providing a rich data set) or retrospectively from therapeutic
drug monitoring databases (sparse data set). The impact on the pharmacokinetics of
midazolam as a result of sorption to neonatal circuit components was investigated
through a prospective clinical study and population pharmacokinetic parameters were
derived from a non-linear mixed effects model. The latter was developed using the
software WinNonMix (Version 2.0.1). The impact of an expanded circulating volume
50
was assessed on three routinely monitored drugs that are water soluble and therefore
have a relatively small volume of distribution. A population phannacokinetic model
was developed for aminophylline using data collected retrospectively from a database.
Similarly, a population model was also developed for vancomycin, however during this
investigation data collected both prospectively and retrospectively was utilised. All
population models were validated using either internal or external methods. Finally, the
consequence of an expanded circulating volume was also assessed through the
comparison of two gentamicin dosing regimens for neonates. Pharmacokinetic
parameters on this occasion were derived using log linear regression analysis.
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2.2 Materials for In Vitro Investigations
2.2.1. Drugs and Other Chemicals
All drugs and chemicals were of a pharmaceutical and chemical standard:-
Diazepam Base: Sigma-Aldrich Company Ltd, Dorset, UK
Diazepam injection (Hlmg/Zcm"): Phoenix Pharmaceuticals Ltd, Gloucester
Lorazepam injection (4mglcm\ Wyeth Laboratories, Maidenhead, Berkshire
Midazolam Base: Hoffman La Roche, Basel, Switzerland (gift)
Midazolam injection (10mgl2cm\ Roche Products Ltd,
Morphine Sulphate (1Omg/crrr'): Martindale Pharmaceutics, UK
Nalorphine Sigma-Aldrich Company Ltd, Dorset, UK
Propofol injection (200mgl20cm3) AstraZeneca, Wilmslow, Cheshire, UK
Plasma-Lyte A Baxter Healthcare Corporation, USA
Human Albumin Solution 4.5%: Bio Products Laboratory, Elstree, Herts, UK
Methanol (HPLC grade): Fisher Scientific, Loughborough, UK
Disodium hydrogen phosphate: MercklBDH, Lutterworth, Leicestershire, UK
Sodium dihydrogen phosphate MercklBDH, Lutterworth Leicestershire, UK
Glacial Acetic Acid Fisher Scientific, Loughborough, UK
2.2.2 Circuit Components




PMP Hollow fibre oxygenator
Norton Performance Plastics, Corby, Northants,
UK
Avecor, Cardiovascular Inc, Minneapolis, MN,
USA
Medos Medizintechnik AG, Stolberg, Germany
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2.3 Methodology for In Vitro Analysis
2.3.1 Preparation and Serial Dilutions of Stock Drug Solutions
For the in vitro analysis of circuit components using HPLC, pharmaceutical (injectable)
preparations of the drug were used to prepare standard solutions. Diazepam Smg/crrr',
lorazepam 4mg/cm3, midazolam hydrochloride Smg/cm", morphine sulphate IOmg/crrr'
and propofol lfhng/crrr'were serially diluted to volumes using double distilled water to
make working standard solutions ranging 1~g/cm3 to SOug/crrr'. At all times the
solutions were kept in the dark. This was achieved by wrapping the glassware in
aluminium foil. All solutions were stored at 4-8°C, and used for up to 2 weeks. For the
flow simulation study, diazepam Smg/crrr', lorazepam 4mg/cm3, midazolam
hydrochloride Smg/crrr', and propofol l Omg/crrr'were used to prepare 3S00cm3 working
standard solutions of 0.4~g/cm3 using double distilled water. All solutions were used
within one day.
For the ex-vivo analysis of circuit tubing using LC-MS, midazolam base was
dissolved in double distilled water and then diluted in a serial format to concentrations
ranging IOng/crrr' to 10~g/cm3. Diazepam, the internal standard, was prepared by
dissolving the powder form in methanol and then diluted in a serial format to
200ng/cm3.
Stability of all drug solutions was monitored by storing aliquots of solution in
glassware for 7 days. The samples were analysed in duplicate 0, 1 and 7 days after
preparation. All the solutions were shown to be stable, with little change in
concentration «3%) over 7 days.
53
2.3.2 Preparation of Clear Prime Solution.
Clear prime solution was prepared by taking 2Ocm3 of Human Albumin Solution 4.5%
and diluting to 100cm3 with Plasma-Lyte A. This ratio mimics normal clinical protocol
relating to clear prime solutions used for ECMO circuits.
2.3.3 Preparation of Phosphate ButTer for HPLC Mobile Phase
Sodium dihydrogen phosphate 11.OO4g(0.092M) and disodium hydrogen phosphate
1.013g (O.OOSM)were dissolved in loocm3 of double distilled water separately and then
made up together to 1000cm3. The mobile phase was made up of methanol: water:
phosphate buffer (SOO:100: 100). The solution was vacuum filtered (0.22Jl) and degassed
in helium. The solution was stored at room temperature and used for up to 2 weeks.
2.3.4 Preparation of Ammonium Acetate ButTer for LC-MS Mobile Phase
Ammonium acetate 3.2Sg was dissolved in 5OOcm3double distilled water. Glacial acetic
acid solution was then added to this solution to adjust pH to 5.4. The mobile phase was
made up of methanol: water: ammonium acetate buffer (800: 100: 100). The solution was
vacuum filtered (0.22Jl) and degassed in helium. The solution was stored at room
temperature and used for up to 2 weeks.
2.3.5 In Vitro Investigation of Drug Sorption into Circuit Components - Static
Conditions
An Scm length of 1,4" pPVC tube was filled with 25Jlglcm3 of drug solution (diazepam,
lorazepam, midazolam, propofol or morphine), sealed using glass stoppers and wrapped
in aluminium foil. Triplicate samples (50JlI) were then taken at 0,5,2040 and 120
minutes with a glass syringe and analysed using HPLC.
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A piece of silicone membrane, 6cm x 7cm, was cut from the 0800 Avecor
oxygenator. This was achieved by opening the outer case of the oxygenator and
unravelling and separating the membrane bilayer from the polypropylene mesh. The cut
piece was stapled together in a cylinder shape and placed in a glass sample tube. The
membrane was covered with approximately 27cm3 of 25J.lglcm3 drug solution
(diazepam, lorazepam, midazolam, propofol, morphine). The glass sample tube was
wrapped in foil and triplicate samples (50J.lI)were then taken at 0,5,2040 and 120
minutes with a glass syringe and analysed using HPLC.
2.3.61n Vitro Investigation of Drug Sorption into Circuit Components Previously
Primed.
An 8cm length of pPVC tube was filled with clear prime solution. The tube was sealed
with glass stoppers and left to stand for one hour, to mimic priming of ECMO circuits
prior to clinical use. The tube was then emptied out and filled with drug solution
(diazepam, lorazepam, midazolam and propofol) and timed serial samples were taken as
described in 2.3.5.
A piece of silicone membrane, 6cm x 7cm (obtained as detailed in 2.3.5), was
placed in a glass sample tube. The membrane was covered with approximately 27cm3 of
clear prime solution and left to stand for one hour. The glass sample tube was then
emptied out and filled with drug solution (diazepam, lorazepam, midazolam and
propofol) and timed serial samples were taken as described in 2.3.5.
2.3.7 Extraction of Midazolam from Previously Exposed Circuit Components
pPVC tubing previously exposed to midazolam aqueous solution as detailed in 2.3.5
was rinsed thoroughly with double distilled water. The tubing was then refilled with
methanol as an extraction solvent, sealed with glass stoppers and then timed serial
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samples were taken as described in 2.3.5. This procedure was repeated with double
distilled water as the extraction solvent.
2.3.8 Simulated Infusions of Sedative Drugs through the ECMO Circuit.
A complete neonatal ECMO circuit (minus double lumen cannula) was assembled in a
linear fashion and consisted of the following components: 6 metres of Tygon S-65-HL
pPVC tubing, a reservoir bag (Sac-R-14), silicone membrane oxygenator (0800 Avecor)
and heat exchanger (ECMOTherrn II, Avecor). The drainage end of the tubing was
submerged in a 3500cm3glass reservoir containing drug solutions (diazepam,
lorazepam, midazolam, propofol) of OAIlg/cm3. A peristaltic pump was attached to
tubing pre-reservoir and the drug solution was pumped through the circuit at a rate of
360cm3/min. Freshly prepared solution was added to the reservoir solution to keep it
topped up and to prevent air passing down the tube. The effluent leaving the circuit via
the re infusion line was sampled at approximately 2 minute time intervals between 0-54
minutes. Triplicate samples (50Jll) from each time point were analysed using HPLC.
2.3.9 Determination of Drug Sorption and Release from In Vitro Circuits by HPLC
HPLC was used to separate and quantify drug concentrations from the static and flow
simulation sorption studies.
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2.3.9.1 HPLC Apparatus and Conditions
Integrator:
Waters 600E System Controller: SIN 60EFR1069
Prodigy 511 ODS (3) 100A 150 x 4.6mm
Luna 511 CIS (2) 150 x 4.6mm with integrated
guard column (Phenomenex, UK)





Diazepam 230nm, Lorazepam 212 nm, Midazolam
219nm, Propofol269 nm
Diazepam (3.3 mins), Lorazepam (2.6mins),




Buffer solution (800: 100: 100 v/v)












Calibration curves were constructed by plotting peak areas against concentration and for
all drugs passed through the origin and were linear over the range 0 - SOmcg/cm3 with
r2values of 0.99. The lower limit of detection was SOng/cm3 and the intra-assay
coefficient of variation was 6-8%.
2.3.10 Preparation of Ex Vivo Circuit for Analysis
All circuits investigated during this analysis comprised of the Medos Hilite® 800 LT
infant hollow fibre oxygenator, as opposed to the silicone membrane oxygenator
utilised in the in vitro investigations.
After surgical decannulation of neonates, the circuit was clamped via the double
lumen cannula to prevent blood spillage. Infusion of all drugs and other infusions were
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transferred from the separated circuit directly to the neonate. The roller pump was
stopped and the circuit detached from the integrated heat exchanger. Using metal
clamps to prevent excessive blood spillage, various components of the circuit were
spliced. Circuit tube samples were taken from the drainage line (Le where blood is
normally drained from the patient), pre oxygenator, post oxygenator and reinfusion line.
Blood was drained and any residues were washed out from the tubes using distilled
water. The oxygenator was prepared by washing out excess blood by pushing water
through the blood inlet port using a 50cm3 bladder syringe and allowing drainage from
the blood outlet port. This was repeated until all visible blood had been removed.
Excess water in the samples was shaken out and then allowed to dry off at room
temperature. All samples were then placed and labelled individually in polythene bags
and stored at -20°C until LC-MS analysis.
2.3.11 Extraction of Midazolam from Ex Vivo Circuits
Samples of tubing isolated from the clinically used circuit (detailed in 2.3.10) were cut
into lengths of 10 to 20cm. The tubes were filled with a measured volume of double
distilled water, sealed with glass stoppers. Serial samples were taken initially at 2, 4, 6,
24 hours and then 12 to 24 hourly thereafter. After each sampling occasion, the tube
was completely emptied of the extraction solution, refilled with fresh double distilled
water and resealed. The extraction solution was transferred into glass vials using glass
pipettes ready for LC-MS analysis. Triplicate samples (O.5cm3) of the extract solution
was mixed with O.5cm3 of diazepam 200ng/cm3 internal standard in a glass vial and
sealed with caps prior to analysis by LC-MS.
The isolated oxygenator was filled with measured volume of double distilled
water by infusing through the blood inlet port using a 50cm3 bladder syringe to the point
water dripped out of the blood outlet port and then sealed using clips. All other ports on
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the oxygenator were capped off. Serial samples were taken at 24 hour intervals. On each
sampling occasion, the oxygenator was completely emptied of the extraction solution,
refilled with fresh double distilled water and resealed. The extraction solution was
transferred into glass vials using glass pipettes ready for LC-MS analysis. Triplicate
samples (0.Scm3) of the extract solution was mixed with 0.Scm3 of diazepam 200nglcm3
internal standard in a glass vial, sealed with rubber bung caps prior to analysis by LC-
MS.
2.3.12 Analysis of Drug Extraction from Ex Vivo Circuits by LC-MS
Acquisition was initially made in scan mode for both reference midazolam and
diazepam (IS) to identify the fragmented ions in the full spectra. Following this, the
extracted solution with added internal standard was identified and quantified using the
selected ion monitoring (SIM) mode. Analytes were ionised by positive ion electrospray
and detected by using an Agilent quadrople mass spectrometer (MS). MS parameters
optimised for the analysis were fragmentor voltage to give the most intense protonated
molecule for each analyte, capillary voltage for maximum signal, and spray chamber
parameters for maximum signal with minimum noise.
2.3.12.1 Chromatographic Conditions
Column: Luna S/1-CIS (2) 150 x 4.6mm with integrated
guard column (Phenomenex, UK)
Methanol:Double Distilled Water: Ammonium

















Nitrogen drying gas flow:
Nebulizer:
Quadropole temperature:
Mass range (Scan Mode):












Midazolam (m1z 325, 326, 327)
Diazepam (m1z 285, 286, 287).
Complete system control and data evaluation were carried out using the Agilent LC-MS
Chemstation Software. Calibration curves were constructed by plotting peak area ratios
of midazolam to the internal standard diazepam against concentration, using a linear
regression model. The assay was linear (r2 0.995) over the concentration range 10 -
500nglcm3 (See Chapter 3, Section 3.12.2). The inter and intra-day coefficient of
variation was less than 3%.
2.4 Clinical Investigations
For all clinical studies, ethics approval was obtained from the Leicestershire Research
and Ethics Committee, prior to the investigation. Data was collected both prospectively
and retrospectively. For prospective investigations, signed assent was obtained from all




For prospective investigations, intensive care observation charts, twice daily serum
biochemistry summaries, blood gases, prescription charts as well as other medical and
nursing records were accessed on a daily basis. In the case of vancomycin administered
intermittently, dosing regimens, including timing of administration was diligently noted
from the prescription charts. Similarly for midazolam, administered as a continuous
infusion, dosing was recorded on an hourly basis from the initiation to termination of
infusion, noting any change in concentrations and infusion rates. Where obvious or
substantiated modifications in the dosing regimen occurred, for example a delay in drug
administration due to nursing priorities or clinical reasons, these were carefully noted.
Any significant clinical occurrences during the period on ECMO, for example a change
(renewal) in the ECMO circuit or surgical interventions requiring anaesthesia were also
noted. Blood sampling times followed study protocol as far as possible. Unavoidable
deviations were again carefully noted. Clarity was sought from the responsible clinician
or nurse when uncertainty or ambiguity arose. All blood samples during VV ECMO
were taken from indwelling arterial cannulas in the patient. During VA ECMO, all
blood samples were taken from the circuit, proximal to drug infusions and the reservoir.
2.4.2 Retrospective Investigations
For retrospective investigations, suitable study populations were identified from an
ECMO database dating back to April 1989. In reality though and in the interest of
minimising confounding variables, patient records pre dating 1997 were not accessed
since it was felt that practices and procedures (including components of the ECMO
circuit) had altered significantly during this period. Inclusion criteria required at least
one plasma drug concentration to be recorded per patient. Assay databases held in the
Department of Biochemistry for aminophylline, and the Department of Microbiology
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for gentamicin and vancomycin, were accessed and compared with the ECMO database.
The medical records of matched patients were then traced and retrieved. Medical
records older than two years at the time of study tended to be microfiche otherwise
original paper records were found. As with prospective investigations, all relevant
aspects of the medical and nursing records were accessed. Where dosing regimens could
not be deciphered or were incomprehensible, patients were excluded from the analysis.
All demographic and clinical data was recorded onto proformas and then collated in to
MS Excel Spreadsheets. Patient identification was anonymised at this stage.
2.4.3 Determination ofmidazolam and 1·0H midazolam in plasma by GC·MS
This analysis was developed and carried out by the Department of Toxicology,
Leicester Royal Infirmary, for the purposes of this study. The analysis identified and
quantified midazolam and the primary metabolite I-OH midazolam in blood samples
collected from 20 neonates during ECMO (see Chapter 4).
2.4.3.1 Extraction
Midazolam was extracted from whole blood using solid-phase extraction (SPE) and
then quantitated using gas chromatography-mass spectrometry (GC-MS). Nalorphine
was used as an internal standard. Half a millilitre of whole blood was diluted to 3ml
with deionised water. After addition of 20111nalorphine (50llglcm3) internal standard,
samples were centrifuged at 3000rpm for 5mins ready for the extraction process. Baker-
Bond Narc-2 mixed phase SPE tubes were pre-conditioned with 3cm3 methanol,
followed by 3cm3 water and finally 3cm3 phosphate buffer. Samples (3cm3) were then
loaded onto the columns. After washing columns with 3cm3 deionised water, followed
by 0.25cm3 lOmmolll acetic acid (pH3), midazolam and I-OH midazolam were eluted
from the columns with ammoniacal chloroform/isopropanol using low vacuum.
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2.4.3.2 Derivatisation
The eluates were dried down under vacuum in a vortex evaporator at 70°C. The residues
were reconstituted with 200111ethyl acetate and then again evaporated to dryness in a
vortex evaporator at 70°C. Pyridine (lOIlI) and MSTFA (30IlI) was then added to the
eluates and heated for 30 minutes in a hot block at 70°C to form Trimethylsilyl
derivatives (TMS).
2.4.3.3 Analysis
Column: HPl (30m x 0.25mm x 22~lm) methylsiloxane column





Oven Program: Initial Temp 90°C for 2mins
Run time:
Retention time:
Ramp 40°C min-I up to 280°C, then by 20°C min-I up to
320°C and held constant for 5 mins
13.5 mins
Midazolam (9.2 min), Nalorphine Internal Standard (9.4
min), I-OH Midazolam (9.6 min)
HP 5973 Mass SpectrometerMS:
Derivatised ions used for identification and quantification (SIM mode):
midazolam (310, 312, 325), I-OH midazolam (398, 413), nalorphine (260, 414, 455).
Calibration curves were constructed by plotting peak area ratios of target analyte to the
internal standard against concentration, using a linear regression model. The assay was
linear (r2 0.999) over the concentration range 10 -1O,OOOnglcm3. The inter and intraday
coefficient of variation was less than 10%.
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2.5 Pharmacokinetic Analysis
2.5.1 Linear Regression Analysis
Routine therapeutic gentamicin monitoring data was analysed using this approach. Peak
(1 hour post dose) and trough (immediately prior to the next dose) plasma
concentrations were fitted by linear regression analysis of log concentrations, assuming
a one compartmental model with first order elimination. Assuming that peak and trough
levels were determined in the elimination phase, the elimination rate constant (K, in hr'
I) was determined directly from the slope.
K, = (Ln Csspeak - Ln Csstrough) 1 r
The volume of distribution (V; Ukg) was determined using the Sawchuk and Zaske
method (Sawchuk et al., 1976):
V = (Dose/Csst).(1I1-e-Ket) • e-Ke.!
Csst= Steady state plasma concentrations at time t
T = time between peak and trough (hour)
t = 1 hour (peak) and trough
Half-life (hours) was calculated as In 21 K, and clearance (Ukg/hr) was determined by
Ke.Vd. Microsoft Excel 7.0 was used to perform pharmacokinetic calculations using the
aforementioned equations.
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2.5.2 Non-Linear Regression Analysis
Initial estimates of vancomycin pharmacokinetics were estimated from the rich data set
by non-linear regression analysis, performed using WinNonLin Standard (Version 3).
Initial exploratory analysis of concentration time profiles revealed a biexponential
elimination phase. Thus for each individual, a two compartment model with first order
elimination was fitted to the plasma concentrations. The mean and variability of
parameter estimates from these individual were then used as initial estimates for the
population model development.
2.5.3 Non-Linear Mixed Effects Modelling
Non-linear mixed effects modelling was performed using WinNonMix Professional
(Version 2.0.1) bundled with Compaq Visual Fortran Compiler Professional Edition,
(Version 6.5). This approach estimates not only the structural (mean) parameters of the
model, but also the interpatient (population) variability in parameters and residual error
(difference between observed and predicted drug plasma concentrations) (Sheiner et al.,
1977). In preliminary analyses, one, two and three compartment models with first order
elimination were fitted to all data from all subjects simultaneously. The compartment
model which demonstrated a more appropriate structural model on examination of the
graphical diagnostic plots as well as the differences in the objective function value
(OFV) i.e. two times the negative log likelihood value, was chosen for further analysis.
Initial parameter estimates were obtained either from the mean parameter estimates
from non linear regression analysis of rich data or previous reports of population
pharmacokinetics in similar populations. Once the base model had been defined, the
influence of various demographic and clinical covariables in the regression models for
clearance and volume of distribution were evaluated. Any covariate present in less than
20% of the population was not tested. In the aminophylline and vancomycin study with
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wide age and weight ranges and due to the multicollinearity of several clinical
characteristics, body weight was included in the model before evaluation of all other
covariates. Allometric scaling transformation of weight (Weighto.75) was also assessed
at this point. Following the inclusion of weight, each covariate was added sequentially
and then (where significant) cumulatively to the initial regression model in a linear and
non-linear manner. The impact of this model building process on the plotted weighted
residuals and the change in the OFV was noted. The difference in the OFV obtained
before and after the addition of covariables is approximately chi-squared distributed
with degrees of freedom equal to the number of parameters that are set to the null
hypothesis value. With two degrees of freedom, a change in the OFV > 7.88 (p<O.OO5)
was accepted as statistically significant.
2.5.3.1 Interpatient Variability
The interpatient variability in clearance and volume of distribution was modelled as
proportional (constant coefficient of variation) deviation from the estimated parameter
values (assuming a log normal distribution), and in this way avoided negative estimates
of parameters.
Bi = B*ebi
Bi= Estimate of structural parameter (clearance and volume) in the ithindividual
B= Population parameter value predicted by the regression model
bi = Random variable, which is normally distributed with variance, ro, mean zero and
represents the interpatient variability in the study population.
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2.5.3.2 Residual Error
The residual error (intrapatient variability), which describes the difference between the
observed and the predicted concentrations, was also estimated:
Cij = Cij + sij
Cij = The jth observed concentration in the ith individual
Cij = The jth predicted concentration in the ith individual
eij = Residual error, normally distributed with mean zero
The variance for sij, (52 , was modelled as:
Fixing a to 1 and b to 0, produces an additive error model, whereas fixing a to 0
and b to 1 produces a proportional error model. Both of these models were also
compared to an additive plus proportional error model (a>O, b=l). Again, the diagnostic
plots and OFV were used to search the most appropriate error model.
Initial modelling was carried out using the First Order linearisation method. The
final fit of the basic model and subsequent covariate testing was conducted using the
First Order Conditional Estimation method (See Appendix II).
2.5.4 Predictive Performance of Models
A measure of the predictive performance of models can be determined by calculating
the median prediction error (MDPE) percent i.e. observed minus predicted
concentrations divided by the predicted value, multiplied by 100, and the absolute
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median prediction error (AMDPE) percent (Sheiner et al., 1981). The MDPE describes
the bias and the AMOPE the precision (variability) of the predictions.
2.5.5 Validation of Models
Validation of models is crucial since unlike scientific hypotheses, a model cannot be
verified directly by an experiment. The validation of a model is not that it is true, but
that it generates good testable hypotheses relevant to the problem in question (Levins,
1966). Two types of model validation methods were used: internal and external (Sun et
al., 1999).
2.5.5.1 Internal Validation
For the midazolam and aminophylline studies, it was not practical to collect new data
prospectively to use as a validation set, and therefore the ability of the final model to
perform in prospective tests was estimated using the cross-validation technique.
Although cross validation is not a truly prospective validation method, it is a recognised
and established approach to estimating model performance assuming identical
experimental conditions (Fiset et al., 1995; Kerbusch et al., 2001; Zomorodi et al.,
1998). The index data set was divided into x smaller groups of y patients each. The
pharmacokinetic model was fitted to the data whilst excluding one group. The estimated
structural parameters from the sub models were then used to predict the concentrations
in the excluded group. This process was repeated x times excluding each group in turn.
Since the excluded group is not used to develop the model, the MOPE and the AMOPE




External validation provides the most stringent method for testing a developed model
and this approach was used for the vancomycin study (Sun et al., 1999). The final
model developed from the index data set was applied to data collected in a separate
group of patients (validation data set).
2.6 Statistical Analysis
2.6.1 Laboratory Data
All data is expressed as mean (SD). A difference between two means was investigated
using the student's t-test and univariate regression analysis was conducted using SPSS
(10.0). In all cases p<0.05 was taken as significant.
2.6.2 Clinical and Pharmacokinetic Data
All clinical and demographic characteristics were reported as mean (SD) or where the
standard deviation was large, median (range). Population pharmacokinetic estimates are
expressed as mean± SE. Parametric and non-parametric (Mann-Whitney U) statistical
analysis was used for analysis of clinical and demographic data whilst all
pharmacokinetic parameters were assumed to follow the normal distribution and thus
only parametric analysis was applied. For comparing more than two means, one or two
way analysis of variance was used depending on the number of classification variables.
Univariate and multivariate regression analysis was conducted in WinNonMix (Version
2.0.1) and SPSS (Version 10.0) to reveal trends in the population studies.
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CHAPTER III




Reduction of the amount of drug available to a patient resulting from interactions with
plastics is a well recognised and documented phenomenon (Trissel, 2001). Previous
studies have only reported loss of drugs from aqueous solutions in contact with infusion
bags (Cloyd et al., 1980; Kowaluk et al., 1981; Roberts et al., 1980), administration sets
(HirschI, 1981; Kowaluk et al., 1982) and filters (Baaske et al., 1980; Parker et al.,
1980). The potency loss appears to be dependent on the physico-chemical
characteristics of the drug and solution, the nature of the plastic and the dynamics of the
system (Kowaluk et al., 1982). However, ECMO circuits are unique in sorption studies
since unlike plastic containers and administration sets used for drug delivery, the
ECMO circuit is an extension of the patient's circulatory system. Therefore in
distinction to sorption in intravenous delivery devices, drug-circuit interactions in vivo
will have a significant influence on pharmacokinetics and hence therapeutic efficacy.
For drug sorption to occur in vivo not only will the drug have to distribute from the
blood phase, at a buffered pH of approximately 7.4 and at body temperature, but the
process will compete with binding to circulating plasma proteins and red blood cells.
The component materials of an ECMO circuit are mainly organic in nature. The
circuit tubing is made from pPVC (Tygon S-65-HL) whilst the gas exchange membrane
in the oxygenator is a silicone membrane construct (see Chapter 2, Section 2.2.2). It is
perfectly plausible that both of these materials lend themselves heavily to drug sorption
since the patient's blood is exposed to a large surface area of each plastic. However, to
date there are only limited reports on the interaction of drugs with components of the
ECMO circuit. Rosen et al (1988) demonstrated fentanyl uptake by the membrane
oxygenator whilst Dagan et al (1993) in their preliminary in vitro evaluation revealed
significant decreases in circuit drug concentration with time. The disposition of
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commonly used critical care sedatives, diazepam, midazolam, lorazepam and propofol
in the ECMO circuit has not been described.
The affect of different priming solutions used to modify the surface
characteristics of the CPB circuit has also been investigated. Hynynen et al (1995) and
Rosen et al (1986) reported a decrease in the drug loss when the a CPB circuit was
primed with blood whereas Hammeren et al (1999) demonstrated that priming CPB
circuits with heparin did not prevent loss of propofol during in vitro tests. No such tests
have been reported for ECMO circuits.
3.2 Aims of the Study
The purpose of this phase of the study was to compare the sorptive profiles of morphine,
diazepam, lorazepam, midazolam and propofol and to evaluate factors determining such
losses, if they occurred.
The investigation was in several stages. First, the different polymeric
components of a neonatal circuit were dismantled and a small portion of the pPVC
tubing (%" diameter) and silicone membrane (from the oxygenator) was isolated. The
interaction between these two polymers with static solutions of the sedative drugs was
then investigated to determine the relative degrees of sorption. Second, these
preliminary studies were repeated after priming the circuit components with clear prime
solution.
In clinical practice it is important to know the real amount of drug that a patient
will receive during the infusion. The primary questions then are, what quantity of the
drug will be lost to the ECMO circuit and what dose the patient will receive. To
evaluate this, an intact neonatal circuit was assembled, and the administration of drug
infusions through the circuit was simulated.
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Previous investigations have not established or proven sorption of drugs in
clinical practice. Therefore in the final investigation, ex vivo neonatal circuits were
examined and evaluated for midazolam sorption.
3.3 Static Sorption Studies of Selected Sedative Drugs
3.4 Materials and Methods
3.4.1. Investigation of Drug Sorption into Circuit Components under Static
Conditions
Stock drug solutions of morphine, diazepam, lorazepam, midazolam and propofol were
prepared as detailed in Chapter 2, Section 2.3.1. Sorption tests were carried out on 8
different samples of the pPVC tube and 8 samples of the silicone oxygenator membrane
taken from 2 nominally identical neonatal ECMO circuits of the same manufacturer.
The method is described in Chapter 2, Section 2.3.5.
3.4.2. Investigation of Drug Sorption into Circuit Components Previously Primed.
Clear prime solution was prepared as described in Chapter 2, Section 2.3.2. pPVC tubes
and silicone oxygenator membrane samples were treated with the clear prime solution
for 1 hour as described in Chapter 2, Section 2.3.6. Tests were carried out on 8 different
samples of the pPVC tube and 8 samples of the oxygenator membrane taken from 2
nominally identical neonatal ECMO circuits of the same manufacturer. The method is
described in Chapter 2, Section 2.3.5.
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3.4.3 Extraction of Midazolam from Previously Exposed Circuit Components
After the exposure experiments, pPVC tube and silicone samples were washed with
double distilled water and then treated with methanol to extract midazolam from the
polymeric material and confirm uptake by the specified component. This procedure was
repeated with double distilled water as an extraction solvent. The method is described in
Chapter 2, Section 2.3.7. This test was not carried out for the primed materials.
3.5 Statistical Analysis
All data is expressed as mean (SD). Differences in means between primed and unprimed
data was explored using Hest. A p value < 0.05 was considered significant.
Monoexponential curve fittings and determination of coefficients for flow simulation
data, was achieved using MS Excel Solver (2000).
3.6 Results
The results obtained were reproducible within each category of test: drug, material and
priming treatment. Reproducible differences between primed and unprimed components
were observed for both the ECMO circuits investigated. Absorbance of the mobile
phase was negligible over the range of wavelengths at which the study drugs were
examined. Unused pPVC tubes filled with methanol caused leaching of plasticiser and
resulted in increasing absorbance with time. A similar but reduced effect was seen with
double distilled water.
3.6.1 Drug Sorption under Static Conditions
Table 3.1 presents the time dependent changes of the drugs in contact with the two
principal plastics, pPVC tubing and the silicone oxygenator. In contact with pPVC and
silicone membrane, concentrations of diazepam, lorazepam, midazolam and propofol
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decreased significantly with time (p<0.005). Lorazepam decreased by ea 40%,
midazolam by ea 68%, diazepam by ea 88% and propofol by 98%. Equilibrium in all
cases was attained between 40 and 120 minutes (Figure 3.1). In contrast, morphine
sulphate only decreased in contact with pPVC and the percentage decrease (16 %) was
less. No appreciable loss seen with the silicone membrane (p>0.05).
3.6.2. Drug Sorption after Priming
The results from the primed pPVC samples revealed an increased loss of
benzodiazepines by about 20% compared to the unprimed samples, although this was
not significant at the p<0.05 level (Figure 3.2). In contrast, a decrease in sequestration
to the primed silicone membrane was observed such that virtually no loss of lorazepam
occurred (p<0.OOO5),whilst both midazolam and diazepam showed reduced losses of
40% and 60% (previously 68% and 88%) respectively (p<0.05).
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Table 3.1. Decreasing concentrations (Jlglcm3)of a standard solution of drugs as a
function of time in contact with the plastic components of an ECMO circuit",
Contact I ! I •
DIazepam Propofol
-pp\iCcT--SWc--- -pP-VCc- ---s"ii"c---
--------------+---------11 -------11-------------+----------+------------- ------------ ----------------~------------------------- -------------o i 2.5 2.5 25.0 i 25.0 ~I 25.0 25.0 25.0 ~ 25.0 25.0 25.0
! I------------------t---------r-------:---------t-------- ---------- --------- --------------------------- --------------------------
5 i 2.4 I 2.4 II 20.0 i 18.8 to 17.5 18.0 8.7 I 16.5 8.4 14.0
I I I I
-------------+-----------t.--------+.---------f---------- ------------ ---------------------------J.------------- --------------- -------------
20 I 2.2 I 2.5 15.1 l17.0 I 11.3 12.8 3.8 110.0 1.3 4.0
---------------+------------t------- ------------1 -----------t------------ ----------- ---------------0 ------------- ---------------- ------------
40 I 2.1 I 2.4 15.0 I 16.8 I 8.8 9.0 3.0 I 6.3 0.5 1.3
I 1 I 1------------------ ~-------------- ------- --------------4------------.L--------------- ------------ ----------------11------------- ---------------- -------------
120 2.1 I 2.5 15.0 116.41 8.5 8.0 3.0 5.8 0.4 0.8
a. Results reported as the mean of eight determinations with a SD of +/- 5% of stated value.
b. P>O.05, difference between initial and final concentrations
c. p< 0.005, difference between initial and final concentrations
pPVC - Plasticised Polyvinyl Chloride tubing
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Figure 3.1. Percentage of original concentrations as a Junction of time for a range of
standard drug solutions in contact with the (A) pPVC and (B) Silicone membrane
components oj an ECMO circuit. A mean of eight determinations is plotted at each time













































Figure 3.2. Percentage of original concentration remaining after 120 minutes in
primed and unprimed (A) pPVC tubing (B) Silicone Membrane
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3.6.3 Drug Extraction
Methanol extraction of midazolam from previously exposed pPVC tubing and silicone
membrane also had an effect of leaching plasticiser, known to be DEHP, causing the
HPLC detector to become overloaded with an off scale signal. This migrant had similar
retention times to midazolam and interfered with the peak normally observed for the
target analyte. Changing the mobile phase to a more inorganic composition (70%
methanol) eliminated plasticiser contamination for the first 40 minutes of analysis.
Using double distilled water as an extraction solution further delayed plasticiser
contamination. The results revealed a cumulative increase in midazolam concentration
with time, with almost total recovery of sequestered midazolam from the silicone
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Figure 3.3. 70%MethanollWater extraction of Midazolam from previously exposed
unprimed circuit components
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3.7 Investigation of Drug Sorption in a Flowing System
3.8 Materials and Methods
The effects of the ECMO circuit on continuous infusion of sedative drugs was
investigated by injecting a therapeutic concentration of 0.4 ug/crrr' solution of all four
drugs into the circuit proximal venous line adjacent to the venous catheter connection
(at the point blood is drained from the patient) and monitoring the level of drugs in the
solution leaving the circuit post oxygenator (at the point blood would be reinfused into
the patient). The flow rate of the circuit was set at 360cm3/min and samples were taken
at two minute intervals. The drug levels were determined by HPLC and all readings
were replicated three times. The method is described in Chapter 2, Section 2.3.8.
3.9 Results
The investigations of a complete ECMO circuit showed that in the early stages, the
concentration of drugs measured in the effluent post-oxygenator were considerably
lower than anticipated. The data in figure 3.4 shows the effluent drug concentration
versus time, and expressed as a percentage of the initial infusion concentration. The
extent of loss of various drugs during simulated infusion through the circuit and the
profile of effluent concentration over a period of time differed for all drugs examined.
In the case of diazepam and midazolam, effluent concentrations were minimal at the
onset of infusion and then increased gradually to a steady-state situation. Concentrations
of lorazepam in the effluent were highest and reached almost 100% of the initial at the
end of the experiment. In contrast, propofol was undetectable in the effluent for the first
36 minutes of infusion, increasing slightly thereafter with time. The fluctuations in the
effluent drug concentration-time profiles shown in figure 3.4 are caused by small
variations in the flow rate of drug solution through the circuit.
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Figure 3.5 shows the cumulative amount of drug sorbed after various times. The
sorption of diazepam and midazolam is slow and time dependent. At the end of the
infusion period sorption is still continuing. In comparison, lorazepam sorption seemed
to rapidly reach equilibrium with very little sorption occurring towards the end of the
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Figure 3.4. Percent of original drug in the effluent at various times during simulated




















Figure 3.5. Cumulative drug sorption by a neonatal ECMO circuit
during simulated infusion at a flow rate of 360 cm'tmin
The relationship between steady state effluent concentration of drug and time can be
expressed in the form of a monoexponential equation:
C C (1 -Ksor.ti)(e) = SS· - e
Where ere) is the effluent concentration of drug at time t, and Ksor is the first order rate
constant for sorption (since fractional loss of drug is independent of concentration) and
ti is the infusion time. The calculated coefficient values for curve fittings are listed in
Table 3.2. Using these coefficient values, the percentage of dose delivered can then be
extrapolated to various time intervals (Table 3.3). The results clearly show that in the
case of lorazepam, after 1 hour of infusion the percentage of dose delivered will be
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greater than 90%. Whereas with propofol, even after 24 hours of infusion only 75% of
the dose will be deli vered.
Table 3.2. Coefficient Values for Determining Sedative Drug Sorption to a Neonatal
ECMO Circuit at a Flow Rate of 360 cm 31min
~:~-t_~~=rE
Lorazepam i 0.9 0.74
r------------~---------------------------- --------------------------------
Midazolam i 0.007 0.91
r----------+-- --r-.---------------------
Propofol I 0.001 0.41
a. Coefficient values are given for the equation C(e)=Css.Cl- e-Ksor,ti)
Table 3.3. Sedative Drug Bioavailability on Initiation of a 0.4 pglcm3 Continuous
Infusion through a Neonatal ECMO Circuit





------~-·~--------~-~L!------t-----~~~---------- - ~?.!- ------- L~ _
1 ! 54.3 I 90.9 35.3 4.5
----------~------------:---------------- -------------------- ---------------------
1.S I 69.7 I 95.4 47.4 7.4
f-----------------------i-----------------r---------------- -------------------- ---------------------
3.0 1 91.2 99.4 71.9 15.3-------------------- ---------------- ------------------ ------------------- ---------_ .._-----------
6.0 99.3 100.0 92.0 29.3
r-------..---.j---------- ..------ ....------.------ ..-----..- ......- ...--...----
12.0 I 100.0 100.0 99.3 50.7
~~:~(tJ£r~=i~~:=:~~~=
48.0 I 100.0 i 100.0 100.0 94.3
8. Neonatal ECMO circuit = Tygon® S-65-I-U. pPVC tubing (691cm) and
Avecor™ 0800 Silicone membrane oxygenator.
b. Calculated using equation and coefficient values listed in Table 3.2.
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3.10 Investigation of Midazolam Release from Ex Vivo Neonatal Circuits
3.11 Materials and Methods
The in vitro studies indicated the amount of drug sorbed for a given dose and set of
experimental conditions. This experiment was conducted in an attempt to extract and
quantify sorbed midazolam from circuits exposed to the drug in a real clinical situation
(and therefore very different conditions).
3.11.1 Patient Selection
Inclusion criteria included neonates who survived to decannulation and had received
continuous infusions of midazolam during the period on ECMO. Patients who had
replacement of circuit components during ECMO, for example oxygenator or raceway
changes, were excluded. Circuits from 5 neonates were collected immediately after
separation from patient. All midazolam infusions during ECMO were administered into
the circuit proximal venous line, pre-reservoir. Clinical, demographic and dosing data
were collected retrospectively from medical and nursing notes.
3.11.2 Preparation and Analysis of Circuit
Circuit samples were prepared immediately after collection of circuit as described in
Chapter 2, Section 2.3.10. In order to obviate problems associated with plasticiser
leaching and HPLC-UV analysis, midazolam was extracted with water (Chapter 2,
Section 2.3.11) and analysed using LC-MS (Chapter 2, Section 2.3.12). The contact




3.12.1 Demographic and Clinical Data
Clinical, demographic characteristics and dosing data are displayed in Table 3.4. All
patients underwent VV ECMO. No patient had received midazolam prior to the
initiation of ECMO. All patients received concurrent morphine infusions as well as
other enteral sedatives such as chloral hydrate.
Table 3.4. Demographic and Clinical Characteristics of Study Group.
MalelFemale 312
1-------------------------------------------- ------------------------------------------------------------
Weight (kg) 3.6 (0.4)
- _==~~~~~~~~~~~Ag;~:~_~kS~=~~~~~=~j-==~~~=~~~~=~~~~~~~~~~E~~~~~~~~~~~~~~~~~~~~~~~~:::
Age at Cannulation (days) r 0.9 (0.2)
=~~~_~~==~~~~~iC;~~~~~~~~~o~~~~~~~=~~~~~~=:::t~-=~~~~~~~:~~~~:~~~:~::~!:~~~~~~~~!.:::~:::::::::::::::::::::::::-
Cumulative midazolam dose (tLg/kg) 18495 (12686)
------------------------------------------.r---------------------------- ---------------------------------------------------------------------------
ECMO Flow Rate (cm /kg/min) 72.7 (23.1)
Urea (mmol/L) 8.5 (4.2)
----------------------------------------------------------- ------------------------------------------------------------------------
Creatinine (tLIDol/L)* 83.9 (34.9)
---------------------------------------------------------- -----------------------------------------------------------------------------
Liver Function Normal in all patients
Data is expressed as Mean (SO)
3.12.2 Le-MS Analysis
The retention times of midazolam and diazepam (IS) were 2.9 and 3.4 minutes
respectively, and the chromatographic peaks resolved on the total ion chromatogram
after the pH of the mobile phase was adjusted to 5.4 (Figure 3.6). The full-scan mass
spectra of midazolam and diazepam are presented in figure 3.7, and the major ions
indicative of midazolam and diazepam were identified:
Midazolam (rn/z): 326, 327, 328
Diazepam (m/z): 285, 286, 287
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The within-day precison, as well as the between-day precision and accuracy
were less than 3 % and satisfactory under all concentrations tested (see Chapter 2,
Section 2.3.12.2). A calibration curve was constructed by plotting peak area ratios of
midazolam to the internal standard diazepam against concentration, and this was used to
quantify midazolam recovered from the circuit components (Figure 3.8).
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Figure 3.6. Total Ion Chromatogram of Midazolam and Diazepam (IS)
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Figure 3.8. Calibration Curve Peak Area Ratio of Midazolam to Diazepam (IS)
Against Concentration (ng/ml).
3.12.3 Midazolam Recovery from the Ex Vivo Circuits
A significant amount of midazolam was recovered from clinically used circuit
components (Figure 3.9). The amounts extracted are mean values from three sections of
the circuit pPVC tubing: drainage, pre oxygenator and post oxygenator. Data from the
hollow fibre PMP oxygenators were not available because of significant contamination
of the extracts with blood residues and other debris. As can be seen from Figure 3.9, the
amount extracted increases with increasing doses administered. This presumes that the
greater the doses administered, the higher the plasma concentrations achieved and since
sorption from earlier investigations appears to be a first order process, a greater amount
will be sorbed. The amount extracted as a percentage of total dose administered (and
therefore circuit exposure) varied between 0.5-2.0%, although in only two patients did
the amount extracted fall below the limit of detection (lOng/ml) suggesting that
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significant amounts of drug was still present in the tubing. Based on cumulative amount
of midazolam sorption estimated in the flow simulation studies, this may represent a
fraction of total drug. It is expected that release of midazolam like uptake, is an
exponential process and thus a limitation of this methodology i.e. it was not possible to
determine total amount sequestered using this approach. Although the method of
recovery was time consuming the major advantage was that the extraction and
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Figure 3.9. Comparison of amount of drug released (mean [SDJ)from ex vivo circuit
tubing (line) versus amount of drug administered (bars).
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3.13 Discussion
Although there is limited data on drug sorption in ECMO circuits, the extent of the
problem and predisposing factors affecting interaction between drugs and plastic
components does not, however, appear to have been determined. Decreased levels of
phenobarbital, heparin, vancomycin, gentamicin and phenytoin have been reported,
however the clinical relevance of such losses has not been quantified (Dagan et al.,
1993; Marx et al., 1991).
All of the sedative drugs examined in the present preliminary survey were lost
from solution in contact with both the pPVC and silicone membrane components of the
ECMO system. The extent of loss varied between drugs, and between the primed and
unprimed components. In contrast, a reduced loss of morphine sulphate was observed in
contact with unprimed pPVC, whilst no loss was observed in contact with unprimed
silicone membrane. The lack of morphine sulphate sorption to the silicone membrane
concurs with the in vivo findings of Geidushek et al (1997).
Table 3.5 shows that the percentage of drug loss from aqueous solution is a
function of the log P value and the solution pH. All the sedative drugs exhibiting
substantial losses have relatively high log P values in the non ionised form, whereas
morphine sulphate has a very low log P value (Table 3.5). In accordance with the pH-
partition hypothesis, a significant correlation was observed between percentage of drug
lost from solution and the log P value of the drug, when in contact with both the pPVC
tubing (~=O.83) and silicone membrane (~=O.89) (Figure 3.10). Although this
relationship may be used for predicting probable losses of other drugs, it does not take
account of the dynamic nature of the sorption process (Roberts et al., 1991). For
example, drugs with a high log P and a low percentage non ionised would show a lower
degree of loss than that predicted by the equation. This is illustrated when the degree of
sorption exhibited by midazolam and diazepam in static solution and during flow
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simulation is compared. There was greater fractional loss of diazepam than midazolam
in static sorption tests, but the converse is true during flow simulation (Figures 3.1 and
3.4).
Table 3.5. Loss of drugs from unbuffered aqueous solutions in contact with pPVC
tubing and Silicone membrane components of ECMO circuit/or 120 minutes
% Losst--------------------T---------------------r-------r-----------j--------------------.------------------ ---------------------------------------
Drug I AcidIBase8 i pH I PKa I :0 ~odn j Log P pPVC Silicone
: :, I iomse
t---------------·---t-----------------+-+-----------t-------------- -----------------------------------------------------
Diazepam I Acid ! 6.8 I 3.4 I 99.99 2.8b 88 I 76.8
------------------+----------------t--------t-----:----------t------------- ----------------------------------------------------
_~ora~pam J--~~~~~~~~---J-~~-.-Lj-ij-t~~~-----I---__!_~ =~=: I ~~_________~~~~ _
Midazolam iii
Hydrochloride I Base I 4.9 'I: 6.2 40 2.7c 66 68
I :'--------------------------t-----------------------.:-----------i----------------- -------------------------------------------------------------------------
Morphine I I i
Sulphate i Base I 3.5 l 7.9 I <0.001 0.8d 16 0
! ! I
-----------------------------t-------------------------------t--------- ----------------l--------------------- -------------------------------------------------------------.
Propofol II Acid i 7.0 I 11 99.99 3.7b 98.4 96.8
i '






































CD PercentageLoss = 34.26Log p. 30.45a. 10 R2=0.8963
0
0 0.5 1 1.5 2 2.5 3 3.5 4
Log P
Figure 3.10. Linear Correlation of Log P value of Drug and Percentage Drug Loss
During Static Conditions in (A) pPVC tubing (B) Silicone Membrane
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The effect of the solution pH on the loss of drug is also significant. For a given
drug, the extent of loss also appears to be directly related to the fraction non ionised
(Kowaluk et al., 1981; Kowaluk et al., 1982). For a weak acid, as pH decreases the
fractional loss of drug increases, in accordance with an increased percentage of drug in
the non ionised form. Similarly for a basic drug, fractional losses will increase with
increasing pH. Such a relationship was observed for the loss of drugs from solutions
stored in plastic infusion bags (Kowaluk et al., 1982). Since drugs administered into the
ECMO circuit will be mixing into blood, the degree of ionisation of drug at
physiological pH (buffered to 7.34 -7.45) is an all important consideration. For
example, at physiological pH the percentage of non ionised morphine will increase to
about 25% and thus a greater propensity for sorption into the circuit. However, since it
has a low log P value, the magnitude of increase is not expected to be great. With
respect to midazolam, not only will the percentage non ionised increase to > 90%, but
the molecule will exhibit increased lipophilicity. A pH dependent equilibrium exists
between the closed-ring midazolam and an open-ring benzophenone structure, at
position 4 of the benzodiazepine nucleus. At pH 4 or less, 80-85% closed-ring and 15-
20% open-ring forms exist (AHFS Drug Information. 2001). The open ring structure has
much reduced lipophilic properties, whereas at physiological pH 7.4, midazolam is
completely in closed-ring form, resulting in increased lipophilicity. In contrast to our
findings, Bianchi et al (1992) and Martens et al (1990) observed little or no loss of
midazolam stored in pPVC containers. They had prepared solutions in glucose 5% (pH
3.5 - 6.5) and sodium chloride 0.9% (pH 4.5 -7.0), and thus potentially a higher degree
of the ionised and open-ring species. A further explanation could be differences in the
percentage of plasticiser present in the containers tested. Plasticiser content of pPVC
medical devices can range between 30 to 80% by weight (Tickner et al., 2001).
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Priming an extracorporeal circuit is an attempt to coat the entire inner surface
area with the primer, or in this case albumin. Albumin is noted for its ability to bind to
drugs and the measured loss for a particular drug should therefore be the same
irrespective of the nature of the primed component. Hammaren et at (1999) and How-
Bow Su et at (1996) reported that priming with either heparin or dextrose/saline has no
effect on drug loss in the circuit. Unger et al (2001) found that priming and perfusing
pPVC tubes with foetal calf serum increased sorption of lignocaine, but not midazolam.
Our results demonstrate that albumin priming does affect sedative drug loss such that
uptake decreased significantly with the silicone membrane oxygenator but not the pPVC
tubing. It is not clear why this should be but one explanation could be the differences in
degree of priming achieved on both components. The albumin boundary layer may be
contributing to an overall diffusional resistance into the silicone membrane. To relate
the effect of priming ECMO circuits with albumin to clinical practice would require this
work to be repeated with whole blood. The impact may be altered since binding to
circuit components is probably competitive with binding to blood components,
including red blood cells and plasma proteins. All the drugs investigated are
significantly bound to albumin in blood: diazepam (99%), lorazepam (92%), midazolam
(96%) and propofol (97%) (Dollery, 1991)
A number of workers have argued that the diffusion model is the most
appropriate mechanistic model to describe the sorption of drugs by plastic devices
(Roberts et al., 1980; Roberts et al., 1991). In this model, it is assumed only the non
ionised species is taken up by the plastic. Also the aqueous solution is well stirred and
the rate of drug uptake is controlled primarily by the diffusion in the plastic.
Furthermore, the plastic is assumed to be an infinite sink. The flow simulation studies
revealed continuous and time dependent cumulative sorption of the sedative drugs. The
continuous loss of drug into the ECMO circuit is consistent with a diffusion controlled
94
sorption of drugs into the plastic matrix reported previously for plastic infusion bags
and infusion systems (Kowal uk et al., 1982). This is in contrast to drugs such as insulin
and heparin (macromolecules), where loss to intravenous delivery systems is an
adsorptive (surface) process, and dependent on the saturation of available binding sites
(HirschI, 1981). The kinetic profile would reveal an abrupt decrease in concentration
followed by an equilibrium state.
Since the sorption of most drugs is a first-order process, controlled by the
diffusion of drug in the plastic matrix, it is also expected to be concentration
independent in buffered solution and blood (maintained at physiological pH). For a
given drug, the amount taken up will increase with concentration, but the fraction taken
up will remain constant. In unbuffered solutions where drug concentration affects the
pH of the solution, the fractional loss may be affected. One other notable exception to
this is chlormethiazole edisylate, where the fractional loss increases with concentration
(Kowaluk et al., 1981). This effect has been attributed to chlormethiazole enhancing its
own sorption and possibly permeation by 'swelling' the pPVC resin.
Fractional loss of drugs to the circuit is also expected to be a function of the
pump flow rates. Such a relationship has been observed for drugs infused through
intravenous administration sets (Roberts et al., 1980; Yliruusi et al., 1986a). The drug
concentration in the effluent is likely to be lowest at the slowest flow rates, since there
is a longer contact time for the drug in solution with the circuit. The effluent drug
concentration is then greatest at the fastest flow rate. However, it is also true that at the
fastest flow rate more drug is presented to the circuit per unit time and therefore the rate
of sorption will also be the greatest. Kowaluk et al (1982) described the relationship
between steady-state effluent drug concentration (Css) and mean contact or transit time
(1) of the solution in the tubing as:
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C - C e-KsorTss - o.
Where Co is the initial concentration of the drug solution to be infused and Ksor is the
first order rate constant for sorption. The contact time, T,may be deri ved from the
volume of solution in the tubing (V) divided by the flow rate (F). Pump flow rates
during neonatal ECMO are the highest at the onset of neonatal ECMO (120cm3/kglmin)
and the support is then weaned to a minimum (50cm3/kglmin) as the patient's lungs
recover. Therefore, drug loss through sorption will be least and percentage of dose
delivered greatest at the onset of ECMO support. During normal clinical practice, where
frequently midazolam is infused continuously from the onset of ECMO to a period post
decannulation, the changing fractional loss will continuously alter its effect on
pharmacokinetic parameters.
Steady state effluent concentration is also a function of the dimensions of the
infusion tubing (Kowal uk et al., 1982; Yliruusi et al., 1986b). As the surface-area (SA)
to volume ratio increases, the fractional loss through sorption increases. Yliruusi et al
(1986b) showed that loss of diazepam was increased in pPVC tubing compared to
pPVC containers and also loss to tubing increased with tubing length. The first order
rate constant for sorption can then be expressed in terms of the SA in contact with
solution and the volume of solution (V) (Kowaluk et al., 1981):
Ksor = kp (SA/V)
Where kp is the permeability constant for the drug in plastic, (although these will be
different for the pPVC and the silicone membrane components of the circuit, Table 3.6).
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Table 3.6. Permeability coefficients for the plastic components of a neonatal ECMO
circuit.
Permeability Coefficient, PlOx 10 ,
Polymer I cm) s.t.p. cm2 sec"
.- -- - ..-- - --- -.- -.- -.-..---~!!!.!!g.~.~~ .
.. ~ n:!ast~~~~ P~=.--------_l_-------------------~-------------------- _
!
Plasticised PVC I 200
----------------------_._ _ __..+_.._----------------_. __ __._-_ _.._------------------_..




a. Crank et al., 1968
b. The polypropylene is not in contact with the drugs in solution
The internal surface area in a pPVC tube is given by the equation:
SA = 27tf1
Where r is the internal radius and I is the length of the tube. Thus as surface area
increases, so does Ksor. According to these relationships, the highest drug delivery rate
in an ECMO circuit will be achieved by maintaining high pump flow rates, ensuring
that the tubing used has the smallest possible diameter and is of the shortest length
possible. The implication here is that fractional loss of drugs will be different in
different sized circuits. Table 3.7 shows that the neonatal ECMO circuit is the longest
and has the highest overall SA to volume ratio. Furthermore, pump flow rates per
bodyweight are greater in a neonate compared to an adult. Approximate pump flows at
the onset of ECMO are 120 and 65 cm3/kg/min and at the weaning stage, 65 and 15
cm3/kg/min, in neonates and adults respectively.
Thus, fractional loss of drug is likely to be greatest in a neonatal EeMO circuit,
and somewhat less in older children and adults. Pharmacokinetics in neonates are
significantly different to older children and adults due to renal and hepatic immaturity,
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and so loss of drug through sorption to the ECMO circuit will further add to the
uncertainty of appropriate drug dosing in this group.
A major difference between drug sorption in polymeric containers and
administration sets is that the ECMO circuit is an integral part or an extension of the
patient's systemic circulation. Drug sorption can potentially alter pharmacokinetics and
hence therapeutic response. The effect on drug disposition will depend on whether the
process is reversible or not. Where drug sorption is a reversible process, a steady state
equilibrium will be established in which a pool of bound drug is in equilibrium with a
pool of unbound drug. In the classic compartmental model this would be modelled as an
enlarged volume of distribution, with the ECMO circuit behaving as a peripheral tissue
compartment. Irreversible sorption of drug to the circuit, therefore, appears as an
increase in clearance (via a peripheral compartment).
The results of this investigation not only demonstrate that midazolam lost
through sorption to pPVC tubes and silicone membranes is reversible through simple
water extractions, but moreover, the identification of bound midazolam to ex-vivo
circuits has for the first time confirmed the sorption of drug during clinical use. This
suggests that the ECMO circuit behaves as a peripheral compartment, distinct from the
patient, into which drugs can rapidly distribute to an equilibrium situation. It also
suggests, once infusion of drug ceases and plasma concentrations decline, circuit bound
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The results from these preliminary in vitro investigations reveal that ECMO circuits
have the potential to sequester substantial amounts of the sedative drugs. This is a
concentration independent process and the fractional loss will depend on physico-
chemical properties of the drug (ionisation status, log P value), pH of solution,
characteristics of the circuit (SA to volume ratio, pump flow rates) and whether the
circuit is primed or not. Drug sorption was also shown to be a reversible process with
the potential to significantly affect pharmacokinetics and therapeutic response.
These simple studies have examined the effect of an ECMO circuit on a single class of
drugs. The results obtained suggest that further work be carried out to extend the range
of drugs examined, to study the effect of various priming solutions and to use more
realistic mobile phases e.g. blood.
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CHAPTER IV
INVESTIGATION OF THE EFFECTS OF




As with neonates supported by mechanical ventilation, adequate sedation of neonates
receiving extracorporeal membrane oxygenation (ECMO) is essential to allay the
physical, emotional and psychological distress that is inherent during intensive care.
Furthermore, adequate sedation during ECMO prevents excessive movement, which can
affect cannula position and hence blood drainage into the ECMO circuit thereby
reducing gas exchange.
Analgesia and sedation are routinely administered in an opioidlbenzodiazepine
combination, for continuous intravenous sedation in neonatal and paediatric patients
requiring mechanical ventilation. Midazolam is considered to be the drug of choice in
most intensive care units in the United Kingdom. Midazolam, a benzodiazepine
derivative with an imidazole [1,3] ring, is preferred over other benzodiazepines because
of its water solubility and perceived rapid clearance (Jacqz-Aigrain et al., 1992). It
undergoes extensive metabolism by the cytochrome P450 3A (CYP3A) subfamily to a
major hydroxylated metabolite (l-hydroxy-midazolam) and several minor metabolites
(4-hydroxy and 1,4-hydroxy midazolam) before glucuronidation by uridine-diphosphate
glucuronosyl transferases (UGT) and excretion in the urine (de Wildt et al., 2001).
There have been several studies of continuous infusions of midazolam in
critically ill neonates involving preterm neonates or neonates of wide gestational age
range (Burtin et al., 1994; Jacqz-Aigrain et al., 1994; Jacqz-Aigrain et al., 1992).
Although its elimination half-life is significantly shorter than that of other
benzodiazepines such as diazepam, elimination is delayed in pre term neonates
compared with older infants and children (Lee et al., 1999). This is due to significantly
reduced hepatic CYP3A activity in neonates (de Wildt et al., 2001).
The effective and appropriate use of midazolam during ECMO requires an
understanding of its pharmacokinetics. However, it may not be appropriate to relate the
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aforementioned studies to neonates on ECMO, who tend to be term or near term.
Moreover, the disposition of drugs is known to be altered during ECMO. In chapter 3 of
this thesis the sorption of midazolam by the polymeric components of the ECMO circuit
was demonstrated with both in vitro and ex vivo studies (Chapter 3). The uptake was
shown to be a first order diffusion process but also reversible. In addition, physiological
changes as a result of the expanded circulating volume, intrinsic increase in intracellular
and extracellular water, non-pulsatile blood flow during VA ECMO and reduced plasma
protein concentrations may significantly affect pharmacokinetics and
pharmacodynamics (see Chapter 1).
4.2 Aims of the Study
This study had two main purposes. First, to investigate the nature of the dose-
concentration relationship for midazolam in neonates receiving ECMO and compare
this to literature reports in non-ECMO neonates. Second, the pharmacokinetics of
midazolam and I-hydroxy midazolam were to be determined. Since significant
midazolam sorption by polymeric components of the ECMO circuit has been
demonstrated, the study investigated the influence of this phenomenon and whether
pharmacokinetics differed if the drug was administered directly to the patient
(intravenous) or into the circuit (extracorporeal).
An understanding of the pharmacokinetics of midazolam during ECMO helps
promote the development of rational dosing approaches and titration to sedation scoring
systems. Appropriate sedation levels reduce the incidence of haemodynamic side effects
associated with over sedation, expediting return to normal mental status following
cessation of the drug. Thus, the main goals were to improve the accuracy of midazolam
administration by determining pharmacokinetic parameters and through simulations to
suggest an appropriate dosing approach.
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4.3 Materials and Method:
4.3.1 Patients
Entry criteria were neonates with severe respiratory or cardiorespiratory failure in need
of ECMO and who received a continuous infusion of midazolam. Twenty neonates were
randornised into two groups; group 1 received the infusion extracorporealy, pre-
reservoir, via a pigtail catheter, whilst group 2 received the infusion via a central or
peripheral venous catheter. Randomisation was completed as soon as the patient arri ved
on to the intensive care unit and the decision to cannulate for ECMO was made. The
Department of Pharmacy carried out all randomisations using a sealed envelope
technique.
4.3.2 Study Design
Midazolam was administered as a continuous infusion, at a rate usually between 50-
250flg/kglhr. Infusion rates were titrated in line with normal practice in the unit using
the sedation scoring system: 1 = wide awake, 2 = awake but sleepy, 3 = asleep but
moves spontaneously, 4 = asleep, but responds to stimulation, 5 =hard to rouse. The
target sedation score in most cases was 4. Sedation scores were assessed when blood
samples were taken for determination of midazolam concentrations. When levels of
sedation were not satisfactory, rates of infusion were increased or decreased as indicated
and additional bolus injections of 50-100flg/kg were given if necessary. Infusions of
midazolam were initiated as soon as cannulation was achieved and extracorporeal blood
flow established. Infusions were continued for the duration of ECMO, and weaned post
decannulation and prior to extubation. If deemed clinically necessary by the responsible
clinician (for assessment of neurological status or due to over sedation), infusions were
temporarily stopped during ECMO.
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As well as continuous heparinisation to ACT of between 160-200 seconds,
various drugs such as antibiotics, inotropes, diuretics, H2 blockers were co-administered
during the study as indicated. ECMO circuits used in all neonates consisted of Tygon®
S-6S-HL pPVC tubing and the Avecor silicone membrane oxygenator. The priming
volume of the circuit was approximately SOOcm3•The clear prime consisted of l00cm3
of human albumin solution 20% and 400cm3 Plasmalyte A, whilst the blood prime
consisted of SOOcm3donor blood, 120 units heparin, IScm3 sodium bicarbonate 8.4%,
and 2.5cm3 calcium chloride 10%.
4.3.3 Blood sampling and Analysis
Blood samples (Icrrr') for assay were collected from indwelling arterial lines or from
the circuit proximal to drug infusions and the venous reservoir. Samples were drawn at
baseline (prior to cannulation for ECMO), at 2hrs, 4hrs, 6hrs, 12hrs, 18 hrs, 24 hrs and
12 hourly thereafter. Samples were immediately stored at -20°C until analysis.
Concentrations of midazolam and the free unconjugated form of its major metabolite 1-
hydroxy midazolam were determined using GC-MS (see Chapter 2, Section 2.3.3). The
assay was validated over the concentration range 10 ng/crrr' to 10,000 ng/cm'. The
within and between day coefficient of variation was < 10%.
4.3.4 Pharmacokinetic Analysis
4.3.4.1 Model Development
Population pharmacokinetics of midazolam were estimated using WinNonMix
Professional, Version 2.0.1, a non-linear mixed effects regression program, bundled
with Compaq Visual Fortran Compiler, Professional Edition, Version 6.S (see Chapter
2, Section 2.4.3).
105
In a preliminary analysis, the parameters of one, two, and three compartment
models were fitted to the data using this approach. The models were parameterised in
terms of volume of distribution (V) and clearance (CL). The interpatient variability in
parameters was modelled as a proportional deviation from the 'true' parameter values
(assuming a log normal distribution). Residual error was estimated with a combined
proportional and additive model.
The influence of demographic and clinical variables on parameters of the model
were also analysed and where significant added to the model to determine whether the
overall variability in the model could be reduced. These included randomisation
(extracorporeal or intravenous), gestational and postnatal age, weight, gender,
creatinine, urine output, continuous veno-venous haemofiltration (CVVH), liver
function tests, plasma albumin concentrations, co-medication, cannulation mode,
duration of ECMO and ECMO pump flow rates.
4.3.4.2 Cross Validation and Predictive Performance
Since it was not practical to collect new data prospectively, the ability of the final model
to perform in prospective tests was estimated using the cross-validation technique (see
Chapter 2, Section 2.5.5). Although cross validation is not a truly prospective validation
method, it is a recognised and established approach to estimating model performance
assuming identical experimental conditions (Fiset et al., 1995; Kerbusch et al., 200 1;
Zomorodi et al., 1998).
The study group was divided into 8 smaller groups of 2 patients each, and 1
group of 3 patients. The pharmacokinetic model was fitted to the data whilst excluding
one group. The estimated structural parameters from the sub models were then used to
predict the concentrations in the excluded group. This process was repeated 9 times
excluding each group in tum. A measure of the predictive performance of models was
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determined by calculating MDPE and AMDPE as described in Chapter 2. Section 2.5.4.
Since the excluded group is not used to develop the model. the MDPE and the AMDPE
are almost unbiased estimates of the predictive capabilities of the model (Zomorodi et
al., 1998).
4.3.5 Metabolic Ratio
In addition, the area under the curve (AVC) plasma metabolic ratio (1-
hydroxymidazolam/midazolam. MR) was determined using the following equation
(Johnson et al .• 2002):
MR = (C (tt) I-hydroxyMDZ+ C (l2)l-hydroxyMDZ)x 0.5
(C o»MDZ+ C (t2) MDZ)x 0.5
where C (tt)l-hydroxyMDZ.C(I2)I-hydroxyMDZ.and C (II) MDZ.C(12)MDZare the concentrations of 1-
hydroxy midazolam and midazolam respectively. at two time points. This ratio has been
used as a marker of CYP3A activity (Johnson et al .• 2002).
4.4 Statistical analysis
Data are expressed as mean (SO). mean ± SE for population parameter estimates. and
median (range). Differences in plasma concentrations and doses between the two groups
were tested using student's t-test. A p value of <0.05 was considered to be significant.
Selection of the optimal model was based on examination of graphical residuals plots
and the OFV (-2 * the logarithm of the likelihood of the results). A change in the OFV >
7.88 (p<0.OO5) was considered statistically significant (See Chapter 2, Section 2.4.3).
The impact of significant covariates was also evaluated using this approach. The MR
was determined as the median MR from all patients.
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4.5 Results
4.5.1 Demographic and Clinical Characteristics
The group characteristics of the study population are given in Table 4.1. Twenty
neonates were recruited into the study; 10 patients received midazolam into the circuit,
10 patients via a peripheral or central venous line. There were no significant differences
in characteristics between the two groups. Veno-venous ECMO is the preferred mode of
ECMO in this unit and was performed in 17 patients; VA ECMO was performed in 3 of
the patients. CVVH was employed in 7 patients in response to acute renal failure and/or
to attain a negative fluid balance. Three patients died during ECMO, 1 patient died post
decannulation. In 3 of the cases, deaths were as a result of pulmonary or
cardiopulmonary failure, whilst myophosphorylase deficiency was the cause in another.
4.5.2 Dose-Plasma Concentration Analysis
The mean (SD) duration of ECMO for all patients was 6.2 (2.9) days. Data on dosing
was collected for 120 hours or until cessation of infusion, whichever occurred sooner. In
9 patients, midazolam was infused for less than 120 hours as a result of early
decannulation; none of these patients continued on midazolam infusion post-
decannulation. Doses of midazolam administered for all patients during the entire study
period were 250 (185) (range 50 -2200) ug/kgrhour, There were no significant
differences between the two groups in total doses administered over 120 hours.
However, the mean (SD) doses administered in the first 24 hours were significantly
greater in the extracorporeal compared to intravenous group (361 (300) versus 258( 190)
ug/kg/hour, p<O.OOI) (Table 4.2).
There was no significant correlation between duration of ECMO and mean doses
administered or between postconceptional age and mean doses administered. However,
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the lowest mean dose (130 ug/kg/hour) administered was to a neonate of 33-week
gestation and 1 day of age, whilst the highest mean doses (>330 ug/kg/hour) were
administered to 3 term babies greater than 7 days of age.
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Table 4.1. Patient Demographics
Randomisation
Intravenous (n=10) Extracorporeal (n=10)
Sex 50% Males 60% Males
Gestational Age (weeks) 40.2 (1.2) 38.9 (2.4)
(38 -41.6) (33-41)
Age at cannulation (days) 3.6 (5.4) 3.6 (5.6)
(0.5 - 16) (0.5 - 18)
Weight (kg) 3.6 (0.6) 3.2 (0.5)
APGAR Score
1 minute 6.5 (3.5) 7.2(1.3)
S minutes 7.8 (1.9) 9.1(0.9)




ECMO Duration (days) 5.6 (2.9) 6.9 (2.9)
(2 - 11) (4.5 - 12)
Length of ICU stay (days) 12.3 (11.8) 11.3(4.3)
(4 - 19) (7 - 21)
CVVH (patients) 3 4





Post Cardiac Surgery 0 2
Metabolic 1 0
Survival 90% 70%
Data are expressed as mean (SO) and (range)
01 (Oxygen Index) = (Pa02 * Mean Airway Pressure) / Fraction of Inspired Oxygen
CVVH = Continuous veno-venous haemofiltration
MAS = Meconium Aspiration Syndrome
PPHN = Persistent Pulmonary Hypertension of the Newborn
CDH = Congenital Diaphragmatic Hernia
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Table 4.2. Infusion Rates and Plasma Concentrations
All Patients Intravenous Extracorporeal
Infusion Rate over 120 250 (185) 250 (181) 248 (187)
hours (Jig /kglhour) (50-2200) (50 -1600) (50- 2200)
Infusion Rate over first 312 (259) 258 (190) * 361 (300) *
24 hours (Jig /kglhour) (50-1600) (50-2200)
Sedation Score at
24hrs 4.3 (1.0) 4.4 (1.0) 4.2 (1.0)
48hrs 4.2 (0.9) 4.6 (1.0) 4.0 (1.0)
72hrs 3.8 (1.0) 3.7 (1.0) 3.9 (1.0)
Plasma Concentrations
(Jig Icm3) at
24hours 1.4 (0.9) 1.4 (1.2) 1.4 (0.9)
(0.08 - 3.2) (0.3 - 3.2) (0.08 - 3.2)
48 hours 1.8 (1.2) 1.7 (1.8) 1.9 (0.7)
(0.1- 4.9) (0.1- 4.9) (0.5 - 2.9)
72 hours 2.6 (1.8) 2.7 (2.6) 2.2 (1.0)
(0.2 -7.5) (0.2 -7.5) (0.8 - 3.6)
Data are expressed as mean (SO) and (range)
* Intravenous vs Extracorporeal, p<O.OOl. No other significant differences between the two groups were
found.
Plasma midazolam concentration profiles of samples analysed from neonates
during ECMO at the set time points are shown in Figure 4.1. The mean profile reveals
significant attenuation of plasma levels during the first 24 hours of ECMO and then a
subsequent and significant increase suggestive of a reduced rate of elimination. The
overall mean plasma concentration from all samples analysed in the first 72 hours was
1.2 (l.4) (range 0.01 - 9.8) Ilglcm3. Mean (SD) plasma concentrations at 24 hrs, 48 hrs
and 72 hrs were 1.4 (0.9) (range 0.08 - 3.2) Ilglcm3, 1.9 (1.2) (range 0.1-4.9) ug/cm"
and 2.6 (1.8) (range 0.2-7.5) ug/crrr' respectively. A wide interpatient variability was
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seen with values below 1 ug/cnr' in 5 (25%) patients, and values greater than 2 ug/crrr'
in 10 (50%) of patients at 48hrs. There were no significant differences in the mean (SD)
plasma concentrations achieved between the two treatment groups over 72 hours.
Sedation scores for all patients at 24, 48 and 72 hours were 4.3 (1.0),4.2 (0.9), 3.8 (1.0),
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Figure 4.1. Plasma concentration-time profiles of MidazolamJrom the study
population, with the mean profile in bold. The mean dose administered over this
period was 250 pglkglhour.
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4.5.3 Pharmacokinetic Analysis
From a total of 210 midazolam plasma concentrations analysed, 45 (21 %) observations
were excluded from the pharmacokinetic analysis. Excluded observations included 13
observations from the patient with myophosphorylase deficiency who exhibited no
decrease in plasma concentrations despite no drug being administered for 50 hours, 15
observations collected during the post-ECMO period as well as 17 observations that
confounded normal physiological principles (e.g. increase in plasma midazolam
concentrations when no drug had been administered).
The one compartment model was selected for further analysis of midazolam
since it demonstrated a more appropriate structural model on examination of the
graphical residual plots. Furthermore, the OFV was not significantly lower with the two
and three compartment models and estimates of the pharmacokinetic parameters were
less precise, probably a reflection of our limited sampling (particularly in the initial
phase of ECMO) and inability to discern peripheral compartments. Plots of model
parameters versus clinical and demographic covariates revealed no significant
influences apart from randomisation allocation (i.e. whether the drug was administered
extracorporealy or intravenously) with V. The latter suggested that those patients
administered midazolam extracorporeally had a higher V (mean±SD: 13.8±S.2 L versus
1O.9±S.9 L) (Figure 4.2). Although this improved the model by reducing the variability
on the V and the OFV by 3.1U, this was not significant at the p< 0.005 level (Table














Figure 4.2. Volume of distribution versus route of administration
A closer inspection of the residuals against time plot (Figure 4.3a) suggested that
the model under-predicted concentrations in the early phase of ECMO. Therefore the
influence of various time covariates, added categorically to both CL and V (ranging 2 to
24 hours), were tested in the model. The model improved measurably with the inclusion
of a 12-hour time covariate on V, producing a drop in the OFV of 16.6 U (Table 4.3).
This time dependent change in V was attributed to reversible sorption of midazolam by
components of the circuit. Thus, after detecting time-dependency as a significant
covariate for V, the phenomenon was incorporated into the structural model. Midazolam
uptake by the circuit was accommodated by allowing the initial value of volume (Vo) to
increase mono-exponentially to an asymptotic value, Vmax. This approach was
analogous to that previously described by Rostami-Hodgegan et al (1999) for time
dependent changes in CL due to enzyme induction.
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Volume (L) = Vrnax- (Vrnax- Vo)eksor.time
(Where, Ksor = the rate constant for midazolam sorption into the circuit and time =
duration of infusion. Initial estimates were taken from the in vitro results, see Chapter 3,
Section 3.9).
The revised model was considerably better at fitting plasma midazolam concentrations,
abolishing the early trend in residuals (Figure 4.3b) and reducing OFV by 21u, although
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Figure 4.3. Weighted Residuals as a Function of Time. (A) Simple One Compartment Model.
The model seems to under predict in the early phases of ECMO. (B) With the inclusion of a
time dependent increase in volume of distribution, the early trend in the residuals diminishes.
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Table 4.3. Model Development, Covariate Analysis and Predictive Performance
i I Precision
_ M~~ ~_~m~~::~ia_~__~:~ ~_~~~ _
One compartment: i -11.9 36.7
! 242.3 !
(Base Model) I ! (-23.0. 0.8) (30.3. 43.5)
, I-----------------------------t-----------~-------------------------------------------- ---------------.-----------------------------I ! Administration method does
Randomisation on I ! 0.2 19.8
: 239.2 i not significantly influence
Volume ! I (-7.6. 7.0) (16.3.25.3)
f
! volume
---------------------------------- -------------L------------------------------------------------ --------------------- --------------------------
12 hour time I I
! I Clearance is not time 0.3 22.0
covariable on I 241.9 I
I, ! dependent (-6.4.6.2) (18.2.25.4)Clearance !
------------------------------------L------------~------------------------------------------------ ---------------------------------------------------
12 hour time I !
i ! -1.4 20.9
covariable on I 225.7 I Volume is time dependent
i ! (-5.2.3.8) (15.8.25)
Volume ! I
---------------------------------------------1----------------~----------------------------------------------------------- ------------------------- -----------------------------
Time dependent! I Volume expansion with time
! : -0.3 20.0
volume" i 204.7 I (defining midazolam sorption)
I II (-5.2.5.0) (16.2.23.1)




Cross Validation of i ! -0.3 19.3
I :
: I
Final Model I I (-5.6.4.8) (15.1, 23.3)
I ', I
! I
a. V (L) = Vss - (Vss - Vo)eksor.time
b. -2 * log Likelihood
c. Assuming a chi squared distribution. a change in the OFV > 7.88 (p<0.OO5) was
accepted as statistically significant
Figures in parenthesis are 95% confidence intervals for the median.
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The mean individual Bayesian posterior V increased by approximately five fold
from the onset of ECMO to the steady state value (median (range»: 3.1 (1.0-8.0) L
versus 14.2 (4.7-35.8) L, respectively (Figure 4.4). These changes were accompanied by
a significant increase in the initial to steady state half-life (median (range»: 6.8 (2.2-
39.8) hours versus 33.3 (7.4-178) hours, respectively (Figure 4.4). Interpatient
variability in CL and V was 73% and 53%, respectively whilst residual error
corresponded to a proportional error of 26% and an additive error of 0.17 ug/crrr' (Table
4.4). The relationship between observed and model predictions and selected individual
patient profiles before and after the addition of the time dependency model are shown in
Figures 4.5 and 4.6, respectively. The individual Bayesian posterior parameters
estimated from the model described the data well with bias of -0.3% and precision of
20%. The cross validation exercise revealed an overall bias and predictive precision for
the sub models of -0.3% and 19.3% respectively, indicating that the full model is likely
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Figure 4.4.lndividual estimates oleA) volume o/distribution (V) and (B) half-life
(t1l2)obtained using the simple one compartment and time-dependent volume models:
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Figure 4.5. Observed versus (A) Population and (B) Individual Bayesian Posterior
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Figure 4.6. Modelfits to the same patient, «observed concentrations, - individual




Plasma concentrations of the free unconjugated l-hydroxy midazolam were assayed in
12 patients (106 observations with no exclusions). The median MR was 0.17 with a
large interpatient variability (range: 0.03-0.9). Seven neonates (35%) exhibited
biochemical signs of liver dysfunction with raised alkaline phosphatase (ALP) and
alanine transaminse (ALT) though no correlation was observed with MR. However, the
lowest MR (0.03) was observed in a patient with significantly deranged liver function
tests (ALT 281 IU, ALP 922 IV, Bilirubin 100 mmol/L), suggesting impaired
metabolism of midazolam. The highest MR (0.9) was observed in the patient with
highest estimate of midazolam CL (0.23 Lkgl.hr"). Midazolam and l-hydroxy
midazolam pharmacokinetics are summarised in Table 4.4.
Table 4.4. Pharmacokinetic Parameters/or Midazolam and I-OH Midazolam in
Neonatal ECMO Patients
Vo (L)a I Vmax(L)a I K.or (hr") a ! CL (L.hr·l)a tv. (0) (hr)" tl/2(ss) (hr)" MRc
I I l---.-.------L-.-----------.-.-~------ ..--------.--. ---.----..----..---..--- -.-------.-.-.---.--..- ..-.-.-.--.--.-- - -.. -- -- --.- ..--.
2.8±1.7!13.9±1.6 i -O.l9±0.07 I 0.28±O.03 6.8(2.2-39.8) 33.3(7.4-178) 0.17(0.03-0.9)
I I
: I I_____________ j_ L ~____________________ _ -------------- _
53%d I 73%d I
Vo=initial vol ume, Vmax=maximum volume. Ksor=midazolam sorption rate constant Cl.eclearance, t 'r. (0)
=initial half-life. tIJ2(ss)=terminalhalf-life. MR= l-hydroxy midazolam AVC/ midazolam metabolic AVC
ratio
a. Population parameter estimates. expressed as Mean ±S.E.
b. Half-lives were not primary structural model parameters and were calculated as median (range) a
posteriori from individual Bayesian parameter values.
c. Data from 12 patients.
d. Interpatient variability in parameter estimates. expressed as coefficients of variation.
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4.6 Discussion
Following the introduction of midazolam into neonatal intensive care practice in the
1980's, there has been a paucity of published information, not only on efficacy and
safety but also appropriate pharmacokinetic and pharmacodynamic data in critically ill
neonates. The neonatal period is one of rapid and profound physiological changes,
including maturation of renal and hepatic function and changes in body composition
(Rowland et al., 1995). Therefore, neonates present a particular challenge with respect
to pharmacotherapy, with rapidly changing drug disposition (Jacqz-Aigrain et al.,
1996). It would also seem sensible therefore that caution is exercised when
extrapolating data from one neonatal age group to another. Within such a background,
the potential effects of ECMO on drug disposition further complicates and somewhat
diminishes the applicability of such data.
To date there have been three studies investigating plasma concentrations and
pharmacokinetics in neonates following bolus doses of midazolam for sedation in
mechanically ventilated neonates (Harte et al., 1997; Jacqz-Aigrain et al., 1990; Lee et
al., 1999). Of these studies, only one was from near term or term neonates (mean
gestational age 37 weeks) (Jacqz-Aigrain et al., 1990); the other reports were of very
premature infants (24 to 31 weeks and 25-30 weeks) (Harte et al., 1997; Lee et al.,
1999). Two studies involved analysis following initial single bolus doses of 0.2mglkg
and 0.1mg/kg, producing peak plasma concentrations of 0.414 and 0.107 ug/cm'
respectively (Harte et al., 1997; Jacqz-Aigrain et al., 1990). In the third bolus dose
study, O.lmg/kg doses were administered as a single dose or as multiple doses every 4
to 6 hours as necessary; mean plasma concentrations of 0.121 ug/crrr' were reported
(Lee et al., 1999).
Following an earlier bolus dose study (Jacqz-Aigrain et al., 1990), the same
group report three studies investigating continuous infusions of midazolam in
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mechanically ventilated neonates (Burtin et al., 1994; Jacqz-Aigrain et al., 1994; Jacqz-
Aigrain et al., 1992). In an initial pharmacokinetic profiling study of premature
neonates (29-41 weeks), a bolus dose ofO.2mg/kg was followed by a constant
continuous infusion of 60 ug/kg/hour for as long as sedation was considered necessary.
The duration of midazolam infusion averaged 60 (23.3) hrs. Mean (SO) plasma
concentrations at 24 and 48 hours were reported as 0.55 (0.24) and 0.83 (0.39) ug/crrr'
respectively (Jacqz-Aigrain et al., 1992). In another report, the authors describe the use
of a population pharmacokinetic approach to elucidate the influence of important co-
variables on midazolam disposition in neonates (gestational age 29 - 42 weeks). The
study included retrospective data from the previous profiling study, as well as a
prospective analysis with subjects receiving a continuous infusion of 69 (63)
ug/kg/hour. The authors report concentrations of midazolam ranging 0 to 7.1 ug/crrr'. Of
these, 19.7% were above 1 ug/cm" and 4.7% above 2 ug/cm", It was not possible
however, to determine from the report the average levels achieved at 24 and 48 hours
(Burtin et al., 1994). None of the studies mentioned thus far comment on the adequacy
of sedation level achieved with the chosen regimen. However, in the third report on
continuous infusions of midazolam in neonates (mean age 32 weeks), sedation and
haemodynamic variables were assessed in a placebo-controlled study. The infusion dose
was 60 flg/kg/hour, decreasing to 30 ug/kg/hr after 24 hours in infants below 33 weeks
gestation. Mean midazolam concentrations were 0.634, 0.628 and 0.543 ug/crrr' at 24,
48 hours and at the end of treatment. Nurses and physicians assessed sedation to be
adequate in 78 and 65%, 78 and 65% and 75 and 55% of neonates at 24, 48 and 72
hours, respectively (Jacqz-Aigrain et al., 1994).
The present investigation in neonates on EeMO has revealed some potentially
important differences. Doses administered and plasma concentrations observed during
this study appear to be significantly higher than previous reports, with the plasma
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concentration-time profiles suggesting a reduced rate of elimination (Figure 4.1). The
mean (SD) infusion rate for all patients was 250 (185) ug/kg/hour, approximately four
times higher than those reported in any previous study of neonates. The average
concentrations achieved at 24, 48 and 72 hours (l.4, 1.9 and 2.6 ug/crrr', respectively)
are approximately 2-3 times greater than those reported in the aforementioned
continuous infusion studies. In fact 48% of all samples analysed in the first 72 hours
were above 1 ug/crrr', and 21 % were above 2 ug/crrr', The results however, are skewed
by a large proportion (35%) of infants who had evidence of liver dysfunction, a
reflection of the severity of illness in this group. If data from these patients are omitted,
then mean (SD) plasma concentrations at 24, 48 and 72 hours are 1.1 (0.9), 1.5 (0.8),
2.2 (1.0) ug/crrr' respectively. Even so these values remain significantly higher than
previous studies.
It must be borne in mind though that patients in the current study do differ in
some important ways. First, almost all (except one) of the infants were term or near
term. Thus, although plasma concentrations between 0.2 to 0.6 J.Lg/cm3have been shown
to produce adequate sedation in older children (Hartwig et al., 1991; Tolia et al., 1991),
there have been no similar pharmacodynamic studies in term or near term neonates.
Second, neonates referred for ECMO are in severe respiratory or cardiorespiratory
failure with a high oxygen index at referral, often associated with shock and sepsis, all
of which have been shown to affect drug metabolism (Gal et al., 1982; Leppik et al.,
1986; Macnab et al., 1986). ECMO itself may affect renal and hepatic blood flow and
hence drug clearance (see Chapter 1, Section 1.6.4). Cerebral hypoperfusion, as a
consequence of impaired autoregulation of cerebral circulation may occur during
ECMO, especially after hypoxia and if VA ECMO is used, potentially reducing the
efficacy of sedatives and analgesics (Burda et al., 1999). Perfusion of tissues may also
be altered as a result of activation of the systemic inflammatory response syndrome
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releasing a variety of autonomic, endocrine and local cytokine reflexes that may affect
not only tissue distribution of drugs, but also clearance mechanisms as well (Gravlee et
al., 2000). Furthermore, in comparison to the aforementioned study (Jacqz-Aigrain et
al., 1994), the adequacy of sedation was adjudged to be satisfactory in all patients
during this study. Whilst on ECMO, and in order not to compromise blood flow through
the circuit and hence oxygenation, adequate sedation to prevent excessive movement is
maintained at all times. Higher plasma concentrations then may have been necessary to
meet the goals of sedation for neonates during ECMO. However an important argument
against this is that there were no significant differences in the sedation scores recorded
at 24, 48 and 72 hours suggesting that adequate sedation was achieved at lower plasma
concentrations of around 1 ug/crrr'.
It appears excessive plasma concentrations observed during this study are due to
markedly altered midazolam pharmacokinetics exhibited by neonates treated with
ECMO compared to previously reported values. Previous investigators have reported
that a two compartment model is optimal for describing the pharmacokinetics of
midazolam, in contrast to the one compartment model developed in this study (Burtin et
al., 1994; de Wildt et al., 2001; Jacqz-Aigrain et al., 1992; Jacqz-Aigrain et al., 1990;
Lee et al., 1999). This may be a reflection of the study design, utilising continuous
infusions of midazolam with limited sampling in the distribution phase and few samples
captured in the elimination phase.
In this study, parameter estimates are based on a model where V expands with
time as ECMO support progresses. The mean initial V on ECMO was estimated at
0.8Ukg, similar to that previously reported by Burtin et al (1994) in non-ECMO
neonates of gestational ages 26 to 42 weeks (lUkg). This initial V is perhaps lower than
expected considering the expanded circulating volume for a child on ECMO. The
normal intravascular volume for a neonate of 80cm3lkg would be significantly diluted at
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cannulation with the addition of a circuit volume of approximately 500cm3. However,
this parameter was imprecisely estimated with a coefficient of variation of almost 63%.
A time dependent increase in V produced a maximum mean population value of
4.1Ukg, three to four times greater than previously reported in neonates (Burtin et al.,
1994; de Wildt et al., 2001; Jacqz-Aigrain et al., 1992; Lee et al., 1999). The
mechanism for this change is attributed to sorption of midazolam by the ECMO circuit.
The uptake of drugs by polymeric components of the ECMO circuit has previously been
demonstrated through in vitro studies (see Chapter 3). This is a first order, concentration
independent process eventually reaching a state of equilibrium. Many physico-chemical
factors will affect the time to equilibrium and the extent of drug loss including lipid
solubility (or log P values) ionisation status of drugs, circuit surface area to volume ratio
and ECMO flow rates (see Chapter 3). The model estimated the rate of midazolam
sorption to be 0.19 hour-I. This value is similar to 0.42 hour", the estimated rate of
midazolam sorption from the in vitro flow simulation study. Differences may be due to
nature of the mobile phase (i.e. blood rather than aqueous solution), degree of ionisation
and ECMO flow rates.
Inflation in V resulted in a mean terminal half-life of 33.3hours, substantially
longer than previous reports in neonates (12±4.9) hours) (Jacqz-Aigrain et al., 1992),
older infants, children and adults (range, 1-7hours)(Hughes et al., 1996; Matthews et
al., 1988; Payne et al., 1989; Wills et al., 1990). This accounts for raised plasma
concentrations of midazolam observed during the latter phases of ECMO (Figure 4.1)
with levels far in excess of those required for adequate sedation «1 ug/crrr'). Similar
increases in plasma fentanyl levels and the development of tolerance during ECMO has
been reported (See Chapter 1, Section 1.7.1.3) (Arnold et al., 1991; Arnold et al., 1990;
Leushen et al., 1993). Analogous to midazolam (log P 2.7), fentanyl, a highly lipophillic
molecule with a log P value of2.9 (Ngiam et al., 1998) has frequently shown to be
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sequestered by polymeric components of the cardiopulmonary bypass circuit (Hynynen,
1987; Koren et al., 1984;Rosen et al., 1988;Rosen et al., 1990; Skacel et al., 1986).
The enlarged V with associated prolonged half-life not only explains the
observed accumulation of midazolam but may also explain the empirical experience of
nurses and clinicians (described in Chapter 1, Section 1.13) in sedating these children.
Sedation of the infant on ECMO is challenging, the desire to simultaneously achieve
sedation, analgesia and relative immobility is paramount. The enlarged V will however
delay time to effective plasma concentrations at conventional doses. Thus, ECMO
specialists responding to sedation levels will increase infusion rates to achieve
therapeutic levels more rapidly. However, once desired plasma concentrations are
achieved and equilibrium is attained with tissues and the ECMO circuit, infusion rates
need to be decreased. It is obvious from the dosing strategies used in this study that this
does necessarily occur leading to excessive plasma concentrations. The latter may also
then lead to tolerance and subsequently further dose increases as well as withdrawal
symptoms after decannulation.
It is interesting to note that the group that received midazolam extracorporealy
had a significantly higher mean doses administered in the first 24 hours and a tendency
towards a higher V. Although the addition of this covariate did not significantly
improve the fit, it is plausible that a higher V during extracorporeal drug administration
exists due to greater distribution of drug into the polymeric components of the circuit.
This implies that midazolam should ideally be administered directly into the patient via
a peripheral or central venous access.
For ECMO neonates, the metabolic CL of midazolam is similar to that
previously reported in non-ECMO neonates. Population estimates of CL in this study
(0.084 L.kg-1.h{l) was comparable to values previously reported in population studies
of neonates by Burtin et al (0.072 Lkgl.hr") and Lee et al (0.054 Lkgl.hr'), but
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significantly lower than those reported in older infants and children (0.3S-0.82 Lkg
l.hfl) and adults (0.38-0.67 L.kg-1.h(1) (Burtin et al., 1994; Hartwig et al., 1991; Lee et
al., 1999; Reves et al., 1987). Reduced midazolam elimination in the current population
was not unexpected, reflecting the pattern for the ontogeny of CYP3A4 (de Wildt et al.,
1999a). In adults, CL of midazolam has been delineated and correlated with CYP3A4/S
activity (Thurnmel et al., 1994). Hepatic CYP3A4 is abundantly expressed in adults
being responsible for catalysing the biotransformation of approximately SO%of
currently used drugs. CYP3AS expression shows large interpatient differences and has
been shown to be present in only 10-30% of liver samples tested (Wrighton et al.,
1990). In contrast, CYP3A7 is the major isoform expressed in the foetal liver, with
probably only marginal contribution to midazolam CL in the postnatal period. CYP3A4
expression is activated during the first few weeks after birth, increasing thereafter to
reach adult values at 1 year of age, with a simultaneous decrease in CYP3A 7 activity
(de Wildt et al., 1999a).
The MR (I-hydroxy midazolamlmidazolam ratio) was used as a surrogate
marker for CYP3A4/S activity. The median (range) values in ECMO neonates (0.17
(0.03-0.9» appear to be significantly higher than previously reported in preterm infants
(0.09) and similar to that in than in older children and adults (0.13 - 0.2S) (Lloyd-
Thomas et al., 1986; Mandema et al., 1992). It has been reported that CYP3A4
expression is activated irrespective of gestational age (Lacroix et al., 1997) and enzyme
activity increases only marginally during the first 2 weeks of life. Though gestational
age range in this group was higher than previous reports (33-42 weeks versus 26-34
weeks), postnatal age ranges were similar (0.S-18 days versus 3-11 days). Thus the
higher MR in this group does not necessarily represent higher CYP3A activity. Rather,
it may be indicative of reduced glucuronidation of l-hydroxy midazolam by VOT and
thus reduced renal elimination. The developmental ontogeny of VOT has not yet been
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delineated (de Wildt et al., 1999b). The wide interpatient variability in elimination of
midazolam and metabolite, and MR, observed in this study concurs with previous
reports (de Wildt et al., 2001) and reflects not only the heterogeneous and critically ill
nature of the ECMO population, but also indicates that CYP3A and glucuronidation
activity in the neonate exhibits large variability.
The clinical implications of the findings are illustrated in Figure 4.7A. The
figure depicts simulated concentrations for a hypothetical neonate on EeMO receiving
continuous infusions of midazolam at various dose rates, using the estimated population
parameters. These simulations closely resemble the mean observed concentration profile
in this population (Figure 4.1) revealing attenuation of plasma levels during the early
phase of ECMO followed by a significant rise. The results also suggest that a higher
initial dose rate in the early phase of ECMO needs to be followed by a significant
decrease in the dose rate to prevent excessive plasma concentrations. Results from this
investigation suggest that for optimum sedation, plasma concentrations of midazolam
up to 1.0 ug/crrr' are required. This was simulated using an initial infusion rate of 350
ug/kg/hour for 6 hours followed by a drop in the dose rate to 50 ug/kg/hour (Figure
4.7B). Cross validation provides a measure of the predictive ability of the model in the
absence of prospectively collected test data. The exercise revealed an insignificant
change in bias or precision, suggesting that the estimated model is likely to perform
well in truly prospective trials.
4.7 Conclusion
The results of this study show that plasma midazolam concentrations of up to 1 ug/cm'
may be required to achieve adequate sedation in neonates receiving EeMO, higher than
previously reported in non ECMO studies. In addition, the pharmacokinetics of
midazolam in neonates undergoing EeMO are significantly altered. The population
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model reveals a significantly enlarged V, through reversible sorption to the circuit.
Consequently, half-life was prolonged and hence midazolam must not be considered a
short acting sedative agent in neonatal ECMO patients. The MR, a surrogate measure of
CYP3A activity, was also found to be higher than previous reports in preterm neonates,
probably attributable to a reduced CL of the metabolite. Using final model parameters,
plasma rnidazolam concentration profiles were simulated at various dose rates and a
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Figure 4.7. Simulated time-concentration profile using parameters from the final
model. (A) Various continuous infusion rates (B) A regimen consisting of a continuous
infusion rate of 350mcg/kg/hr for 6 hours and then 50mcg/kg/hr thereafter is utilised to




AMINOPHYLLINE DURING PAEDIATRIC ECMO
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5.1 Introduction
Susceptibility of the kidney to hypoperfusion in the patient referred for ECMO is very
high. At the time of initiation of ECMO, patients commonly have hypotension,
decreased tissue perfusion or hypovolaemia secondary to volume loss or vascular
redistribution. In addition ECMO itself may affect renal function. During ECMO,
glomerular filtration rate is transiently reduced due to renal perfusion at a pressure
outside the autoregulatory range. Non-pulsatile blood flow during VA ECMO can also
affect renal cortical blood flow, renal venous return and renal tubular physiology. Other
renal effects of ECMO have included the demonstration of elevated levels of atrial
natriuretic factor, which affects fluid balance and urine production. Plasma renin
activity also appears to be increased in infants during ECMO. This increased activity
may affect blood pressure and fluid balance (ECMO: Extracorporeal Cardiopulmonary
Support, 2000).
There is substantial evidence supporting the diuretic and naturetic effects of
theophylline both in normal subjects and adult patients with congestive cardiac failure
(Davis et al., 1949; Sigurd et al., 1977). More recently it has been shown to be
beneficial in the management of fluid overload in critically ill patients (Lochan et al.,
1998; Pretzlaff et al., 1999). Theophylline is a methylxanthine derivative and its
primary mechanism of diruretic action is to cause vasodilation of the afferent arteriole
and thereby increase renal blood flow and glomerular filtration rate. It appears that the
resulting increased glomerular filtration rate can enhance the diuretic action of
frusemide. In adults and older children, theophylline is extensively metabolised in the
liver by CYPIA2, with only about 10% being excreted unchanged in the urine. In the
premature neonate, theophylline is primarily excreted unchanged in the urine and
approximately 10% is metabolised to caffeine (Dollery, 1991).
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At this institution, continuous infusions of aminophylline are commonly
employed during ECMO ( in conjunction with conventional agents) for its diuretic
properties and in response to renal failure or to manage fluid overload. However, it had
been noted by clinicians, nurses and the researcher that plasma concentrations of
theophylline reported in neonates on ECMO were frequently at potentially toxic levels
(>20mgIL). Although the pharmacokinetics of theophylline in paediatric patients has
been extensively studied (Aranda et al., 1976; Driscoll et al., 1989; du Preez et al.,
1999; Elliott et al., 1976; Gilman et al., 1986; Karlsson et al., 1991; Lee et al., 1996;
Loughnan et al., 1976; Moore et al., 1989; Nassif et al., 1981; Rosen et al., 1979),
suggesting age and weight as the most important determinants of CL and V, there are no
similar studies in patients receiving ECMO
5.2 Aims of the Study
The purpose of this investigation was to determine the influence of the expanded
circulating volume during ECMO on pharmacokinetics of theophylline. A major
advantage of the population approach is that it enables estimates of pharmacokinetic
parameters from sparse drug concentration data obtained from a large number of
patients such as that available from routine therapeutic drug monitoring. This makes it
particularly attractive in the paediatric population, as it does not require a large number
of drug concentration points per patient. Furthermore, since it employs data generated
during routine care, it does not require the patients to be managed under the rigors of a
traditional study protocol.
The interpatient variability of derived parameters and any residual error arising
from assay error and model misspecification was also investigated. Finally, the
influence of patient factors (covariables) on these parameters was explored (Sheiner et
al., 1991; Sheiner et al., 1977).
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5.3 Materials and Methods
5.3.1 Patients
Data were collected retrospectively from medical records and routine therapeutic drug
monitoring database for theophylline, in 75 children admitted for ECMO on the
paediatric intensive care unit. Eligibility criteria included all patients receiving
aminophylline during ECMO with at least 1 serum concentration measurement. The
ECMO circuit used in the study population consisted of Tygon ® S-65HL polyvinyl
chloride tubing and the Avecor™ silicone membrane oxygenator. The approximate
priming volumes of the circuit depend on the patients' age and bodyweight and are
displayed in Table 5. 1.
Table 5.1. Priming Volumes of Extracorporeal Circuits
I I I N I C' I tl A . te .
W . ht lOt I p' . 1 orma ircu a 109 pproxima increaseeig xygena or I nmmg V I a •• I ti I
Range I (Aveeor) Volume 0 urnes m circu ~"I~gvo ume
---- --------t--------------------- ------------------. ---------------------------------------------------------------------------------
Up to 4.9 Kg I osoo I 500 cnr' t' Up to 400 cnr' 125
--------------------------t-------------------~---I-------------------- ---------------------------------------- -----------------------------------------------
5 - 9.9 Kg t- 1500 600 em] Up to 792 cm' 75-__________ _ L____________________________ _ _
U1trox II 3 I10 - 49 Kg . 'I 1200 cm U t 4000 J 25i or 3 poemI Ultrox III I 1000 em I-------------------T2-X-Uitiox-i---tl-------------;-~---------------------------------------- ----------------------------------------------
50 + Kg I or 2200 emJ Up to 5-6000 em] 25 - 33
I 2 x U1trox II i 1500 em
a. Calculated from assumed circulating volume of 80 cm'zkg (Forfar et al./984)
5.3.2 Study Design
Theophylline was administered as a continuous intravenous infusion of aminophylline
into the ECMO circuit, pre-reservoir, initiated at a rate between 5-15J.lglkglmin. Apart
from 2 patients, no loading doses were administered. The decision to initiate treatment
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once the patient had been cannulated for ECMO was made by the responsible clinician
based on clinical and biochemical status. All blood samples were taken from an arterial
line in the patient, or from the circuit proximal to drug infusions and venous reservoir,
at time intervals determined by the attending clinician or clinical pharmacist. The
precise date and time of sampling was recorded on the analysis request form and
transferred with the final results of the analysis onto a computer database.
Demographic and clinical characteristics documented for each serum sample
were: age (postnatal age in neonates), weight, gender, cannulation mode (VV or VA),
pertinent medical history (congenital heart defect, sepsis/pneumonia, congenital
diaphragmatic hernia), urea and creatinine, ECMO flow rates, co-medication (macrolide
and quinolone antibiotics, imidazaole antifungals, phenytoin and phenobarbitone), liver
function tests, requirements for CVVH and c-reactive protein.
5.3.3 Analytical Assay
Serum concentrations were analysed by the Olympus Theophylline enzyme
immunoassay method (Olympus Diagnostica GmbH) in the Department of
Biochemistry, Leicester Royal Infirmary. The limit of determination is 0.8mgIL and the
intra-assay coefficient of variation at 5.5, 13.9 and 26.9 mgIL is 3.0, 1.9 and 1.5 %
respecti vel y.
5.3.4 Pharmacokinetic Analysis
Population pharmacokinetic modelling was performed using WinNonMix Professional,
Version 2.0.1, a non linear mixed effects regression program, bundled with Compaq
Visual Fortran Compiler, Professional Edition, Version 6.5 (See Chapter 2, Section
2.5.3).
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In a preliminary analysis, one and two compartment models with first order
elimination were fitted to all data from all subjects simultaneously. The one
compartment model was selected for further analysis since it demonstrated a more
appropriate structural model on examination of the graphical diagnostic plots as well as
the differences in the OFV values (844 for one compartment model, 843 for two
compartment model). Initial parameter estimates were obtained from a previous report
of population pharmacokinetics in a paediatric population (Driscoll et al., 1989). Once
the base model had been defined, the influence of various demographic and clinical
covariables in the regression models for clearance (CL) and volume of distribution (V)
were evaluated (see Chapter 2, Section 2.5.3).
5.3.5 Cross Validation and Predictive Performance
The predictive performance of our model was tested using the cross-validation
technique (Sun et al., 1999) (See Chapter 2, Section 2.5.5). This method was used since
it was not practical to collect new data prospectively. Although cross validation is not a
truly prospective validation method, it is a recognised and established approach to
estimating model performance assuming identical experimental conditions (Fiset et al.,
1995; Kerbusch et al., 2001; Zomorodi et al., 1998).
The study group was randomly divided into 5 smaller groups of 15 patients
each. The pharmacokinetic model was fitted to the data whilst excluding one group. The
estimated structural parameters were then used to predict the concentrations in the
excluded group. This process was repeated 4 times excluding each group in tum. A
measure of the predictive performance of models can be determined by calculating the
MDPE and AMDPE as described in Chapter 2, Section 2.5.4 (Sheiner et al., 1981).
Since the excluded group is not used to develop the model, the MDPE and the AMDPE
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are almost unbiased estimates of the predictive capabilities of the model (Zomorodi et
al., 1998).
5.4 Statistical Analysis
All clinical and demographic characteristics were reported as mean (SD) and (range).
Population pharmacokinetic estimates are expressed as mean ± SE. Univariate and
multivariate regression analysis was used to reveal trends in the population studies. A p
value < 0.05 was taken as significant.
5.5 Results
5.5.1 Demographic and Clinical Characteristics
The clinical and demographic characteristics of the study population are shown in Table
5.2. A wide range of patients was included, with respect to age, weight and diagnoses.
All neonates were term, and accounted for 49% of the total group. Patients were sedated
with continuous infusions of a benzodiazepine and opioid combination and received
antibiotics based on culture and sensitivity results or as prophylaxis. In 31% of cases
aminophylline was initiated on day 1 of ECMO (range 1 -12 days). A mean of 2.2
(range 1 to 8) serum theophylline concentrations per patient were analysed. Samples
were taken over a wide range of times (median 88.4 (range 9.8 to 431.7) hours)
revealing a median concentration of 15 (range 1 to 38.8) mg/L. The distribution of
sampling times and serum concentrations is presented in Figure 5.1. Serum
concentration exceeded 20mg/L in 27% of cases. Although 10 patients required CYYH,
no patient exhibited significant liver dysfunction apart from neonatal
hyperbilirubinaemia.
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5.5.2 Development of a One Compartment Model
A one compartment model with first order elimination, associated with a proportional
error model for interpatient variability and an additive error model for residual error
produced the best scatter plots of weighted residuals (Figure 5.2 and 5.3) and the lowest
OFV values. Figure 5.2A demonstrates that the weighted residual were randomly
distributed around the zero ordinate with no systematic deviations related to predicted
concentrations, suggesting that the error model chosen was appropriate. Figure 5.2B
similarly resembles random scatter against time suggesting that the one compartment
model was appropriate. During the covariate screening phase, only weight and age
significantly reduced the OFV (>7.88) when added individually. Figure 5.3A shows the
under prediction when weight is low, and over prediction when weight is high when
weight has not been included in the basic model. Figure 5.3B shows the improvement in
the weighted residuals on inclusion of weight in the model. No other covariate
significantly contributed to explaining the variability in the structural parameters and in
fact resulted in poor parameter estimates.
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Table 5.2. Demographic and Clinical Characteristics
Overall Neonates Infants Children(0 -lmonth) (1 - 12 months) ( > 12 months)
Number of Patients 75 38 14 23
Gender
Males 39 27 2 10
Females 36 17 11 8
Weight (kg) 10.3 (15.7) 3.3 (0.5) 4.8 (2.0) 25.3 (22.1)
(2.1 - 85) (2.1 - 4.1) (2.7 -9.0) (9.3 - 85)
Age (days) 713 (1487) 8.4 (5.9) 122 (107) 2236 (1980)
(2-6205) (2 - 28) (29 - 368) (394 - 6205)
Cannulation
VV 57 32 10 15
VA 18 12 3
3
Diagnosis
Post Cardiothoracic 12 4 3 5Surgery
MASIPPHNIRDS 22 22 - -
CDH 10 9 1 -
ARDS 7 - - 7
Pneumonia 11 2 3 6
Sepsis 2 1 - 1
RSV/CLD 5 - 4 1
Other 6 1 3 2
CVVH 10 7 2 1
Co-Medication 29 10 7 12
Number of Serum 160 72 37 51
Concentrations
Number> 20mg/L 43 22 8 13
Infusion Dose 9.2 (2.6)
(ILeIk2Imin) (4 - 16.6) - - -
Data IS expressed as Mean (SO) and Range.
VV - Venovenous, VA - Venoarterial, MAS - Meconium Aspiration Syndrome. PPHN - Persistent
Pulmonary Hypertension of the Newborn. RDS - Respiratory Distress Syndrome. CDH - Congenital
Diaphragmatic Hernia. ARDS - Acute Respiratory Distress Syndrome. RSV - Respiratory Syncitial
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Figure 5.3. Weighted Residuals versus significant covariate Weight (A) before
inclusion in the model and (B) after inclusion in the model
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A significant correlation between CL and weight (r=O.97) as well as age
(r=O.13) was demonstrable. In the cumulative model building process, weight was
optimally modelled as a continuous function on CL and V. Exponential functions of
weight resulted in very similar changes in OFV and thus the simpler model was chosen.
Although the parameter estimate for age in CL was not estimated very precisely
(coefficient of variation (CV) 96.4%), it's inclusion did significantly improve the
model. In contrast, the combination of age with weight in V did not, and thus age was
omitted from V (Table 5.3). The parameter estimates of the final structural and error
models are shown in Table 5.4.
Table 5.3. Covariate Model Building: Effect on Objective Function Value of the
Significant Covariables Weight and Age as Determinants of Clearance and Volume
r- ~dc!~!~!!~.L~_~var:!~.~!~+Q-FVa +__~_!.,!!~eb + ~~~_~_~~~~_~~ _
! f I
CL, V (base model, with no covariate ii'
influence) ! 1154 I
! ! I----------------------------------------------r-------1--------------T----------------------------------------------------------
CL with Weight iii Weight significantly influences
V ( with no covariate influence) I 1061 I P < 0.005 clearance
-------------------------------------!-------4.--------t---------------------------------------------------------------
I ! !
CL ( with no covariate influence) I I I··· .
V • h . h I 1116 l P 0005 I Weight significantly InfluencesWit weig t I! <. t I! i mu~
r---------------------------------------------l---------l------------- --------------------------------------------------------------
CL with weight i I I
V with weight ! 995 I P < 0.005
--- L + ---1------------------------------------------------ __------- _
i I I, , ,
CL with Weight and Age ! i "
V • h W . h i 985 i P < 0.005 Age significantly influencesWit elg t I I clearance
----------------------------------------------------------------t------------+----------------t---------------------------------------------------------------
CL with Weight I! I Age does not significantly influence
V with Weight and Age I 989 I P> 0.005 volume
! ! I
a. - 2 x log likelihood
b. Assuming chi-squared distribution. a change in the OFV > 7.88 (p<O.005) was accepted as
statistically significant.
145
Table 5.4. Population Pharmacokinetic Parameter Details for the Final Model of
Theophylline in Paediatric ECMO Patients
I Estimate" I CV (%)b
----------------------------1--------------------------------------------~------------------------------------------------------
: I
_:~ I O.023±O.OOI6 -+---'--E~--'-
0.000057 ± 0.000055
_._-------------+------------------------- -------------------------------------------------
P3 ! 0.57 ±0.053 9.3----------------------1----------------------------------- r-----------------------------------------------------
Interpatient variability in
1-- c_le_a_ra_n_c_e -t- 0__·(.~_8_~_0_%0_)_~_8. .~.- ..- ..- ..~~_ _ .
Interpatient variability in I







23.7Residual Error 13.0± 3.09(S.D = 3.6mgIL)
81.2
a. Data is expressed as Mean ± SE
b. Precision of the parameter estimates expressed as percentage coefficient of variation (CV).
c. Parameters of interpatient variability expressed as coefficient of variation.
CL (UhT) = f31*Weight(kg) + 132 x Age (days)
V (L) = 13 3 X Weight (kg)
The values of CL and V were estimated with high precision (CV's of 6.9 and
9.3% respectively). The CV of interpatient variability for CL and V were 39 and 42%
(precision 23 and 80% respectively). The additive error model for residual error
estimated a standard deviation of 3.6mgIL. Since this error is constant over the
concentrations studied, the CV in serum theophylline concentrations of 5,10 and 20mgll
would be 72,36 and 18% respectively. The relationship between observed and final
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Figure 5.4. Observed versus (A) Population and (B) Individual Bayesian Posterior
Predicted Concentrations (mgIL)from the Final Model
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5.5.3 Predictive Performance and Cross Validation
The predictive performance of the base model (CL and V modelled with weight only)
when compared to the final model (the addition of age in CL) further confirmed the
superiority of the latter (Table 5.5). The bias of the model reduced from 6.4 to 4.3%
whilst the precision improved from 30.6 to 27.6%. The worst and best predictive
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Figure 5.5. The worst and best time-concentration profiles predicted by the final model. Worst:.,
observed; -, predicted (P); ----, predicted (I). Best (two individuals):*, observed; -, predicted (P);
., observedi-s--« predicted (I)
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The cross validation analysis of the final model revealed estimates of structural
parameters (and their CV's) comparable to those of the final model, suggesting that the
model is likely to perform well in a truly prospective trial during similar conditions. The
validation exercise revealed an increased bias of 9.2% indicating that the model had a
small tendency to over predict. The predictive precision from the cross validation was
determined to be very similar at 29.5% (Table 5.5).
Table 5.5. Predictive Performance and Cross Validation
I
I:-----------------r---------------,--------------------------- -----------------------------------
BiasB (%) i 6.4 (-0.9, 16.3) I 4.3 (-6.6, 13.2) 9.2 (2.9, 16.5)
I II----------------------i----------------r------------------------------------ ----------------------------------------
Preelslon'' (%) I 30.6 (26.6, 34.8) I 27.6 (22.2, 33.6) 29.5 (24.8, 36.0)
: I
Base Model Full Model Cross-Validation
a. Bias (%) = median ([observedij-predictedi/predictedij]*lOO),i (ith individual),j (jth
concentration)
b. Precision (%) = absolute median (lobservedq-predictedj/predictedq]'" 100), i (ith individual),
j (jth concentration)
Figures in parentheses are 95% Confidence Intervals for the median.
In the study by Pretzlaff et at (1999), increased diuresis was observed at
theophylline levels between 6 and 12 mg/L, lower than that required in asthma therapy.
Thus, a proposed new dosing regimen to achieve average steady state concentrations of
10mg/L following a loading dose are displayed in Table 5.6, based on calculations from
the CL and V parameters determined in the final model.
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Table 5.6. Maintenance Doses of Aminophylline (Jlglkglmin)for Continuous Infusion
to Achieve Average Steady State Concentration of lOmglL







































Recommended maintenance infusion rates following an initial Loading Dose (0.57 * Weight
(kg) * lOmgIL). Maintenance infusion rate calculated from: Average steady state concentration
= Rate of infusion I Clearance (using clearance parameters determined in the final model).
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5.6 Discussion
ECMO patients comprise a group from the extreme spectrum of critical illness,
supported with intensive medical interventions and multiple pharmacological agents.
The use of bolus doses of theophylline as a diuretic in ECMO neonates has previously
been reported, revealing an increased urine flow rate when compared with frusemide
alone (Lochan et al., 1998). However, this is the first time that population
pharmacokinetics of theophylline has been reported in paediatric patients receiving
ECMO. Furthermore, in contrast to previous population pharmacokinetic studies, the
model was developed through data obtained from continuous intravenous infusions of
aminophylline.
As with previous studies, weight and age emerge as the most important factors
affecting CL (Aranda et al., 1976; Driscoll et al., 1989; du Preez et al., 1999; Elliott et
al., 1976; Gilman et al., 1986; Karlsson et al., 1991; Lee et al., 1996; Loughnan et al.,
1976; Moore et al., 1989; Nassif et al., 1981; Rosen et al., 1979). Both these covariates
are strong indicators of hepatic and renal maturation. However, in the study reported by
Moore et al (1989), CL was modelled as a non-linear exponential function of weight
showing a disproportionate increase in CL with weight. Even though this investigation
included a wide weight and age range, the regression analysis suggested a linear
relationship with CL. Moreover, exponential functions of weight did not improve the
model. The inclusion of age in the CL model further improved the parameter estimate
and reduced interpatient variability.
As can be seen from Table 5.7, the estimated CL of theophylline from this study
appears to be significantly lower than previous reports of similar age groups. It is
difficult to make a comparison of neonates, since previous studies involved premature
infants of lower birth weights. Neonates in this investigation were full term, of greater
birth weights and would be expected to demonstrate greater CL rates. Nevertheless, CL
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rates determined in this investigation were similar to those found in premature neonates
from traditional pharmacokinetic studies. Although previous population studies in
premature infants by Lee et al (mean weight 1.15kg, mean gestational age 28.5 weeks)
and Moore et al (mean weight 1.5kg, gestational age 31 weeks) have reported similar
models, the differing neonatal populations make comparisons difficult (Lee et al., 1996;
Moore et al., 1989). Estimates of CL in older infants and children are undoubtedly
substantially lower than previous estimates {Figure 5.6) (Driscoll et al., 1989; Elliott et
al., 1976; Loughnan et al., 1976; Rosen et al., 1979).
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Figure 5.6. A comparison of the estimated theophylline clearances based on age
determined by the present study (at U/h, 5r1h and 9r1h percentile weights) and a
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There may be a number of reasons for reduced theophylline CL in an ECMO
population. First, the volume in the ECMO circuit significantly expands the total
circulating blood volume in the patient and therefore would be expected to increase
theophylline's V and may also reduce CL by affecting plasma protein binding (Table
5.1). Theophylline is 50-60% protein bound, and the fraction bound will increase with
an expanded blood volume, decreasing the unbound pool. Since theophylline is a low
extraction ratio drug, a decrease in fraction unbound will result in a reduced clearance.
In the present study, V was modelled as a simple function of weight and the final
estimate of 0.57Ukg may be indicative of an enlarged V in comparison to previous
reports in similar age groups (Elliott et al., 1976; Loughnan et al., 1976; Rosen et al.,
1979). Although sorption to the circuit components may also contribute to an enlarged
V, this is unlikely for theophylline since it has a low log P value of 0.96 (Dollery,
1991).
Second, the majority of these patients have significant and prolonged periods of
hypoxia prior to cannulation for ECMO, often resulting in ischaemic insult to the
kidneys and liver, potentially affecting excretion of unchanged drug in the urine (the
main elimination route in neonates) and hepatic metabolism. Previous workers have
reported significantly reduced theophylline CL in neonates with hypoxia and birth
asphyxia (Estelle et al., 1981; Gal et al., 1982; Gilman et al., 1986). Unfortunately it
was not possible to test the influence of these covariables since an index of hypoxia at
or before cannulation was not available in many patients nor was it possible to ascertain
birth asphyxia in many of the neonates. There was also no discernible relationship
between serum creatinine data and CL. As revealed in Table 5.2,10 patients (13.3 %) in
the study population required renal support in the form of CVVH but no significant
influence on the model was demonstrable.
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Third, although no overt manifestations of hepatic failure were seen, 9 patients
(12%) in the group were referred with congenital diaphragmatic hernia (CDH), a
surgical condition known to alter hepatic blood flow (MacGillivray et al., 1994).
Although this is most likely to affect those drugs with a high hepatic extraction ratio,
significant changes in blood flow may also influence drugs of low to intermediate
extraction such as theophylline (Mckindley et al., 1998). No significant influence was
demonstrable. It is known that cardiac failure can significantly decrease theophylline
CL (Jusko et al., 1979; Self et al., 2(00). Twelve (16%) ECMO patients in this study
were postoperative cardiac surgical patients, often requiring multiple inotropes and
vasopressor agents for cardiovascular support. Once again an influence could not be
detected.
Finally, reduced CL (and higher V) may also be a consequence of the blood
recirculation phenomena during VV ECMO (see Chapter 1). It is inevitable that a
fraction of blood that has been oxygenated in the circuit flows directly from the
reinfusion site to the drainage catheter and back into the circuit instead of the patient's
circulation. The proportion of blood that recirculates is thought to depend on circuit
pump flow, catheter position, cardiac output and right atrial size (ECMO:
Extracorporeal Cardiopulmonary Support, 2000). Since drugs are administered into the
circuit during EeMO, recirculation could significantly affect the removal of drugs. In
addition, high flow rates during VA ECMO produce apulsatile blood flow that can also
alter perfusion of tissues, reducing capillary circulation and aerobic metabolism (Shevde
et al., 1987). Although it was not possible to show a significant influence of cannulation
method on the model, there was a tendency towards an increased V in the VV group.
The ECMO population consists of patients with extremely severe pulmonary or
cardiopulmonary disease as a result of wide ranging primary diagnoses. The
heterogeneous characteristics of the study population may help explain the wide
156
interpatient variability estimated for CL (39%) and V (42%). The study population
included patients with congenital and acquired respiratory failure (infective and non-
infective aetiology), congenital cardiac defects, septicaemia, CDH, post-operative
cardiac and thoracic cases. As described above, the influences of these subgroups in the
model were not detected probably as a result of limited numbers. Furthermore, since the
ratio of extracorporeal:patient volume decreases in older children (see Table 5.1), this
may have contributed to the increased variability in V. Age did not significantly affect
V, however there was a tendency towards a negative relationship with age. It is also not
surprising that the precision with which these were estimated was better for CL (23%)
than V (80%) since a large majority of the serum theophylline concentrations were
sampled at steady state, of which the major influential pharmacokinetic parameter is CL
(Rowland et al., 1995). The estimate of residual error (3.6mglL) is higher than
previously reported and reflects model misspecification, sampling and dosing errors as
well as changing parameters during the period of analysis. The latter point may be
particularly relevant during ECMO since the recirculation phenomenon (affecting CL
and V) would be expected to be less prevalent towards the end of ECMO treatment
when the pump flow rates are significantly lower.
The predictive accuracy and validity of the proposed final model was evaluated
using the cross-validation method. It is evident from the methodology described
(Chapter 2, Section 2.5.5) that cross-validation is a conservative measure of the
expected performance since each sub-model is based on a reduced data set. The analysis
revealed a greater bias than with the complete data set model, suggesting that the
measured values tended to be on average slightly higher than predicted. There was no
great change in the magnitude of the variability in the prediction error (27.6 vs. 29.5%)
confirming that our final model seems to be able to predict with reasonable precision.
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Although it was not a priori aim of this investigation to define an aminophylline
dose regimen for diuresis in paediatric ECMO patients, since ideally this is only reliable
in a well designed prospective pharmacokinetic-pharmacodynamic investigation, the
results of this investigation provide a valuable dosing guide. A large proportion (20%)
of the measured plasma concentrations in this investigation were potentially toxic
(greater than 20m gIL) suggesting a reduction in the maintenance infusion dose rate
prescribed in the study (Table 5.6). The long half-life in this study group (mean 16.6
hours) suggests that an initial loading dose is necessary to achieve effective plasma
concentrations rapidly.
5.7 Conclusion
This is the first report of population pharmacokinetics of theophylline in paediatric
EeMO patients. The estimated CL is significantly lower and the V higher than
previously reported in this age group. These differences are probably as a result of the
expanded circulating volume during EeMO, but also the extreme nature of critical
illness this group comprises, as well as altered renal and hepatic physiology. The large
interpatient variability observed reflects the heterogeneous nature of patients treated on





NEONATAL ECMO PATIENTS: OPTIMISATION OF DOSING
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6.1 Introduction
Neonatal sepsis occurs at an estimated rate of 1 to 2 cases per 1000 live births, with
positive blood cultures in up to 20% of infants in neonatal intensive care units. The
organisms responsible for early onset (first week of life) sepsis include Group B
Streptococcus (GBS) and Escherichia coli and account for 70 to 80% of blood and
cerebrospinal fluid cultures. Although less common, enterococci, Listeria
monocytogenes, and species of gram-negative enteric bacilli other than Escherichia coli
are known to cause disease in neonates (Baltimore et al., 2001).
The aminoglycoside gentamicin is commonly combined with a beta lactam for
prophylaxis and treatment of early onset sepsis in preterm and term neonates(Fanos et
al., 1999). Since the inception ofthe ECMO programme at Glenfield Hospital in 1989,
early onset sepsis has accounted for approximately 9% of the neonates treated on
ECMO. However, a combination of benzyl penicillin and gentamicin is administered to
all neonates cannulated for ECMO, unless otherwise indicated by microbiological
culture and sensitivity reports or if deterioration in clinical condition necessitates a
change in antibiotic therapy. As a result of gentamicin's low therapeutic index and large
interpatient pharmacokinetic variability, plasma level monitoring during therapy is
necessary (Zaske et al., 1982; Zaske et al., 1980). Furthermore, the heterogeneity of the
neonatal population particularly with respect to maturation of renal function requires
dosing regimens to be individualised in order to minimise toxicity (Murphy et al.,
1998).
The pharmacokinetics of gentamicin during ECMO has previously been
investigated (see Chapter 1, Section 1.7.7.1) (Bhatt-Mehta et al., 1992; Cohen et al.,
1990; Dodge et al., 1994; Munzenberger et al., 1991; Southgate et al., 1989). In two of
these studies, pharmacokinetic parameters were compared on and off ECMO (Cohen et
al., 1990; Dodge et al., 1994). All apart from one study suggest altered gentamicin
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disposition during ECMO (Munzenberger et al., 1991). An increased volume of
distribution (V), reduced clearance (CL) and prolonged half-life during ECMO led
many of the investigators to suggest an altered dosing regimen (Cohen et al., 1990;
Dodge et al., 1994). However, to date no study has evaluated a modified dosing
approach during ECMO. At Glenfield Hospital, clinical staff had empirically noticed
that initial dosing regimens quoted by formularies such as Medicines for Children
(2000) and Paediatric Formulary (5th Edition), Guy's, St. Thomas' and Lewisham
Hospitals for term neonates (2.5-3.5mglkg 8-12 hourly) frequently resulted in
potentially toxic trough levels (>2mgIL). This led to repeated measurement of plasma
gentamicin concentrations and many dosage alterations. As a result and following
review of studies undertaken by Cohen et al (1990) and Murphy et al (1998), a
modified initial dosing regimen of 2.5mglkg once a day was trialed over a six month
period.
6.2 Aims of the Study
The aim of this investigation was a retrospective comparison of the steady state peak
and trough levels achieved prior to and after modification of the dosing regimen. This
would allow an evaluation of recommended starting doses. The pharmacokinetics of
gentamicin in neonates during ECMO was also determined and where possible re-
evaluated once the patient came off ECMO.
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6.3 Materials and Methods
6.3.1 Patients
A retrospective analysis of neonates who received gentamicin therapy during ECMO
over a 12 month period was conducted. For the first six months investigated, gentamicin
doses of between 2.S-3.Smglkg 8-12 hourly had been administered on initiation of
therapy. In the subsequent six months, the initial dosing regimen had been modified to
2.Smglkg once a day. Gentamicin was administered as a slow bolus over 3-5 minutes
via the circuit, pre-reservoir and proximal to the oxygenator. Blood samples were
collected just before (trough) and 1 hour after the end of the bolus dose (peak). Patients
were selected by comparing an ECMO admissions database with a gentamicin assay
database held by the Department of Microbiology. Inclusion criteria included all
neonates who had received gentamicin during ECMO and had steady state (3rd dose and
beyond) peak and trough plasma levels recorded. In the event gentamicin treatment
continued post ECMO, plasma levels repeated at a new assumed steady state were also
included. Data on doses administered, demographic and clinical data (urea, creatinine,
urine output, liver function tests) were also collected from the medical records,
discharge summaries and prescription charts. All data was collated and entered into a
Microsoft Excel spread sheet.
6.3.2 Assay Method
All samples were analysed in the Department of Microbiology using the
INNOFLUORTM Gentamicin Assay System (Opus Diagnostics Inc. Fort Lee, NJ) a
fluorescence polarization immunoassay, and using the TDxFLx® analyser (Abbott




Peak and trough plasma concentrations were fitted by log-linear regression analysis,
assuming a one compartmental model with first order elimination. The elimination rate
constant (K, in hr') was determined directly from the slope of the monoexponential
terminal phase (see Chapter 2, Section 2.5)
6.3.4 Statistical Analysis
Clinical characteristics and pharmacokinetic parameter estimates were reported as mean
(SD) or median (range). To ascertain whether clinical covariables were correlated with
pharmacokinetic parameters, single linear regression analysis was performed for each
covariate against V, CL and half-life. The covariates tested included gestational age
(GA), postnatal age (PNA) at cannulation, duration of ECMO, urea, creatinine and urine
output. Differences between the two dosing groups were investigated using the students
t-test, a p value <0.05 was considered statistically significant. All statistical analysis was
conducted using SPSS 10.0 software (SPSS, Chicago, Illinois, USA).
6.4 Results
6.4.1 Demographics and Clinical Characteristics
Clinical and demographic characteristics of the study population are shown in Table
6.1. Although 28 patients satisfactorily met the inclusion criteria, the medical records of
only 22 neonates were located. Ten patients (group 1) received the normal dosing
recommendation for term neonates ranging 2.5-3.Smg 8-12hourly (mean dose
4.Smglkglday). 12 patients (group 2) received the modified dose of 2.5mglkg once a
day. In 13 patients (59%) meconium aspiration syndrome was the primary diagnoses, 3
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(13.6%) patients suffered persistent pulmonary hypertension of the newborn, 3
congenital diaphragmatic hernia and 3 patients with suspected congenital pneumonia.
All patients were term; gestational ages ranging from 36-42 weeks. The majority of
patients (86%) were cannulated for ECMO within 24 hours of birth. All patients
underwent VVcannulation. There were no significant differences in clinical
characteristics between the two groups, apart from serum creatinine concentration. The
latter was lower in group 1 compared to group 2 (74.0 (16.5) versus 94.2 (18.6) umol/L
respectively, P<0.OO5). One patient in each group required renal support in the form of
CVVH during gentamicin therapy. Liver function tests were normal in all patients.
6.4.2 Pharmacokinetic Analysis
A total of 29 peak and trough steady state levels were analysed from the 22 patients.
Figure 6.1 shows the observed plasma concentrations from both groups. The agreed
optimum therapeutic range for peak and trough plasma concentrations was 5-lOmgIL
and <2m gIL respectively. Peak serum concentrations were significantly higher in group
1 than in the group 2 (6.3 (1.5) versus 5.2 (2.0) mgIL, p<O.05) (Table 6.2). Similarly,
the trough levels were also significantly higher in group 1 (2.0 (1.0) versus 1.5 (0.4)
mg/L, P< 0.05). On further analysis, 2 (15.4%) peak levels in group 1 and 5 (31%) peak
levels in group 2 were below the minimum effective concentration of 5mglL. No levels
greater than lOmgIL were reported in either group. With respect to the trough levels, 6
(46%) and 1 (6.3%) of reported concentrations were greater than 2mglL in group 1 and
2 respectively. In terms of the percentage of combined peak and trough concentrations
'hitting' the target range, the dosing approach in group 2 was better than group 1
(62.5% versus 38.5% respectively).
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Table 6.1. Clinical and Demographic Characteristics
--------------l--- Grou~_l (n=~~~ j_ ~_~_~~~_: __~~:_~_~!._
MalelFemale I 8/2 i 6/6
---------------------r-------------------------------------1---------------------------------------------------Weight (kg) . 3_5(0_8) i 3.6 (0.7)
~------------------------------l--------------------------------------L---------------------------------- _
Gestational Age (weeks) i 39_5 (1.4) i 40_2 (1.3)
I It---------------------~----------------------t--------------------------------------------
~~~~~l-~~~~=~
Creatinine (J1IlloVL)* i 74_0 (16.5) I 94.2 (18.6)
!--------------3-------------·---------------------------------------- ---------------------------------------------------
Urine Output (em Ikglhr) I 4_7 (6_5) 3.4 (2_5)
-.-----------------------~------------------------------ f-----------------------------------------------------
Survival i 90% 75%
I
Data expressed as Mean (SD). Median (range)
* p<O.OO5
Table 6.2. Pharmacokinetic Analysis
I Overall Group 1 Group 2 P
r-----------------------~----------------------- ----------------------------------------------------------------------------------
Peak (mgIL) i 5_6 (1.4) 6.3 (1.5) 5_2 (2.0) P<0.05
-------------------ri ---------------------------------------------------------------------------------------------------------------
Trough (mgIL) 1.7 (0.8) 2.0 (1.0) 1.5 (0.4) P<0_05
r------------------~------------------------- -----------------------------------------------------------------------------
V (L/kg) I 0_8 (0.3) j 0_8 (0_2) 0.8 (0.4) p>O_05
f-------------------~-------------------- -------------------------------------------------------------------------
CL (L/kglhr) I 0_044 (0.01) 0.051 (0.009) 0.039 (O.OOS) P<O.005
----------------------------r----------------------------- ----------------------------- -----------------------------------------------------------
Half-Life (hrs) I 12.S (4.4) I 11.6 (2.7) 14.1 (5.4) p>O.05
! !
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Figure 6.1. Steady State Peak and Trough Gentamicin Concentrations
Achieved with the Two Dosing Regimens
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The overall values of pharmacokinetic parameters, V, CL and half-life
determined from the 22 patients were, 0.8 (0.3) Ukg, 0.044 (0.01) Ukglhr and 12.8
(4.4) hours. The estimated parameters when regressed with covariates suggested
significant correlation between serum creatinine and CL (r=0.22) and serum creatinine
and half-life (r=0.28 ) (p<0.05) (Figure 6.2). In the sub analysis, CL was significantly
greater (p<O.05) in group 1 (0.051 (0.009) Ukglhr) compared to group 2 (0.039 (0.008)





















Figure 6.2. Linear Correlation between Serum Creatinine (umol/L) and (A) Half-
Life (hours) and (B) Clearance (Ukglhr)
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In 5 patients (two from group 1, three from group 2), steady state gentamicin levels
were also collected after the child came off EeMO. Increase in peak concentration post
ECMO were observed with no real differences in trough concentrations (Table 6.3). A
comparison of parameters during and post ECMO revealed a significant decrease in V
and half-life and a marginal decrease in CL (Table 6.3 and Figure 6.4).
Table 6.3. Change in Pharmacokinetic Parameters after Decannulation from ECMO
I 00 ECMO (0=5) OtTECMO (0=5)
------------------------------~--------------------------------- --------------------------------------------
Peak (mgIL) i 5.3 (1.6) 7.6 (2.2)
I
----------------------------------------+------------------------------------------------- ------------------------------------------------------
Trougb (mgIL) I 2.0 (1.1) 2.0 (1.6)
I
-------------------------t---------------------------- -------------------------------------------------------




Half-Life (bours) I 16.1 (9.0) 9.7 (2.3)
I
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Gentamicin and other aminoglycosides exhibit concentration dependent bacterial killing
and thus efficacy depends on the peak serum concentration and the ratio of peak serum
concentration to minimum inhibitory concentration (MIC) of bacteria (Rotschafer et al.,
1992). In adults however, trough concentrations below 2mgIL are also desirable to
reduce the incidence of nephrotoxicity and otovestibular toxicity (Munckhof et al.,
1996; Prins et al., 1996; Triggs et al., 1999). Similar evidence for gentamicin associated
nephrotoxicity in neonates is derived from a study that showed raised N-acetyl-beta-
glucosaminidase (a marker of proximal renal tubular injury) in neonates exposed to
gentamicin compared with controls (Rajchgot et al., 1984). In addition, in vitro studies
suggest that exposing bacteria to high aminoglycoside concentrations for prolonged
periods of time can result in down regulation of drug transport into bacterial cells,
whereas a drug free period can increase penetration (Rotschafer et al., 1992). The
results of the present investigation reveal that gentamicin dosing regimens commonly
recommended for term neonates are inappropriate during ECMO, frequently resulting in
potentially toxic trough levels. Furthermore, the pharmacokinetics of gentamicin are
significantly altered during EeMO.
Less than 40% of patients in group 1 achieved satisfactory combined peak and
trough concentrations with the normal dosing recommendations. Although peak
concentrations were adequate in 84.6% of patients, potentially toxic trough
concentrations were observed in almost half of all patients. The dosing schedules used
in these patients were derived from nationally recognised paediatric formularies.
Medicines/or Children (2000) recommends in term neonates a dose of 3.5mglkg 8
hourly (PNA < 7 days old) and 3mglkg 8hourly (PNA > 7days old). The Paediatric
Formulary (5th Edition), Guy's, St Thomas' and Lewisham, recommends in term
neonates a dose of 2.5mglkg 12hourly « 7 days old), and 8 hourly (> 7days old). The
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high troughs observed in group 1 indicate that the dosing intervals were too short. Since
ECMO patients may have severe hypoxic renal insult, reflected in the high serum
creatinine values, it is important to avoid potentially nephrotoxic gentamicin trough
concentrations. In contrast, more than 60% of patients in group 2 achieved satisfactory
combined peak and trough concentrations. It must be noted though that the peak
concentrations were lower, with steady state concentrations below 5mg/L in 31 % of
patients.
This is of potential concern since peak concentrations have been correlated with
outcome. It has been suggested that peak serum concentrations 6 to 10 times the MIC
for the organism are required to optimise bactericidal activity (Blaser et al., 1987;
Moore et al., 1987). A positive linear correlation between clinical response and the peak
serum gentamicin concentrations to MIC (peak:MIC) ratio has been demonstrated in
adults (Moore et al., 1987). Compared with a peak:MIC ratio of2:1, the relative odds of
a clinical response were 4.4 times higher when the peak:MIC ratio was 6 to 8: 1, and 8.4
times higher at a ratio of 10: 1. It is also thought that a peak:MIC ratio of at least 10: 1
may prevent the emergence of aminoglycoside-resistant pathogens (Karlowski et al.,
1994). Since the median MIC of most gram-negative organisms (apart from
Pseudomonas and Serratia) is 0.8 to 1.6 mg/L, dosing regimens that attain high peak
concentrations have been advocated (Rastogi et al., 2002). The target peak range of 5-
lOmgIL during this investigation was agreed in conjunction with the Department of
Clinical Microbiology. It was felt that slightly lower peaks were acceptable because of
the synergistic effects when aminoglycosides are combined with beta lactam antibiotics.
Moreover, a lower peak was particularly acceptable in neonatal ECMO patients at this
centre, where gentamicin combined with benzylpenicillin is used primarily as
prophylaxis. Indeed, neonates referred to the ECMO centre with suspected sepsis or
pneumonia are usually initiated on second or third line agents (3rd generation
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cephlasporins, 4-quinolones, carbapenems, glycopeptides), empirically or as guided by
culture and sensitivity results from the referring hospital. Clearly a higher peak
(>7mgIL) would be desirable when gentamicin is initiated for the purpose of treatment
of an infection. This may be achieved with higher doses at less frequent intervals. From
the parameters estimated during ECMO, a new dosing regimen was calculated using the
equations stated in the methodology. It is predicted that a dose of Smg/kg administered
every 36 hours is required to achieve a peak (lhour post dose) plasma concentration of
7mg/L and a trough below 2mgfL.
The overall estimates of gentamicin pharmacokinetic parameters suggest that V
is enlarged and half-life is prolonged during ECMO. In a recent population
pharmacokinetic study in non ECMO neonates, the V in neonates of gestational age >
34 weeks, was estimated to be 0.50 Ukg (Stolk et al., 2002). Similarly, Murphy et al
(1998) in their sub analysis of a neonatal population estimated V in neonates of
GA>38weeks to be 0.41Ukg. Our overall estimate of 0.8 Ukg (no differences between
the two groups) suggests V is significantly expanded during ECMO. Clearance was
estimated as O.44Ukglhr, and significantly higher in group 1 compared to group 2. This
is a result of poorer renal function in group 2, reflected in the higher serum creatinine
values. It is worthy of note that despite groupl having a higher gentamicin clearance,
mean trough levels were higher than group 2. These estimates for CL do not differ
significantly from previous reports involving term non-ECMO neonates (Murphy et al.,
1998; Stolk et al., 2002). Secondary to the enlarged V, a significantly longer half-life
was also estimated compared to previous reports in non-ECMO neonates (12.8 versus
8.8 hours respectively) (Hayani et al., 1997).
However, it must be remembered that the use of linear regression can result in
imprecise pharmacokinetic parameter estimates. For example a 1 hour post dose peak
assumes complete distribution, which may not be the case in critically ill neonates and
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particularly during ECMO. A change in the sampling times, for example 3 and 10
hours, may have improved the precision of estimates. In addition, errors in the recording
of dosing and sampling times would be expected to affect V more than CL (Sun et al.,
1996). Also, Hoie (1993) reported that bolus doses administered pre-reservoir might
stagnate at the top of the reservoir particularly at low pump flow rates (see Chapter 1,
Section 1.6.1). Since all gentamicin doses administered during this investigation were
by bolus injections into the circuit, pre-reservoir, parameter estimates may have been
affected.
The influence of ECMO on pharmacokinetics and the response to drug therapy
has been studied throughout this thesis by comparisons with previous reports from non-
ECMO patients. Although this strategy has been necessary as a consequence of clinical
and logistical practicalities, it is less than ideal. Such a design inevitably suffers from
greater variability and loss of efficiency since many more patients are required to allow
a firm conclusion to be drawn about the effect of ECMO. The ideal is a longitudinal
cross-over design in which plasma concentration data is collected both during and after
ECMO for each patient (Rowland et al., 1995). That is to say, each patient acts as his or
her own control, an opportunity that presented itself in this investigation. The five
patients from whom it was possible to repeat steady state levels post cannulation clearly
demonstrated a change in pharmacokinetics. There was a significant contraction in the
V and a decrease in the half-life, a phenomenon previously reported (Cohen et al., 1990;
Dodge et al., 1994). The difference in V (accounting for mean weight of 3.4kg) pre and
post ECMO was 1.4 L and larger than previously reported by Cohen et al (1990) or
Dodge et al (1994). This difference in V is not simply accounted for by the neonatal
circuit volume of 500cm3, but highlights the critically ill nature of these patients.
Neonates referred for ECMO have often been aggressively fluid resuscitated with
intrinsic increases in intracellular and extracellular water (Anderson et al., 1992). It has
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also been suggested that sequestration of gentamicin by components of the ECMO
circuit may also contribute to the enlarged V (Dagan et al., 1993). However, this is not
substantiated by similar studies in non-ECMO polymeric devices. Kowaluk et al (1981)
showed that gentamicin sulphate 40mgIL in sodium chloride 0.9% in pPVC bags did
not exhibit significant sorption to the plastic during one week of storage at room
temperature (15 to 20°C). In another study, no loss due to sorption was observed during
a seven-hour simulated infusion through an infusion set consisting of a cellulose
propionate burette chamber and 170 cm of pPVC tubing (Kowaluk et al., 1982).
Although an actual log P value of gentamicin was not determined or located in the
literature, it has previously reported as being very low (Jenke, 1994). Thus, on this basis
one would not expect significant sorption to the circuit components. The change in
parameters post ECMO suggests that continuation of gentamicin treatment after
decannulation, requires dosing regimens to be altered in line with normal








As with other critically ill patients, ECMO patients are at an increased risk of serious
infections because of invasive investigations and monitoring, central catheter related
bacteraemias, multi-organ failure and immunosuppression. In addition, ECMO patients
may have increased risks related to the circuit with prolonged exposure of blood to large
polymeric surface areas and multiple ports of entry for organisms. At this institution,
vancomycin is administered prophylactically as a single dose immediately post
cannulation for ECMO, and also to treat serious infections caused by staphylococci,
particularly coagulase-negative staphylococci. However the narrow therapeutic index of
vancomycin, in particular the risk of nephrotoxicity, has lead to an interest in the
pharmacokinetics of this antibiotic.
Previous studies of vancomycin pharmacokinetics during ECMO seem to
provide conflicting results (Amaker et al., 1996; Buck et al., 1998; Hoie et al., 1990).
Although an expanded volume of distribution (V) with consequent reduced elimination
is hypothesised, many of the studies did not seem to corroborate this. These studies
involved neonates or infants and were limited by small numbers. Furthermore,
pharmacokinetic parameters were determined using non-population approaches and thus
population variability and the influence of significant covariates were not identified
satisfactorily. Little or no emphasis was placed on dosage regimen design.
7.2 Aims of the Study
The purpose of this study was to determine the population pharmacokinetics of
vancomycin in neonates, older children and adults treated on ECMO, and to characterise
the population variability. In addition, by identifying significant covariates, new dosing
guidelines could be recommended.
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7.3 Materials and Method
7.3.1 Patients
This study was approved by the Leicestershire Research Ethics Committee and utilised
both prospective rich and retrospective scant data. For those patients enrolled in the
prospective study, assent was obtained from parents or relatives. All patients in whom
vancomycin was administered during ECMO support were eligible for study.
Vancomycin was administered as a one hour infusion and initial doses were determined
according to age and weight. In the prospective study, plasma samples were taken from
those patients administered vancomycin prophylactically as a single dose post
cannulation or after the first and fourth doses when it was used to treat suspected or
confirmed infection. Samples for analysis were taken at baseline prior to initiation of
infusion and then 0,30,60, 120, 180,360 minutes post infusion. Sparse and routine
plasma concentration data collected during vancomycin treatment was obtained
retrospectively from an assay database held in the Department of Microbiology, cross-
referencing with the patients' medical records. All concentrations were steady state,
usually obtained as peak (lhour post infusion) and trough levels (end of dose interval).
The following continuous and categorical clinical data were documented for all
patients where possible: age (post natal, post- conceptional and gestational for
neonates), gender, weight, diagnosis, duration of ECMO, cannulation mode, outcome,
urea, creatinine, urine output and requirements for CVVH.
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7.3.2 Analytical Assay
Vancomycin assays were performed by the Department of Microbiology using the
Innofluor® fluorescence polarization immunoassay. The limit of determination is
1mgIL and the intraassay coefficient of variation is less than 6.0%.
7.3.3 Pharmacokinetic Analysis
Rich prospective and sparse retrospective data were collated, evaluated and entered into
an Excel spreadsheet, and then analysed using the mixed effects non-linear regression
modelling programme, WinNonMix Professional (Version 2.0.1) bundled with Compaq
Visual Fortran Compiler Professional Edition (Version 6.5) (See Chapter 2, Section
2.4.3). Initial parameter estimates were derived from non linear regression analysis of
the rich data set using WinNonLin (Version 3.0) as described in Chapter 2, Section
2.5.2).
7.3.4 Validation Data Set
To validate the model and the population pharmacokinetic parameter estimates, plasma
concentrations of vancomycin observed during routine monitoring in a separate group
of 20 patients were compared with the concentrations predicted by the model. A
measure of the predictive performance of models can be determined by calculating the
MDPE and AMDPE as described in Chapter 2, Section 2.5.4.
7.3.5 Statistical Analysis
All clinical and demographic characteristics were reported as mean (SD) and (range).
Population pharmacokinetic estimates are expressed as mean± SE. For comparison of
parameter estimates between the three age groups, one way analysis of variance was
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used. Univariate and multivariate regression analysis was used to reveal trends in the
population studies. A p value < 0.05 was taken as significant.
7.4 Results
7.4.1 Clinical and Demographic Characteristics
The clinical and demographic characteristics of the study group are summarised in
Table 7.1. A total of366 plasma vancomycin concentrations from 45 patients were
included in the analysis. Of these, 26 patients were investigated prospectively, providing
227 (62%) plasma concentrations. In 9 of these patients plasma sampling followed a
single dose that was administered following cannulation and once extracorporeal blood
flow had been established, whilst in 17 patients sampling followed the first and fourth
doses during the treatment of suspected or confirmed infections. Two patients were
excluded from the original data set because of misplaced medical records.
The overall distribution of sampling times is shown in Table 7.2. Prophylactic
doses of vancomycin were 15 mg/kg in neonates and children, and l000mg in adults.
For treatment, initial doses ranged between 10-15 mg/kg every 6 to 24 hours in children,
and 750-1000 mg every 12 to 24 hours in adults. The overall mean (SD) peak and
trough concentrations at steady state were 30.0 (10.1) and 11.9 (6.B) mg/L respectively.
(The reference range for vancomycin serum levels at this institution is trough 5-15 mg/I,
peak 20-30 mg/l). All neonates in the study were term or near term with median (range)
gestational age 40.4 (34.3-42) weeks. Where determined (n=3B), the majority of patients
(B4%) underwent VV ECMO, the most popular mode at this institution. The mean
duration of ECMO was longer in adults (30B.Shours) compared to neonates and older
children (220.2 and 257.9 hours respectively), reflecting the typically longer and more
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complicated course of illness amongst adult ECMO patients. Mean (range) serum
creatinine levels were significantly higher amongst adults (125.1 (48.3-224.5»,
compared to neonates and older children (79.6 (39-180) and 73.5 (26.5-158.9) umol/L
respectively). However, a greater number of children (42%) were supported with
CVVH than neonates or adults (13% and 33% respectively).
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Table 7.1. Clinical Characteristics of Study Group
Overall Neonates Children Adults
(O-lm) (lm-18yrs) (> 18 yearsl
Number of Patients 45 15 12 18
Male 29 8 9 12
Females 16 7 3 6
Weight (kg) 36.0 (38.2) 3.5 (0.5) 14.3 (16.1) 78.8 (20.3)
(2.5 - 116) (2.5 -4.5) (2.4 - 57) (49.5 - 116)
Age (days) 4800 (5870) S.2 (10.7) l358 (1712) 11472 (4344)
(0-22452) (0 - 2S) (62 -5493) (6109 - 22452)
Sparse Data Group 19 2 5 12
Rich Data Group 26 l3 7 6
Number of samples per
patient
Sparse S.2 (4.1) 8 (2.9) S (4.2) 6.9 (4.9)
(2 - 20) (4-12) (3-18) (2-20)
Rich 7.3 (2.S) 5.8 (2.8) a.i (2.5) 9.5(3.1)
(4-12) (4-12) (4-12) (5-12)
Serum Creatinine 97.3 (54.2) 79.6 (30.8) 73.5 (38.9) 125.1 (61.3)
("mollL) (26.5 - 224.5) (39 -180) (26.5-158.9) (4S.3 -224.5)
CVVH l3 2 5 6
Cannukuion
VV 33 12 4 17
VA 6 2 3 1
Undetermined 6 1 5 0
Duration of ECMO 264.4 (197.3) 220.2 (14S.9) 257.9 (157.8) 30S.5 (243.1)
(hrs) (50-907) (50-494) (73-550) (86-907)
Outcome
Survived 27 11 5 11
Deceased IS 4 7 7
Data are expressed as Mean (SD) and (Range)
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Table 7.2. Number of Vancomcyin Plasma Samples
Rich Data Number
Sample Time (hours post
infusion)
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7.4.2 Development of a Two Compartment Model
The two compartment model was chosen in preference to the one compartment model
since it demonstrated a more appropriate structural model on examination of the
graphical residual plots and a lower OFV. Although a three compartmental model
resulted in a further lowering of OFV, it was not explored because the parameter
estimates were imprecise, probably reflecting insufficient sampling to allow three
compartments to be discerned. Residual error was best described by a combined
additive and proportional structure. Significant improvement in model fit was achieved
when weight was associated linearly (without an intercept) with each parameter, and as
stated in the methodology (Chapter 2, Section 2.5.3), before investigation of other
covariates. Allometric transformation of weighto.75 was also tested, but did not further
improve the fit Plots of Bayesian posterior estimates of parameters from the basic
model versus the covariates revealed significant correlations (Figure 7.1): CL with
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creatinine and age, central volume (VI) and intercompartmental clearance (Q) with age,
Q with ECMO pump flow rates. The significance of these relationships was investigated
by hypothesis testing of full and reduced model during the covariate screening stage
(Table 7.3). The largest decrease in OFV (97U) was observed when creatinine was
incorporated into a non-linear model of CL (CL: el *Cr 62, where e is to be estimated).
Since the estimate of e2 was -0.9, the model was simplified to el/Cr, without a
significant change in OFV. Clearance was linearly related to age in neonates and
children up to 1000 days, but beyond this, was independent of age. Surprisingly, there
was no significant difference in CL between those patients on and off CVVH (p=O.183).
Although V I decreased with age, there appeared to be a bimodal distribution with a
break point at 4000 days. Thus the influence of age on VI when included into the model
as a dichotomous variable resulted in a significant drop in OFV. Although the
incorporation of an inverse relationship between age and Q in the model reduced OFV
significantly, it was not included in the final model since it had little influence on the
scatterplots or interpatient variability. By the same rationale, the positive influence of
ECMO pump flow rates on Q was also omitted from the final model. The final
structural model and parameter estimates are displayed in Table 7.4. The weighted
residuals associated with the final model were randomly distributed (Figure 7.2).
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CL=Clearance, Q=Intercompartmental Clearance, Vl=Central Volume, V'Te'Volume of TIssue
Compartment, Cr=Serum Creatinine
a. A change in the OFV > 7.88 (p<0.005) were accepted as statistically significant.
b. 92estimated when age was less than 1000days.











Figure 7.2. Frequency distribution of Weighted Residuals from the final model
The relationship between observed and model predictions and selected
individual patient profiles obtained using the basic and final models are shown in
Figures 7.3 and 7.4, respectively. The parameters estimated from the final model
described the data well with a bias of -1.9% and precision of 20.3% (Table 7.7). The
mean Bayesian posterior estimates of CL, VI, volume of distribution at steady state
(Vss) and half-life determined by the final model for each age category are displayed in
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Figure 7.3. Scatterplot of observed versus population predicted plasma vancomycin
concentrations (mgIL) indicated a closer distribution around the line of unity for the
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Figure 7.4. Model fits to the same patient, • observed concentrations, -population
predictions: (A) Basic model (B) Final Model. Daily dose was increased/rom
1000mg twice daily to 1500mg twice daily at 71 hours.
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Table 7.4. Population Pharmacokinetic Parameter details for the final model of




Age < 1000days 0.18
_____________________________________L ~~_~~:~~~ ~_~_~~_~~~_~ ~ ._
4.3/Cr (umol/L), if Age>
1000days
-------------------------------t----------------------------------------- ----------------------------------------------
Q (Llkglhr) I 0.09 0.023
!------------------------------+----------------------------------------- ------------------------------------------------
I
VI (Llkg) I 0.45, if Age <4000 days 0.038
I 0.37, if Age> 4000 days 0.042
---------------------------1-------------------------------------- ---------------------------------------------





CL I 25 %
-----------------------------------------------1--------------------------------------------- ------------------------------------------------







Residual Error I 12.1% ± 2.1 mgIL
0.24
a. Expressed as coefficient of variation
189
Table 7.5. Summary of Bayesian posterior parameter estimates in the age related
categories
I Overall Neonates Children Adults
r--.--------}-------------l-------------------- -----------------------------------------------------------
i I




Vss (L/kg) I 0_71(0.20) I 0.67
r---------------1------------------1---------------------- ------------------------------------------------- --------------
I I



















The 20 patients in the validation group (8 neonates, 4 children, 8 adults) provided a total
of 108 plasma concentrations for evaluation (Table 7.6). These observed concentrations
were compared with predictions made by the final model. A scatter plot of residuals
(observed minus predicted concentrations) against the observed concentration revealed
homogeneous scatter around the zero ordinate (Figure 7.5). The bias for the validation
set was -7.7%, indicating that the model has a slight tendency to over predict. The
predictive precision of the model was found to be 26.7%, indicating that on average the
size of the error was less than 26.7% of the predicted concentration (Table 7.7).
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Table 7.6. Clinical and Demographic Characteristics of Validation Group





Number of Patients I 20
i----M-;;i;W;;;;;I~----------!---14i6--- ------6/f----- --------li3----------- -- ---iiT---------
II-----------------------+------~--------------------------------r--- -- ---- -- -- ----·--
Weight (kg) I 42.4 (44.5) 3.6 (0.6) 21.9 (23.0) 91.4 (20.7)
r--------------------------------------L--------------- ------------ ---------------------------.----------------------
Age at cannulation (days) I 6157 (7436) 5.5 (8.8) 2196 (2597) , 14290(4403)
--Cannulation(VViv A) -bm-~m---3fj---~---IiJO--
f--.----------------------l---------- f------ ------------.---+----------------------.---
CVVH ! 13 4 3 I 6
r----gerumc..eaiinui.iPffio~i:5(74_1)- -65:6(34.4.) 56:9iI7:9>"+"15'i3(79:6)
I I-:.----------------------------+--------- -------------------------------------t------------------·----·---
Number of samples per patient I 5.4 (3.1) 4.9 (4.2) 4.3 (1.5) I 6.5 (2.3)
I i
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Figure 7.5. Assessment of predictive performance of final population model in a
separate set of 20 patients (108 observations): Plot of residual (observed minus
predicted) versus observed plasma vancomycin concentration.
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Table 7.7. Model Validation and Predictive Performance
I Base Model Full Model Validation
I
~·----------------------------t----------------------------- _ .._--------_ ...-..__ ............ _------- ----------------------------------------
-7.7Bias" (%) i -0.8 -1.9
- I (~.5~.4l __ _j_-----(:-~~~-~}~91---------__________t}~: 2~_~_~:~2________
Preelsion" (% ) I 29.5 20.3 26.7
I (25.8, 32.4) (18.2,22.5) (17.5, 36.9)
a. Bias = median ([observedij-predictedij/predictedij]*lOO), i (ith individual), j (jth concentration)
b. Precision = absolute median (lobservedq-predictedypredictedjl" 100), i (ith individual), j (jth
concentration)
Figures in parentheses are 95% Confidence Intervals for the median.
The population parameter estimates from the final model and two compartment
model equations, entered into Excel spreadsheets, were used to determine dosing
regimens required to achieve approximate peak and trough concentrations of 30 and 10
mgIL respectively, for a range of age and creatinine values (Table 7.8). For illustration
purposes, these developed dosing regimens and final model parameters were used to
simulate plasma profiles as displayed in Figures 7.6 and 7.7.
Table 7.8. Dosing Guidelines
Dose (mgIkg) I
Interval (bours) Age (days)
1 1000 >4000365 1000·4000
Creatinine (pmoIlL)
,...._-------------------------- --------------------- ----------------- ----------------------- ------------------------ -------------------------
25 15/8 20/8 20/6 20/6 20/6,...------------------- ---------------t----------------------- ----------------- -----------------------------------------------
50 10/12 10/8 10/8 10/6 10/6
100 10/24 15/24 10/12 15/ 18 10 /12
r---------------- ------------- ---------------------------------------------------------------
------------------------ ---------------------- -------------------- r---------------------- ------------------------- -------------------------
150 15/48 15/36 12.5 /24 15/24 12.5/24
f-.------------ ---Re-do~-;~fle";-----I------------- -----------------------------------------------------------
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Recent years have seen an increased usage of intravenous vancomycin in intensive care
patients. Nephrotoxicity and ototoxicity associated with vancomycin was originally
related to impurities in the preparation as well as high serum concentrations but with
purification and improvement in formulation, the incidence of toxicity is not thought to
be as prevalent (Odio et al., 1984). Furthermore, there are no definitive studies
correlating toxicity with serum vancomycin concentrations, raising questions as to
whether or not there is a need to monitor serum levels (Bhatt-Mehta et al., 1999).
However, since vancomycin exhibits concentration independent, time dependent
bacterial killing, maintaining minimum plasma levels is crucial and monitoring of
trough levels is stilI considered necessary, particularly in critically ilI patients exhibiting
wide interpatient variability (Duffull et al., 1994; Lowdin et al., 1998; Zimmermann et
al., 1995). Although pharmacokinetic data has become more readily available in this
population, there have been limited and contradictory reports from ECMO patients.
There have been four previous reports of vancomycin pharmacokinetics during
ECMO (Amaker et al., 1996; Buck et al., 1998; Capparelli et al., 2001; Hoie et al.,
1990). Three of these studies were specifically designed to investigate ECMO patients
and determined parameters utilising traditional pharmacokinetic approaches. Hoie et al
(1990) investigated six term neonates, fitting either a one (n=3) or a two compartment
model (n=3). They report a combined mean VI and V~ ofO.68 Ukg and CL of
0.066Ukglhr, concluding values were similar to previous reports from non-ECMO
infants. However, the dosage regimen of 20mg/kg 18 hourly they propose in patients
with normal renal function suggests reduced CL and enlarged V. In contrast, Amaker et
al (1996) investigated 12 infants undergoing ECMO (mean gestational age 39 weeks,
mean creatinine 99 umol/L), revealing a larger Vss (mean±SD; 1.06± 0.45 Ukg), a
lower CL (0.047 ± 0.011 Uhlkg) and a prolonged tl12P(16.9 ± 9.5 hours). Buck et al
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(1998) compared ECMO patients (n=15) with a control group (n=15) utilising steady
state peak and trough measurements, and found no significant differences in V and CL
but a longer half-life in ECMO patients (8.29±2.23 versus 6.53±2.05 hours). A recent
population study of 374 infants (including 15 ECMO patients) identified ECMO
patients as displaying an enlarged V and reduced CL, although not significantly so, once
serum creatinine and gestational age had been included in the final model (Capparelli et
al.,2oo1).
Vancomycin is excreted by glomerular filtration with 80 to 90% of the dose
recovered unchanged in the urine 24 hours after administration in healthy adults
(Rodvold et al., 1997). The present study population involved wide, age range related,
serum creatinine values. In total, 10 neonates (66%) and 5 children (42%) had creatinine
values above 60 micromol/l, whilst 11 adults (61%) exhibited values greater than 120
micromollL These creatinine values reflect the critically ill nature of ECMO patients
with likely hypoxic ischaemic renal injury prior to the initiation of ECMO. A high
proportion of patients (29%) also required CVVH support, often initiated to improve
fluid balance. Similar to previous population studies in non-ECMO patients,
vancomycin CL was strongly associated with renal function, the model improving
substantially when serum creatinine values were associated with CL (Capparelli et al.,
2001; Grimsley et al., 1999; Yasuhara et al., 1998). Furthermore, estimates of creatinine
corrected vancomycin CL during ECMO were substantially reduced compared to those
reported in non-ECMO patients (Healy et al., 1987; Lamarre et al., 2000; Naqvi et al.,
1986; Polard et al., 1999; Rotschafer et al., 1982; Rybak et al., 1990; Schaad et al.,
1980; Seay et al., 1994).
Caparelli et al (2001) determined the CL in a typical study infant (creatinine= 53
umol/L, weight = 1.8 kg, GA =33.5 weeks, age=27days) to be 0.066Ukglhr. The mean
Bayesian posterior estimate of CL for term neonates in this study was 0.041Ukglhr
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(creatinine =79.6 umol/L, weight=3.5kg, GA= 39.8 weeks, age=8.2 days). Although
serum creatinine values are higher in the present study, one would nevertheless expect a
higher CL in term or near term neonates. Two previous studies involving infants and
children, reported CL of 0.071Ukglhr and 0.08Ukglhr in their sub-analysis of term
neonates (Naqvi et al., 1986; Schaad et al., 1980). Creatinine clearance in neonates has
been shown to increase exponentially by a factor of 8 between 28 and 40 weeks
conceptional age (Rowland et al., 1995). Furthermore, 4 of the neonates in the present
investigation were of postnatal age below 3 days, and so mean creatinine may have been
skewed by residual maternal derived creatinine (Drukker et al., 2002).
The observed increase in CL with age (up to 1000 days) during this study is in
line with age related maturation of kidneys. Although renal clearance is slow in the
neonate, it has been shown to increase rapidly with age so that clearance in children is
considerably higher (Rowland et al., 1995). Previous studies have reported total body
clearance of vancomycin to be 2 to 3 times higher in the paediatric population
(O.283Ukglhr) compared with adults (O.084Ukglhr) (Rodvold et al., 1988; Schaad et
al., 1980). The mean Bayesian posterior estimate of CL for children and adults in this
study were 0.057 and 0.044 Ukglhr respectively. In the study by Rodvold et al (1988)
non ECMO adults with mean serum creatinine of 97, 123, 185 umol/L displayed a mean
vancomycin CL of approximately 0.09, 0.047,0.022 Ukglhr respectively. In
comparison and from a sub analysis of the present investigation, 9 adults with mean
serum creatinine of 72 (21.3) umol/L revealed a CL of 0.062 (0.02) Ukglhr.
Interestingly, there was no significant difference in CL or other parameters in those
patients requiring CVVH, suggesting that creatinine is a more appropriate indicator of
vancomycin CL even during CVVH.
Decreased creatinine corrected vancomycin CL in ECMO compared to non-
ECMO patients of similar age may be due a number of factors. An obvious difference
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during ECMO is the expansion in circulating blood volume. This will necessarily
enlarge the V for a water soluble molecule like vancomycin, and may also reduce CL.
Increase in total blood volume is related to circuit size and ranges between 25% (adults)
and 125% (neonates) (see Chapter 5, Section 5.3.1). This was reflected in the population
estimates of VI, determined to be higher in neonates and younger children (age < 4000
days) compared to older children and adults (0.45 versus 0.36Ukg respectively). The
estimate ofVss (0.71Ukg) is less than previously reported in ECMO infants by Amaker
et al (1.06Ukg), but higher than that reported in non-ECMO studies (0.38-0.64Ukg)
(Naqvi et al., 1986; Rodvold et al., 1988; Schaad et al., 1980). Changes in V may not be
simply due to the extra circulating volume, but also due to increased extracellular fluid
and increased renin and atrial natriuretic peptide release secondary to non-pulsatile renal
blood flow during VA ECMO (Bartlett, 1990).
An additional but thus far little investigated phenomenon during VV ECMO is
recirculation of blood, where a fraction of oxygenated blood from the circuit flows
directly from the re-infusion site to the drainage catheter and back into the circuit
instead of the patient's circulation (See Chapter 1, Section 1.6.4.2). At high flow rates
(circa 12Ocm3/kglmin) as much as 60% of blood returning from the circuit may
recirculate. In the compartmental model, the ECMO circuit may constitute a peripheral
compartment, distinct from tissues. During the early period of ECMO with high flow
rates, recirculation of blood will significantly affect distribution of drug into systemic
circulation and hence elimination of drug. However, as ECMO support is weaned with
lower flow rates, recirculation is significantly reduced «10%) and no significant
influence is expected. Although the model developed in this investigation did not
incorporate this phenomenon, intensive sampling during and immediately post infusion
would enable the 'ECMO compartment' to be characterised. This phenomenon also
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suggests that pharmacokinetic parameters will necessarily change with time, reflected in
the residual error.
The validation group had similar characteristics to the study group. Although the
proportion of paediatric patients in the data set was less, they were spread over the age
range: one aged 44 days, weight 3 kg; one aged 2.3 years, weight 11kg; one aged 5
years, weight 18.5 kg; one aged 16 years, weight 55kg. However, there was a greater
degree of renal dysfunction in the validation set with 65% of the patients having
received CVVH support compared to 29% of the study group. The validation set also
had higher serum creatinine levels (111.5 versus 97.3 umol/L), This may explain the
slight tendency of the model to over predict.
Dosing guidelines constructed using parameter estimates from the final model
highlight the influence of two significant covariates, age and serum creatinine. Using
these dosing regimens, plasma concentration profiles and associated 95% confidence
intervals of the population variability were simulated. Since minimum plasma
vancomycin concentration is all important for antimicrobial efficacy, the aim was to
maintain trough levels between 1O-15mg/L, and to avoid the lower and upper
confidence intervals falling outside 5 and 20mg/L respectively (de Hoog et al., 2(00). It
is also important to note, though mean plasma concentration profiles obtained in all
simulations were acceptable, the confidence intervals highlight the difficulty in
predicting vancomycin pharmacokinetics in an individual during ECMO.
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7.6 Conclusion
In a study group consisting of the full spectrum of term neonates, older children and
adults with a wide range of primary diagnoses, a population pharmacokinetic model for
vancomycin during ECMO was developed for the first time, based on serum creatinine
and age. Parameter estimates reveal significantly reduced vancomycin CL and expanded
V when compared to critically ill non-ECMO patients of similar age and confirms
altered disposition during ECMO. The pharmacokinetic parameter estimates were used
to develop a guide to vancomycin dosing for those involved in the care of this specialist





Patients on ECMO support represent the extreme end of the critical illness spectrum.
Often these patients are in multi-organ failure with accompanying haemodynamic
compromise and a high predicted mortality with conventional management. As such,
ECMO patients may require multiple drug therapy for organ support, analgesia,
sedation and the treatment of systemic infections. It is thus crucial that consistent and
predictable drug delivery is achieved to ensure optimal patient care, improving the
prospects of recovery. The disposition of drugs during ECMO is a complex issue with
the interplay of many factors: an expanded circulating volume with consequent
haemodilution and protein binding changes, changes in physiology (hepatic and renal
function), sorption by components of the circuit and the influence of injection sites and
flow rates. Although literature in ECMO has become extensive in recent years, studies
and discussions regarding pharmacotherapy has been, at best, minimal. Limited in vitro
studies had suggested that drug sorption by the ECMO circuit may be an important
influence on drug disposition, however the influence of this phenomenon on plasma
drug concentrations and hence pharmacokinetics had not been investigated. Although a
number of studies have determined the pharmacokinetics of gentamicin and
vancomycin, these produced conflicting results and importantly, did not use the
estimated parameters to develop more appropriate dosing regimens. The series of
investigations described in this thesis start with the chemical analysis of drug loss in in
vitro systems and combines this data with clinical pharmacokinetic studies to establish
the influence on drug disposition of two ECMO circuit related phenomenon: drug
sorption and expanded circulating volume. The parameters derived from these
investigations were used to develop more appropriate dosing regimens for the major
drugs used in the ECMO unit at Glenfield Hospital.
Static sorption studies revealed a time dependent decrease in sedative drug
concentrations in contact with pPVC tubing and silicone membrane from the
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oxygenator. In contrast, morphine sulphate showed limited losses in contact with pPVC
and no loss in contact with the silicone membrane. As with previous studies
investigating drug interactions with intravenous administration containers and sets, the
degree of loss was correlated with the appropriate log P value, and ionisation status. The
results reveal significant potential for drug loss in an ECMO circuit. These simple static
sorption studies provide the basis for more physiological models to be developed.
The studies require to be repeated at normal body temperature. It is expected that
the rate and extent of drug sorption will be much greater at higher temperatures as
molecules interact with the polymer with increased frequency. In addition, drug sorption
in more physiological solutions such as blood need to be compared. Indeed one could
then determine the influence of drug binding to plasma proteins such as albumin and at
acid glycoprotein as well as red blood cells. Such binding may significantly reduce drug
available for sorption by the polymers. Interestingly, priming the polymers with an
albumin solution seemed to significantly decrease sorption of all drugs by the silicone
membrane, but not pPVC. In fact, there seemed to be an increased loss of drugs with the
latter. It is difficult to provide a mechanistic explanation for this. It is possible that
differing levels of surface coating was achieved, such that a more uniform coating of the
silicone membrane resulted in an 'albumin boundary layer' and resistance to the
diffusion of drugs into the polymer. Future studies need to investigate the influence of
priming times and changing the concentration of albumin in the priming solution on
sorption of drug.
In order to explore drug sorption in a dynamic model, flow through an ECMO
circuit was simulated by infusing drugs at constant concentration. The results from these
studies revealed significant capacity of the circuit to sequester drugs and to affect drug
delivery. In the case of propofol, the most lipophilic of all drugs tested, it was estimated
that even after 24 hours of a constant infusion rate, only 75% of the original dose would
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be delivered to the patient. Again, this simple model could be further developed with
more physiological components. Using blood as a mobile phase, warmed to body
temperature, is an important next step as already described. It would also be interesting
to explore the effects on fractional loss of drug of different pump flow rates and circuit
sizes (with differing surface area: volume ratios). A limitation of the current model is
that flow through the circuit (and hence the drug) is not in a loop i.e. the patient is
missing. Thus drug in the effluent is not recirculated (albeit at an expected lower
concentration as drug distributes through the body), and time to equilibrium may have
been artificially extended. Ultimately, future studies may be more creative and
informative through the development of an animal ECMO model. Such a model would
allow blood concentrations to be simultaneously monitored in the reinfusion cannula,
arterial circulation and drainage cannula. This would then enable investigation of not
only circuit related factors and physico-chemical properties of drugs, but also the effects
of mode of cannulation (VV or VA).
In contrast to previous investigations of drug sorption in non-ECMO appliances,
a primary aim at the outset of this research was to assess the effect of drug sorption on
pharmacokinetics. The ex vivo analysis of circuits confirmed sorption of midazolam in
vivo by the pPVC circuit tubing. Furthermore, simple water extractions showed that this
is a reversible process. The evaluation of midazolam pharmacokinetics in neonates
revealed a significant influence of reversible sorption to the circuit. The studies also
revealed doses of midazolam administered that were substantially higher than
previously reported in preterm neonates for mechanical ventilation, with consequently
elevated plasma concentrations. Comparison of plasma midazolam concentrations with
the sedation score suggested that levels up to 1ug/crrr' might be required to achieve
appropriate sedation in an ECMO patient. However, analysis of the sedation scores
revealed poor correlation with plasma midazolam concentrations. Scores were noted at
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the time of blood sampling only, and since this did not necessarily coincide with dose
alterations, they were not a sensitive marker of pharmacodynamic effect. Nevertheless,
the typical plasma concentration-time profile reveals plasma concentrations, as ECMO
progresses, rising in excess of those normally required for adequate sedation.
It was also an aim of the study to see whether route of midazolam
administration, intravenous or extracorporeal, affected dosage requirements and
pharmacokinetics. Along with higher dosage requirements in the first 24 hours, the
extracorporeal group also had a tendency towards a higher volume of distribution (V).
This concurs with the midazolam sorption model since infusion through the circuit, as
shown through the in vitro simulation studies, is expected to have an immediate effect
on drug delivery. In contrast during intravenous administration sorption is likely to have
a more gradual impact on arterial concentrations by virtue of lower initial circuit
concentrations. It is however anticipated that final equilibrium concentrations, in blood
and circuit, would be the same.
The population pharmacokinetic model developed included a time dependent V
that was significantly larger than previously reported in neonates. Typically the
residuals shown in figure 4.3, Chapter 4, indicates the need for an additional distribution
compartment. The addition of a second compartment did improve from the base model
but plots of residuals versus time, observed versus predicted concentrations, and
residuals versus predicted concentrations revealed there was a greater tendency to under
predict, particularly at later times and at higher concentrations. This was also borne out
in the predictive performance evaluation, which revealed a bias of +6%. In addition,
estimates of parameters were less precise. However, an alternative approach to an
ordinary bi-exponential decay model is to represent V as a function of time, where drug
distributes initially in a volume corresponding to Vo and then gradually reaching a
pseudo-equlibrium at Vrnax,where Vrnaxcorresponds to Vp in a two-compartment model
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and Ksor is the first-order sorption rate constant (Gabriels son et al., 2000). This approach
provided more precise parameter estimates, and reduced bias, as evidenced by the plot
of residuals and the predictive performance of the model. Although a less conventional
approach, this resulted in a better model.
Though the model performed well during cross validation and in the
simulations, this was an observational kinetic study and as such it can be argued that the
experimental design determined the kinetic model. For example previous studies have
shown that midazolam behaves as a two compartment model. Had it been possible to
conduct more intensive blood sampling the kinetics may have been better characterised
presumably as a three compartment model. The present study also did not collect
samples after cessation of midazolam infusion during the elimination phase and this is
reflected in the high interpatient variability for clearance (CL).
In 12 neonates it was also possible to determine the l-hydroxy
midazolamlmidazolam MR as a surrogate marker for CYP3A4/5 activity. However, the
higher MR obtained in term ECMO neonates as compared to preterm neonates, suggests
reduced activity of uridine-diphosphate glucuronosyl transferases (VOT). In contrast to
cytochrome P450, knowledge concerning the impact of development on VOT is far
from complete. The lack of specific probe drugs capable of assessing the activity of
individual VGT isoforms and their specificity for the biotransformation of important
VGT substrate drugs has contributed to this lack of knowledge (de Wildt et al., 1999).
In addition, the influence of critical illness on VOT activity is not known so that these
results may be a reflection of the critically ill nature of ECMO patients. Due to the
importance of VGTs in human drug metabolism more complete characterisation of
these critical enzymes is important and deserves attention. The results also highlight the
fact that these studies were performed in ill patients in an intensive care unit. The
disposition of midazolam is therefore more likely to be affected by both exogenous
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factors, for example the administration of co-drugs capable of altering CYP3A activity
or other pathways of metabolism (glucuronidation) and elimination (renal compromise)
and endogenous factors (e.g. hepatic disease, altered hepatic blood flow). The
development of an animal ECMO model, as already suggested, would allow for these
covariates to be controlled and enable the ECMO impact on pharmacokinetics to be
more clearly delineated.
The remainder of this thesis investigated the impact of the enlarged circulating
volume on three water soluble molecules with consequent small V: aminophylline
(theophylline), gentamicin and vancomycin. It is worthwhile bearing in mind when
comparing pharmacokinetic parameters estimated in the studies presented in this thesis
with published data, that ECMO neonates are unique in neonatal intensive care. Apart
from being 'sicker', the majority of the babies are term or near term whereas the
majority of non-ECMO neonates are preterm. The majority of reported pharmacokinetic
studies are therefore in preterm neonates. Since gestational age has a major influence
not only on renal and hepatic maturation but also the body water content, caution must
be exercised when comparing one group to another. Not withstanding this point, there is
little doubt that pharmacokinetics are significantly different compared to previous
reports in non-ECMO neonates.
The pharmacokinetics of theophylline has previously been well characterised
showing age and weight related CL. Although similar influences of covariates were
detected on parameter estimates from the population model developed in the present
study, there were also major differences. Theophylline CL during paediatric ECMO was
shown to be significantly impaired. This was not only reflected in the empirical
experience of staff involved in the care of these patients, but also in the proportion
(27%) of potentially toxic (>20mgIL) plasma levels reported. Although the estimate of
V did not appear to be significantly high and was in fact less than previous estimates in
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preterm neonates, plasma observations used in this investigation were primarily steady
state values obtained through routine therapeutic drug monitoring. As such, only CL can
be estimated with a high degree of confidence as reflected in the precision with which
the interpatient variability was estimated. The clinical implication of this is that the
loading dose recommended may not be sufficient to achieve therapeutically effective
levels. The impact of ECMO specifically on the V of theophylline warrants further
study, preferably with sampling during the distribution phase.
Linear regression analyses of gentamicin peak and trough plasma concentrations
not only highlighted the impact of an expanded circulating volume on V but also how
this can result in potential toxicity if 'normal dosing regimens' are utilised.
Furthermore, the study was also unique in that pharmacokinetic parameter estimates in
5 patients could be repeated after decannulation from ECMO. Although this study was
limited in its design with inherent errors in the model, assumptions made and an
inability to estimate variability around parameter estimates, it does reflect practice on
the ECMO unit. The future development of a population model will provide accurate
estimates of pharmacokinetic parameters and through the use of Bayesian forecasting
programs, can then be utilised a priori in conjunction with one or two plasma
observations to determine parameter values in individual patients. This is then a much
more powerful tool to tailor individual dosing regimens.
The population pharmacokinetic investigation of vancomycin utilised both rich
and sparse data and thus was able to characterise the impact of an expanded circulating
volume more accurately. Although an enlarged V and reduced creatinine corrected CL
was confirmed, the influence of blood recirculation during VV ECMO (Chapter 1,
Section 1.7.4.2) was not elucidated. The importance ofthe recirculation phenomenon in
affecting drug disposition is likely to be significant and requires urgent further work. At
the onset of ECMO with high flow rates, recirculation will be prominent and delay
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delivery of drug into the systemic circulation. Although more intensive sampling may
be able to parameterise recirculation, such a study may not be ethically possible in
children. Again the development of an animal model may be a more realistic approach.
Recirculation may also provide a further explanation as to why during the midazolam
study the extracorporeal group had a higher dose requirement at the onset of ECMO.
A limitation of all the pharmacokinetic studies presented in this thesis is that
research involving collection of blood samples from children has inherent difficulties
including ethical issues, sample size and sample availability (see Chapter 1, Section
1.9). These are legitimate concerns, protecting the health and overall well being of the
child. The quantity of blood and the number of samples necessary are two extremely
important variables to adequately describe and evaluate a drug's concentration-time
profile. Pharmacokinetic models and parameters defined in this thesis can help
circumnavigate blood sampling issues in follow up studies by using the optimal
sampling theory (OST) (Reed, 1999). OST incorporates mathematical models (e.g. D-
optimality criterion) to define the optimal sampling times that allow the investigator to
obtain the least number of blood samples whilst targeting the most 'information-rich'
areas of the drug concentration-time profile (Mentre et al., 1997). Such designs increase
the efficiency of pharmacokinetic studies, especially in the case of sparse data.
The clinical implications of findings in this research project will depend on the
stage of ECMO that treatment is initiated and is perhaps better appreciated in Figure
8.1. In the pre-ECMO phase, the patient is likely to be significantly hypoxic,
hypotensive and possibly also septic with consequent altered tissue perfusion and
metabolism. On cannulation, hypoxia, hypotension and tissue perfusion will be resolved
however the attachment of an extracorporeal circuit is associated with physiological and
non-physiological consequences as described throughout this thesis. On decannulation
and in the post-ECMO phase, the circulating volume has returned to normal but also the
209
patient is expected to be significantly 'less critical' with improved cardiovascular,
hepatic and renal function. Thus, drugs administered pre-ECMO will have significantly
different pharmacokinetics from that during ECMO and immediately post ECMO.
Healthcare professionals involved in the care of these patients need to bear this is mind.
Whilst the studies described in this thesis help answer important questions
regarding the disposition of drugs during ECMO, a vast amount of research remains to
be undertaken. Continued in vitro and in vivo animal and human clinical studies are
required in order to optimise drug therapy in this critically iII group of patients.
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Appendix I
Tabulated Data from Chapter 3
Table A.I Mean data from triplicate determinations of drug samples after single
passage through ECMO circuit.
Ratio of the measured concJinitial conc. as %
Sample TIME/min Midazolam Diazepam Lorazepam Propofol
1 2 4 3 68 nd
2 4 6 5 75 nd
3 6 7 6 73 nd
4 8 7 6 69 nd
5 10 7 6 68 nd
6 12 12 7 76 nd
7 14 11 9 72 nd
8 16 13 9 73 nd
9 18 10 10 71 nd
10 20 11 17 72 nd
11 22 12 23 79 nd
12 24 15 28 79 nd
13 26 18 31 78 nd
14 28 20 31 80 nd
15 30 21 35 77 nd
16 32 25 38 82 nd
17 34 26 40 79 nd
18 36 29 42 85 nd
23 46 23 40 98 4
27 54 32 48 99 9
Mean of Triplicate Determinations
nd = not detected
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Table A.II Cumulative amount of drug sorbed (JIg).
Sample Time Midazolam Diazepam Lorazepam Propofol
(min)
1 2 276.5 279.4 92.2 288.0
2 4 547.2 553.0 164.2 576.0
3 6 815.0 823.7 241.9 864.0
4 8 1082.9 1094.4 331.2 1152.0
5 10 1350.7 1365.1 423.4 1440.0
6 12 1604.2 1633.0 492.5 1728.0
7 14 1860.5 1895.0 573.1 2016.0
8 16 2111.0 2157.1 650.9 2304.0
9 18 2370.2 2416.3 734.4 2592.0
10 20 2626.6 2655.4 815.0 2880.0
11 22 2880.0 2877.1 875.5 3168.0
12 24 3124.8 3084.5 936.0 3456.0
13 26 3361.0 3283.2 999.4 3744.0
14 28 3591.4 3481.9 1057.0 4032.0
15 30 3818.9 3669.1 1123.2 4320.0
16 32 4034.9 3847.7 1175.0 4608.0
17 34 4248.0 4020.5 1235.5 4896.0
18 36 4452.5 4187.5 1278.7 5184.0
23 46 5561.3 5051.5 1307.5 6566.4
27 54 6344.6 5650.6 1319.0 7614.7
230
Table A.lll Mean Datafrom the Priming Studies
Unprimed PVC Unprimed Primed PVC Primed
Silicone Silicone
Lorazepam
0 25 25 25 25
5 20.18 20 24.94
20 15.18 16.95 12.23 25.09
40 14.96 16.7 12.1 24.84
120 14.98 16.4 12.05 24.66
Midazolam
0 25 25 25 25
5 17.6 17.99 16.93 22.23
20 11.29 12.86 6.3 17.23
40 8.79 9.05 6 15.89
120 8.39 7.95 6 13.99
Diazepam
0 25 25 25 25
5 8.73 16.55 7.24 21.36
20 3.81 9.9 1.23 14.78
40 2.99 6.2 1.06 12.39
120 2.91 5.61 1.01 9.98
Propofol
0 25 25 25 25
5 8.15 14 3.86 19.49
20 1.16 3.93 0.04 11.5
40 0.53 1.24 0.04 7.55
120 0.34 0.86 0 6.01
Table A.lV Recovery of Midazolam from Ex Vivo Circuits
Amount Extracted (~g)
Patient Duration Duration Amount Pre Post Drainage Mean %
of of Infused oxygenator Oxygenator Line (ug) Recovered
ECMO Infusion (~g)
1 199.0 168 31298.0 176.7 161.2 131.0 156.3 0.5
2 66.0 66.0 34200.0 283.6 258.6 308.6 283.6 0.8
3 82.0 82.0 48008.0 353.4 331.0 359.5 348.0 0.7
4 167.0 132 65940.0 795.7 978.4 1062.9 945.7 1.4
S 156.0 156.0 146015.0 647.4 529.3 543.1 573.3 0.4
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APPENDIX II
Estimation Algorithms for Population Pharmacokinetic Modelling
WinNonMix gives the option of two regression methods for performing the estimation:
The Two Stage Method and Inference by First Order Linearisation. The latter method
was used for all estimation during this project, since it is the method of choice when
data are sparse or when a particular covariance structure is required. The linear
approximation of the non-linear mixed effects model allows the linear mixed effects
model, population model parameters and covariance parameters to be estimated via the
same algorithm.
Three methods of inference based on linearisation are provided by WinNonMix:
(Simple) First Order, (GLS) First Order, and First Order Conditional methods. Only
(simple) First Order and First Order Conditional methods were used throughout this
project. Each method employs an approximation to the marginal likelihood based on a
Taylor series linearisation of the model (Davidian et al., 1995). The conditional first
order method (Lindstrom et ai, 1990) employs a more sophisticated approximation
which accommodates updating of the linearisation at each iterative step, based on the
most recent estimate of the random effects. This yields a superior approximation,
particularly when interpatient variability is large, however at the expense of
computational complexity and longer model run times (WinNonMix Version 2.0.
Reference Guide. (1998-2000).
Standard Error
Standard errors of fixed and random effects were calculated in WinNonMix by using
the sandwich method (WinNonMix Version 2.0. Reference Guide. (1998-2000).
Optimisation Method.
The regression was optimised by using the Quasi-Newton algorithm (Davidian et al.,
1995). The objective function was used as the convergence criterion for regression:
default tolerance was set at 0.000 1.
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APPENDIX III
Compartmental Models used by WinNonMix to Fit Plasma Concentration Data
1. One Compartment Model, Constant IV Infusion, First Order Output
Constant Rate IV 1.... :--..J:Klro..IIIQ,O---..
C(t) = Dose/ti x INxKJO x (e<-KJOx tOo)_ e<-KIO*t»
Where
C(t)= concentration in plasma at time, t
ti = length of infusion
t"' = t-ti for t>ti




2. Two Compartment Model, Constant IV infusion, First Order Output





e(t) = (A.e-a x t _ e-a x 1*) + (B.e-~ x t _ e-~ x t*)
Where
A = (Dose/ti x V) [(K21 - a )/(a -~) x a]
B = (-Dose/ti x V) [(K21- ~ )/(a -~) x ~]
a = Yz (K12 + K21 +KIO + -..j «K12 + K21 +KIO)2 - 4. K21 +KIO»
~ = Yz (K12 + K21 +KIO - -..j «K12 + K21 +KlOi - 4. K21 +KIO»
a. ~= K21 . Kw
a + ~= K12 + K21 + Kw
Estimated Parameters:
VI =D/A+B
Vss = [A.~2 +B.a2 I (A.~ + B.a)2].Dose










2 Number of Subjects 19
3 Total Observations 165
4 Minimum Objective Function Value -98.54141067
5 ML Log Likelihood -102.3541526
6 Akaike's Information Criterion (AIC) 218.7083053
7 Schwarz's Bayesian Criterion (SBC) 240.4499236
8 -2 * ML Log Likelihood 204.7083053
9 Actual Number of Iterations 3
10 Convergence Achieved Yes
11 Number of excluded observations 0
12 Hessian of Objective Function Not Positive Definite
Final Fixed Effects
A B C
1 Parameter Estimate StdError
2 V 0 13.92326391 1.64580627
3 V 1 2.7697781 1.73552704
4 V 2 -0.18560615 0.06751771
5 CL 0 0.27659139 0.03440851
Interpatient Variability
A B C
1 Random Effect V ETAO CL ETAO
2 V ETAO 2.80E-01












2 Number of Subjects 75
3 Total Observations 160
4 Minimum Objective Function Value 691.7571768
5 ML Log Likelihood -492.9087537
6 Akaike's Information Criterion (AIC) 997.8175074
7 Schwarz's Bayesian Criterion (SBCl 1016.26855
8 -2 * ML Log Likelihood 985.8175074
9 Actual Number of Iterations 3
10 Number of excluded observations 0
11 Convergence Achieved Yes
Final Fixed Effects
A B C
1 Parameter Estimate StdError
2 V 0 0.57139175 0.05330473
3 CL 0 0.02315136 0.00159435




1 Parameter Estimate StdError






2 Number of Subjects 45
3 Total Observations 326
4 Minimum Objective Function Value 1254.446925
5 ML Log Likelihood -926.7974242
6 Akaike's Information Criterion (AIC) 1879.594848
7 Schwarz's Bayesian Criterion (SBC) 1928.824514
8 -2 * ML Log Likelihood 1853.594848
9 Actual Number of Iterations 3
10 Convergence Achieved Yes
11 Number of excluded observations 2
12 Hessian of Objective Function Not Positive Definite
Final Fixed Effects
A B C
1 Parameter Estimate StdError
2 Vl 0 0.45187962 0.03799769
3 Vl 1 0.09383609 0.04270538
4 CL 0 2.356579 0.18293873
5 CL 1 0.00175742 0.00069456
6 CL 2 4.30703004 0.23908122
7 V2 0 0.2505241 0.03324401
8 CLD20 0.08737405 0.02325717
lnterpatient Variability
A B C D E
1 Random Effect CL ETAO V1 ETAO V2 ETAO CLD2 ETAO
2 CL ETAO 6.37E-02
3 V1 ETAO 1.08E-02 6.36E-02
4 V2 ETAO 2.27E-01
5 CLD2 ETAO -4.35E-01 8.33E-01
A B
1 Parameter Estimate
2 Sigma 0.01477491
3 A 286.4664686
4 B 2
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